Clinical trial NCT04075513
Conditions: Type 1 Diabetes Mellitus
Sponsor: Sanofi
Start date: 2019-10-09; Completion date: 2021-09-16
Enrollment: 343 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Primary Objective:

To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.

Secondary Objective:

To evaluate the glycemic control and variability parameters in each treatment group at Week 12 using Continuous Glucose Monitoring.

To evaluate the safety of insulin glargine 300 U/ml in comparison to insulin degludec 100 U/ml.

Detailed description:
The duration of the study per participant was around 18 weeks: 1 or 2 weeks of screening followed by a 4-week run-in period, a 12-week treatment period and a 2 to 4 days follow-up period.

Arms: arm 1: Toujeo (Insulin Glargine, 300 U/ml) subcutaneous (SC) injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog. arm 2: Tresiba (Insulin Degludec, 100U/ml) SC injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
Interventions: intervention 1: Insulin glargine, 300 U/ml intervention 2: Insulin degludec, 100U/ml intervention 3: Background therapy: Rapid acting insulin analogs
Intervention descriptions: intervention 1: Pharmaceutical form: solution for injection in a prefilled pen

Route of administration: SC injection intervention 2: Pharmaceutical form: solution for injection in a prefilled pen

Route of administration: SC injection intervention 3: Route of administration: SC injection

Protocol documents:
Prot_000.pdf: 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity 
According to template: RDSD-002540 VERSION N° 2.0 (11-OCT-2018) based on TransCelerate CPT version 5 
Page 1 
CLINICAL TRIAL PROTOCOL 
Protocol title: 
A 12-week randomized controlled trial to compare 
TOUJEO® and TRESIBA® in terms of glucose values in 
target range and variability during continuous glucose 
monitoring in patients with type 1 diabetes mellitus 
Protocol number: 
LPS14947 
Amendment number: 
Original protocol 
Compound number 
(INN/Trademark): 
HOE901-U300 
(Insulin Glargine 300 U/mL/ Toujeo®) 
Short title: 
Comparison of glucose values and variability between 
TOUJEO and TRESIBA during continuous glucose 
monitoring in type 1 diabetes patients (inRange) 
Sponsor name: 
Legal registered 
address: 
Monitoring Team’s 
Representative Name 
and Contact Information 
Regulatory agency identifying number(s): 
EudraCT number: 
2017-002756-91 
IND number: 
Not applicable 
WHO number: 
U1111-1197-8171 
NCT number: 
Not applicable 
Approval Date: 
31 May 2019 
Total number of pages: 86 
VV-CLIN-0514702 2.0
NCT04075513


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 2 
 
TABLE OF CONTENTS 
CLINICAL TRIAL PROTOCOL  ...................................................................................................................... 1 
TABLE OF CONTENTS .................................................................................................................................. 2 
LIST OF TABLES ........................................................................................................................................... 5 
LIST OF FIGURES .......................................................................................................................................... 6 
1 
PROTOCOL SUMMARY ................................................................................................................. 7 
1.1 
SYNOPSIS ....................................................................................................................................... 7 
1.2 
SCHEMA ........................................................................................................................................ 13 
1.3 
SCHEDULE OF ACTIVITIES (SOA) .............................................................................................. 14 
2 
INTRODUCTION ............................................................................................................................ 19 
2.1 
STUDY RATIONALE ...................................................................................................................... 19 
2.2 
BACKGROUND ............................................................................................................................. 19 
2.3 
BENEFIT/RISK ASSESSMENT ..................................................................................................... 21 
3 
OBJECTIVES AND ENDPOINTS ................................................................................................. 22 
3.1 
APPROPRIATENESS OF MEASUREMENTS .............................................................................. 23 
4 
STUDY DESIGN ............................................................................................................................ 25 
4.1 
OVERALL DESIGN ........................................................................................................................ 25 
4.2 
SCIENTIFIC RATIONALE FOR STUDY DESIGN ......................................................................... 26 
4.3 
JUSTIFICATION FOR DOSE ........................................................................................................ 27 
4.4 
END OF STUDY DEFINITION ....................................................................................................... 27 
5 
STUDY POPULATION .................................................................................................................. 28 
5.1 
INCLUSION CRITERIA .................................................................................................................. 28 
5.2 
EXCLUSION CRITERIA ................................................................................................................ 29 
5.3 
LIFESTYLE CONSIDERATIONS ................................................................................................... 30 
5.4 
SCREEN FAILURES ...................................................................................................................... 31 
6 
STUDY INTERVENTION ............................................................................................................... 32 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 3 
6.1 
STUDY INTERVENTION(S) ADMINISTERED .............................................................................. 32 
6.1.1 
Devices........................................................................................................................................... 34 
6.2 
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY ....................................................... 34 
6.3 
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING ....................................... 35 
6.4 
STUDY INTERVENTION COMPLIANCE ...................................................................................... 37 
6.4.1 
Drug accountability ......................................................................................................................... 37 
6.4.2 
Training to use injection devices .................................................................................................... 37 
6.5 
CONCOMITANT THERAPY .......................................................................................................... 38 
6.6 
DOSE MODIFICATION .................................................................................................................. 38 
6.6.1 
Basal insulin ................................................................................................................................... 38 
6.6.1.1 
Starting dose .................................................................................................................................. 39 
6.6.1.2 
Dose adjustment ............................................................................................................................ 39 
6.6.2 
Mealtime insulin ............................................................................................................................. 40 
6.6.3 
Monitoring of insulin titration .......................................................................................................... 42 
6.6.4 
Evaluation of participants not meeting glycemic targets ................................................................ 42 
6.7 
INTERVENTION AFTER THE END OF THE STUDY ................................................................... 42 
7 
DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ........................................................................................... 43 
7.1 
DISCONTINUATION OF STUDY INTERVENTION  ..................................................................... 43 
7.1.1 
Definitive discontinuation ............................................................................................................... 43 
7.1.2 
Temporary discontinuation ............................................................................................................. 44 
7.1.2.1 
Rechallenge ................................................................................................................................... 44 
7.2 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY .................................. 44 
7.3 
LOST TO FOLLOW UP.................................................................................................................. 45 
8 
STUDY ASSESSMENTS AND PROCEDURES ........................................................................... 46 
8.1 
EFFICACY ASSESSMENTS  ........................................................................................................ 46 
8.1.1 
Continuous glucose monitoring (CGM) .......................................................................................... 46 
8.1.1.1 
CGM performance .......................................................................................................................... 46 
8.1.1.2 
CGM qualification and data transfer .............................................................................................. 47 
8.1.2 
Glycated hemoglobin A1c .............................................................................................................. 48 
8.1.3 
Fasting plasma glucose ................................................................................................................. 48 
8.1.4 
Self-monitoring of plasma glucose ................................................................................................. 48 
8.1.5 
Insulin dose (including IMP during the treatment period) .............................................................. 50 
8.1.6 
Patient-reported Outcomes (PROs) ............................................................................................... 51 
8.1.6.1 
DTSQs............................................................................................................................................ 51 
8.1.6.2 
DTSQc............................................................................................................................................ 51 
8.1.6.3 
MOS Sleep ..................................................................................................................................... 52 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 4 
8.1.6.4 
WPAI .............................................................................................................................................. 52 
8.2 
SAFETY ASSESSMENTS  ............................................................................................................ 53 
8.2.1 
Physical examinations.................................................................................................................... 53 
8.2.2 
Vital signs ....................................................................................................................................... 53 
8.2.3 
Clinical safety laboratory assessments .......................................................................................... 53 
8.2.4 
Hypoglycemia ................................................................................................................................. 54 
8.3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ........................................................... 55 
8.3.1 
Time period and frequency for collecting AE and SAE information ............................................... 56 
8.3.2 
Method of detecting AEs and SAEs ............................................................................................... 56 
8.3.3 
Follow-up of AEs and SAEs ........................................................................................................... 56 
8.3.4 
Regulatory reporting requirements for SAEs ................................................................................. 56 
8.3.5 
Pregnancy ...................................................................................................................................... 57 
8.3.6 
Guidelines for reporting product complaints .................................................................................. 57 
8.4 
TREATMENT OF OVERDOSE ...................................................................................................... 57 
8.5 
PHARMACOKINETICS .................................................................................................................. 58 
8.6 
PHARMACODYNAMICS ............................................................................................................... 58 
8.7 
GENETICS ..................................................................................................................................... 58 
8.8 
BIOMARKERS ............................................................................................................................... 58 
8.9 
HEALTH ECONOMICS .................................................................................................................. 58 
9 
STATISTICAL CONSIDERATIONS  ............................................................................................. 59 
9.1 
STATISTICAL HYPOTHESES ....................................................................................................... 59 
9.2 
SAMPLE SIZE DETERMINATION  ................................................................................................ 59 
9.3 
POPULATIONS FOR ANALYSES ................................................................................................. 60 
9.4 
STATISTICAL ANALYSES ............................................................................................................ 60 
9.4.1 
Efficacy analyses ........................................................................................................................... 60 
9.4.2 
Safety analyses .............................................................................................................................. 62 
9.4.3 
Other analyses ............................................................................................................................... 63 
9.5 
INTERIM ANALYSES  ................................................................................................................... 63 
10 
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS ........................ 64 
10.1 
APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS ....... 64 
10.1.1 
Regulatory and Ethical Considerations .......................................................................................... 64 
10.1.2 
Informed Consent Process ............................................................................................................ 64 
10.1.3 
Data Protection .............................................................................................................................. 65 
10.1.4 
Committees Structure .................................................................................................................... 65 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 5 
10.1.5 
Dissemination of Clinical Study Data ............................................................................................. 66 
10.1.6 
Data Quality Assurance ................................................................................................................. 66 
10.1.7 
Source documents ......................................................................................................................... 67 
10.1.8 
Study and Site Closure .................................................................................................................. 67 
10.1.9 
Publication Policy ........................................................................................................................... 67 
10.2 
APPENDIX 2: CLINICAL LABORATORY TESTS ......................................................................... 68 
10.3 
APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING................................................. 69 
10.4 
APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION .............................................................................................................................. 73 
10.5 
APPENDIX 5: QUESTIONNAIRE .................................................................................................. 77 
10.5.1 
The Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs)  ............................ 77 
10.5.2 
The Diabetes Treatment Satisfaction Questionnaire Change Version .......................................... 78 
10.5.3 
MOS Sleep ..................................................................................................................................... 79 
10.5.4 
WPAI .............................................................................................................................................. 81 
10.6 
APPENDIX 6: ADA HYPOGLYCEMIA DEFINITIONS ................................................................... 82 
10.7 
APPENDIX 7: COUNTRY-SPECIFIC REQUIREMENTS  ............................................................. 83 
10.8 
APPENDIX 8: ABBREVIATIONS ................................................................................................... 83 
11 
REFERENCES ............................................................................................................................... 84 
 
LIST OF TABLES 
Table 1 - Objectives and endpoints ............................................................................................................... 22 
Table 2 - Overview of study interventions administered ............................................................................... 32 
Table 3 - Basal insulin dose adjustments ...................................................................................................... 39 
Table 4 - Rapid-acting insulin dose adjustment ............................................................................................ 41 
Table 5 - Carb counting: insulin-to-carbohydrate ratio .................................................................................. 41 
Table 6 - Populations for analyses ................................................................................................................ 60 
Table 7 - Efficacy analyses ........................................................................................................................... 61 
Table 8 - Safety analyses .............................................................................................................................. 62 
Table 9 - Protocol-required laboratory assessments .................................................................................... 68 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 6 
LIST OF FIGURES 
Figure 1 - Graphical study design ................................................................................................................. 13 
 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 7 
1 
PROTOCOL SUMMARY 
1.1 
SYNOPSIS 
Protocol title: A 12-week randomized controlled trial to compare TOUJEO® and TRESIBA® in 
terms of glucose values in target range and variability during continuous glucose 
monitoring in patients with type 1 diabetes mellitus 
Short title: 
Comparison of glucose values and variability between TOUJEO and TRESIBA 
during continuous glucose monitoring in type 1 diabetes patients (inRange) 
Rationale: 
The fluctuations in blood glucose, regular short-duration periods of hyperglycemia and 
hypoglycemia, which are not detected by the measurements of glycated hemoglobin (HbA1c), 
may possibly contribute to vascular pathological processes and diabetic complications.  
Insulin glargine U300 (HOE901-U300, Toujeo®) is a more concentrated formulation of insulin 
glargine U100 (HOE901) which showed a prolonged and flatter glucose-lowering activity (up to 
36 hours) compared to Lantus (Insulin glargine U100), resulting in less circadian fluctuation in 
blood glucose levels (1). Given these features of the pharmacokinetic (PK)/pharmacodynamics 
(PD) profiles, Toujeo is considered to be well suitable for constant, peakless 24-hour basal insulin 
supply in diabetes management, with the expectation of less hypoglycemic risk at equal to tighter 
blood glucose control. 
Tresiba® is a basal insulin that forms soluble multi-hexamers upon subcutaneous (SC) injection, 
resulting in a depot from which insulin degludec is continuously and slowly absorbed into the 
circulation leading to a flat and stable glucose-lowering-effect. This recombinant analog of human 
insulin provides basal insulin supply beyond 42 hours after injection in euglycemic clamp 
conditions in type 1 diabetes (2).  
The present study LPS14947 is designed to further explore similarities and differences between 
Toujeo and Tresiba in terms of an effect on continuous glucose profile, while the conventional 
glycemic control as measured by HbA1c is anticipated to be similar between the 2 treatments. 
Objectives and endpoints 
 
Objectives 
Endpoints 
Primary 
To demonstrate the noninferiority of insulin glargine 300 U/mL 
in comparison to insulin degludec 100 U/mL on glycemic 
control and variability in participants with diabetes mellitus 
 
Percent time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to 
≤10 mmol/L) at Week 12, obtained using continuous glucose 
monitoring (CGM) 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 8 
Secondary 
To evaluate the glycemic control and variability parameters in 
each treatment group at Week 12 using CGM 
At Week 12, the following endpoints will be assessed: 
 
Glucose total CV  
 
Glucose within-day and between-day CV  
Other secondary endpoints: 
 
Change from baseline to Week 12 in HbA1c 
 
Change from baseline to Week 12 in central lab FPG 
 
Percent time and mean hours per day with 
glucose<70mg/dL (on all time and during the night 
[00:00 to 05:59]) 
 
Percent time and mean hours per day with 
glucose>180mg/dL 
 
To evaluate the safety of insulin glargine 300 U/mL in 
comparison to insulin degludec 100 U/mL  
Number of participants with adverse events (see Section 8.3)  
Number of participants with at least one hypoglycemic event 
from baseline to Week 12 
Number of hypoglycemic events per participant year from 
baseline to Week 12 
Overall design: 
This is a multicenter, randomized, active-controlled, parallel-group, 12-week open-label study to 
compare the efficacy of Toujeo with Tresiba using 20-day CGM glucose profiles at Week 12. The 
CGM during study period will be blinded to both the Investigators and patients. 
Study population will consist of participants with type 1 diabetes mellitus (T1DM), treated with 
multiple daily injections (MDI) using basal insulin once daily and rapid acting insulin analogs for 
at least one year, and having HbA1c ≥ 7% and ≤ 10% at screening (see full list of inclusion and 
exclusion criteria in Section 5).  
Number of participants: 
Approximately 338 patients will be randomly assigned to study intervention for an estimated total 
of 131 evaluable participants per intervention group (with the assumption of a non-evaluability 
rate of 22%). 
Intervention groups and duration: 
The study is planned to randomize 338 patients in 2 parallel treatment groups: 
 
Toujeo group, n=169 patients. 
 
Tresiba group, n=169 patients. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 9 
The duration of the study per patient will be around 18 weeks (1 or 2 weeks of screening followed 
by a 4-week run-in period, a 12-week treatment period and a 2 to 4 days follow-up period). 
Study interventions 
Investigational medicinal products 
 
Formulation:  
Test drug: Toujeo (insulin glargine 300 U/mL) is supplied as a sterile, non-pyrogenic, 
clear, colorless solution for SC injection in the Toujeo SoloStar prefilled, disposable pen. 
Each Toujeo SoloStar contains in total 450 units of insulin glargine (1.5 mL of 300 U/mL 
insulin glargine solution). 
Control drug: Tresiba is supplied as a sterile, non-pyrogenic, clear, colorless solution in 
the marketed Tresiba FlexTouch prefilled (disposable) pen (insulin degludec 100 U/mL 
solution for SC injection). Each Tresiba FlexTouch contains in total 300 units of insulin 
degludec (3.0 mL of 100 U/mL insulin degludec solutions). 
 
Route of administration: subcutaneous. 
 
Dose regimen: At randomization, patients will switch from their current basal insulin to 
either Toujeo or Tresiba in the morning. The initiation doses of Toujeo and Tresiba will be 
the patient’s current doses of their basal-insulin analogs. During the titration phase 
(expected to be up to Week 8), doses of either Toujeo or Tresiba will be titrated to achieve 
glycemic targets without hypoglycemia. The dose will be titrated at least weekly (but no 
more often than every 3 days), until the patient reaches a target fasting SMPG of ≥70 to 
<100 mg/dL (≥3.9 to <5.6 mmol/L) while avoiding hypoglycemia episodes. Dose 
adjustments are based on a median of fasting SMPG values from the last 3 days, which 
includes the value measured on the day of titration, as measured by the patient using 
glucometers and accessories supplied by the Sponsor. Sponsor will ensure adequate 
monitoring of basal insulin titration. 
 
a Median refers to intermediate SMPG value (the value between the lowest and the highest SMPG values when the values are ranked in a 
growing order). 
b Prior to additional basal insulin titration, mealtime insulin should be titrated to achieve a bedtime and pre-breakfast glucose delta <50 mg/dL, 
if so considered helpful by Investigator. 
 
Mediana fasting pre-breakfast SMPG values (last 3 days) 
 
Basal insulin dose adjustments (U/day)b  
≥140 mg/dL (≥7.8 mmol/L) 
+4 units  
≥100 and <140 mg/dL (≥5.6 and <7.8 mmol/L) 
+2 units  
≥70 and <100 mg/dL (≥3.9 and 
<5.6 mmol/L) 
No change 
≥56 and <70 mg/dL (≥3.1 and <3.9 mmol/L) 
-2 units 
<56 mg/dL (<3.1 mmol/L) or occurrence of 2 (or more) symptomatic 
hypoglycemic episodes or one severe hypoglycemic episode 
-4 units or at the discretion of the Investigator or 
medically qualified designee 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 10 
Noninvestigational medicinal products(s) 
 
Formulation: rapid-acting (mealtime) insulin analog (eg, insulin glulisine, insulin lispro or 
insulin aspart). The cost of the mealtime insulin analogue may be reimbursed if not 
covered by health insurance and if allowed by local regulations. Alternatively, the sponsor 
provided insulin glulisine may be offered. 
 
Route of administration: subcutaneous. 
 
Dose regimen: The injection time and frequency of rapid-acting (mealtime) insulin will be 
at the Investigator’s discretion, in accordance with the National Product Label. During the 
study, the doses of the mealtime insulin analog should be actively titrated to achieve and 
maintain the 2 hour postprandial SMPG in the range ≥130 to ≤180 mg/dL (≥7.2 to 
<10 mmol/L) while avoiding hypoglycemia. Dose adjustment of mealtime insulin can be 
based on a pattern of post-meal SMPG data from the prior 3 days (simple titration) OR the 
carbohydrate content of the meal. Sponsor will ensure adequate monitoring of mealtime 
insulin titration.  
Simple titration: Titration of mealtime insulin based on a pattern of post-meal glucose 
median <130 / >180 mg/dL in the prior 3 days using the table below. 
 
Mealtime dose of Insulin 
Pattern of Postprandial Plasma 
Glucose values <130 mg/dLa 
Postprandial Plasma Glucose 
values >180 mg/dLa 
≤10 units 
Decrease dose by 1 unit 
Increase dose by 1 unit 
≥11-19 units 
Decrease dose by 2 units 
Increase dose by 2 units 
≥20 units 
Decrease dose by 3 units 
Increase dose by 3 units 
a If more than half of the mealtime plasma glucose (2-hours postprandial plasma glucose) values for the week were above target. 
OR 
 
Carb counting: (insulin-to-carbohydrate ratio) group. 
Starting recommendation 1 unit to 15 grams carbs 
Consider calculating insulin to carb (I:C) ratio = 500/total daily dose (TDD) of insulin. 
 
Mealtime dose of Insulin 
Pattern of Postprandial Plasma 
Glucose values <130 mg/dLa 
Pattern of Postprandial Plasma 
Glucose values >180 mg/dLa 
1 unit/20 g 
Decrease to 1 unit/25 g 
Increase to 1 unit/15 g 
1 unit/15 g 
Decrease to 1 unit/20 g 
Increase to 1 unit/10 g 
1 unit/10 g 
Decrease to 1 unit/15 g 
Increase to 2 unit/15 g 
2 unit/15 g 
Decrease to 1 unit/10 g 
Increase to 3 unit/15 g 
3 unit/15 g 
Decrease to 2 unit/15 g 
Increase to 4 unit/15 g 
a If more than half of the mealtime plasma glucose values for the prior 3 days were above target. 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 11 
Statistical considerations: 
 
Sample size  
The sample size calculation is based on the percent time spent in glucose range of ≥70 to 
≤180 mg/dL (≥3.9 to ≤10 mmol/L) at Week 12, assessed from CGM measurements obtained 
from Weeks 10 to 12. 
For this criterion of percent time in range, there is no predefined non-inferiority margin. 
A relative non-inferiority margin of 10% is considered. 
Let m1 and m0 be the true means for the Toujeo and Tresiba groups, respectively. 
The non-inferiority null hypothesis would be H0: m1-m0 ≤ -0.1*m0 or H0: m1-0.9*m0 ≤0 
and the alternative hypothesis (H1): m1=m0. 
Toujeo would be considered non-inferior to Tresiba if the lower limit of the 95% confidence 
interval (CI) for the adjusted difference estimate of m1-0.9*m0 at Week 12 is > 0. 
To ensure 90% power, the sample size should satisfy: 
1.96 −(0.1 ∗𝑚0)
√1.81 ∗𝑆𝐷2
𝑛
= − 1.282 
Where -1.282 is the 10th percentile of a standard normal distribution and standard deviation 
(SD) the common SD. 
which leads to: 𝑛=
(1.96+1.282)2∗1.81∗𝑆𝐷2
(0.1∗𝑚0)2
 
Assuming a common SD of 14.7%, an average percent time in range in the Tresiba treatment 
group of 56% (value from LPS14587), no true difference between both arms under H1, and a 
relative non-inferiority of 10%, a sample size of 131 evaluable patients per treatment group 
would provide at least 90% power to show non-inferiority of Toujeo with respect to Tresiba 
on the percentage of time plasma glucose within the range of ≥70 to ≤180 mg/dL at Week 12. 
With the assumption of a non-evaluability rate of 22%, 338 patients (169 per treatment arm) 
will have to be randomized. 
 
 
Primary analysis: 
The primary endpoint (percent time in glucose range of ≥70 to ≤180 mg/dL [≥3.9 to 
≤10 mmol/L] at Week 12) using available data from the 12-week randomized period will be 
analyzed using an analysis of covariance (ANCOVA model including the fixed categorical 
effects of treatment group (Toujeo, Tresiba), randomization stratum of screening HbA1c 
(<8.0% versus ≥8.0%), as well as, the continuous fixed covariate of baseline percent time in 
range value. This procedure will provide baseline adjusted least-squares means estimates at 
Week 12 for both treatment groups, as well as, the differences of these estimates, with their 
corresponding standard errors (SEs) and 95% CI. 
To assess non-inferiority, the lower bound of the two-sided 95% CI for the adjusted difference 
estimate of m1 - 0.9*m0 at Week 12 will be compared to 0. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 12 
Non-inferiority will be demonstrated if the lower bound of the two-sided 95% CI of the 
adjusted difference estimate of m1 - 0.9*m0 at Week 12 on the intent to treat (ITT) population 
is >0. 
 
Analysis of secondary endpoints: 
The CGM endpoints will be analyzed using the same model as described for the primary 
endpoint using the ITT population. 
Change in HbA1c will be analyzed using an ANCOVA model including the fixed categorical 
effects of treatment group (Toujeo, Tresiba), as well as, the continuous fixed covariate of 
baseline HbA1c value. 
Change in FPG will be analyzed using ANCOVA model including the fixed categorical effects 
of treatment group (Toujeo, Tresiba), the randomization stratum of HbA1c at screening 
(<8.0%, ≥8.0%), as well as, the continuous fixed covariate of baseline FPG value. 
Change from baseline in 7-point SMPG profiles (preprandial and 2-hour postprandial plasma 
glucose at breakfast, lunch and dinner, and at bedtime) to Week 12 will be described by 
treatment group using mean and SD. 
To control the type I error, a hierarchical step-down testing procedure described by Hochberg 
and Tamhane (3) will be applied for the primary efficacy endpoint and the main secondary 
endpoint: 
- 
Step 1 proceeds to assess non-inferiority of Toujeo versus Tresiba on the percent time 
in range in 70-180 mg/dl, 
- 
Step 2: only if step 1 is demonstrated, then non-inferiority of Toujeo versus Tresiba on 
the glucose total CV will be tested with a relative non-inferiority margin of 10%, 
- 
Step 3: only if step 2 is demonstrated, then difference between Toujeo and Tresiba on 
the percent time in range in 70-180 mg/dl will be tested.  
No multiplicity adjustment will be made on other secondary/other efficacy variables; 95% CI 
and P-values presented for these endpoints will be done for descriptive purpose only. 
Data Monitoring Committee: No
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 13 
1.2 
SCHEMA 
Figure 1 - Graphical study design 
 
TOUJEO QD morning
TRESIBA QD morning
Open label treatment period: 12 weeks*
1:1
2-arms, RCT
T1DM (N =338)
Adult patients with T1 diabetes, age 
between 18 and 70 years
HbA1c  ≥7%  - ≤10%
MDI regimen with any QD basal insulin 
and rapid acting analogues
Prior basal: no TOUJEO or TRESIBA in 
the last 30 days.
R
Run-in
(stabilization of insulin regimen + 
CGM )
4 weeks 
W1 0 -W1 2 : CGM
W1 2 : 7 -po int
SMPG
Sta biliza tio n o f 
Insulin
W -4 /-3
CGM W-3 /-1
7 -po int SMPG 
(befo re R)
Screening
(1  to  2  weeks) 
Basal insulin titration: 8 weeks*
* Telephone calls to monitor insulin 
titration weekly between site visits for all 
patients, unless attending the study site for 
sensor replacement. Option to come to site 
on D(-)10 and D74 for sensor replacement. 
 
Abbreviations: CGM = continuous glucose monitoring, HbA1c = glycated hemoglobin, , MDI = multiple daily injection, R = randomized, SMPG = self-monitoring of plasma glucose, T1 diabetes = type 1 diabetes. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 14 
1.3 
SCHEDULE OF ACTIVITIES (SOA) 
 
Procedure 
Screening 
(weeks) 
Run-in (weeks) 
 
 
Intervention period (weeks) 
Follow up 
Notes 
-6/-5 
-4 
-3 
-2 
-1 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
EOTc 
2 to 4 
days after 
last IMP 
dose 
Visit Windows:  
Site visits : ±3 days  
Phone call visits : 
±1 day  
relative to Visit 6 
Visita 
1 
2 
3 
4 
 
5 
 
6 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
15 
16 
 
17 
 
18b 
 
19d 
 
 
Day 
-42/-35 
-28 
-20 
-14 
-7 
1 
7 
14 
21 
28 
35 
42 
48 
56 
64 
71 
78 
84 
 
86-88 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To be repeated in 
case of rescreening 
Inclusion/Exclusion criteria 
X 
X 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demography 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Full physical examination 
including height and weight 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical, surgical and 
diabetes history 
Method of mealtime insulin 
titration 
X 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current method at 
screening and the one 
to be followed during 
treatment period at 
randomization 
Vital signs and body weight  
X 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
X 
X 
 
Vital signs include 
heart rate and blood 
pressure (sitting 
position) 
Dispensation/collection of 
study diary 
 
X 
X 
 
 
X 
 
 
 
 
 
 
 
X 
X 
 
 
X 
X 
 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 15 
Procedure 
Screening 
(weeks) 
Run-in (weeks) 
 
 
Intervention period (weeks) 
Follow up 
Notes 
-6/-5 
-4 
-3 
-2 
-1 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
EOTc 
2 to 4 
days after 
last IMP 
dose 
Visit Windows:  
Site visits : ±3 days  
Phone call visits : 
±1 day  
relative to Visit 6 
Visita 
1 
2 
3 
4 
 
5 
 
6 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
15 
16 
 
17 
 
18b 
 
19d 
 
 
Day 
-42/-35 
-28 
-20 
-14 
-7 
1 
7 
14 
21 
28 
35 
42 
48 
56 
64 
71 
78 
84 
 
86-88 
 
Dispensation of study 
intervention 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
IMP compliance check 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
X 
X 
 
Collecting and 
counting used and 
unused pens 
IRT calle 
X 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
X 
X 
 
 
Randomization 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Documentation and review of 
basal and mealtime insulin 
dose 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Prior and concomitant 
medication 
X 
X 
X 
 
 
X 
 
 
 
 
“ 
 
 
X 
 
 
 
X 
X 
X 
 
CGM device dispensation ; 
blinded CGM and training 
including insertion of CGM 
sensor  
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
X 
 
If required, 
Investigators can 
arrange for patient’s to 
attend the site after 
the first 10 days of 
CGM for the sensor to 
be replaced at the 
study site. 
CGM recordingf 
 
 
20days 
 
 
 
 
 
 
 
 
 
20 days 
X 
 
 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 16 
Procedure 
Screening 
(weeks) 
Run-in (weeks) 
 
 
Intervention period (weeks) 
Follow up 
Notes 
-6/-5 
-4 
-3 
-2 
-1 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
EOTc 
2 to 4 
days after 
last IMP 
dose 
Visit Windows:  
Site visits : ±3 days  
Phone call visits : 
±1 day  
relative to Visit 6 
Visita 
1 
2 
3 
4 
 
5 
 
6 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
15 
16 
 
17 
 
18b 
 
19d 
 
 
Day 
-42/-35 
-28 
-20 
-14 
-7 
1 
7 
14 
21 
28 
35 
42 
48 
56 
64 
71 
78 
84 
 
86-88 
 
Collect CGM device and 
upload CGM data 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
Upload CGM data to 
the site computer with 
QuintilesIMS Study 
Management Suite 
Software 
Training: Glucometer, SMPG 
profiles, study diary 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glucometer dispensation 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fasting SMPGg 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Values of last 3 
measurements before 
each visit must be 
recorded in eCRF 
2hPPG  
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
Regularly as 
instructed by 
investigator 
 
7-point SMPG 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
 
SMPG data upload to site's 
PC 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
X 
 
 
X 
X 
X 
Server independent 
from eCRF 
Re-training: Glucometer, 
SMPG profiles, study diary 
 
X 
X 
 
 
X 
 
 
 
 
 
 
 
X 
X 
 
 
X 
 
 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 17 
Procedure 
Screening 
(weeks) 
Run-in (weeks) 
 
 
Intervention period (weeks) 
Follow up 
Notes 
-6/-5 
-4 
-3 
-2 
-1 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
EOTc 
2 to 4 
days after 
last IMP 
dose 
Visit Windows:  
Site visits : ±3 days  
Phone call visits : 
±1 day  
relative to Visit 6 
Visita 
1 
2 
3 
4 
 
5 
 
6 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
15 
16 
 
17 
 
18b 
 
19d 
 
 
Day 
-42/-35 
-28 
-20 
-14 
-7 
1 
7 
14 
21 
28 
35 
42 
48 
56 
64 
71 
78 
84 
 
86-88 
 
HbA1c, FPG 
X 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
Xh 
X 
 
Central lab 
h:In case of premature 
EOT, : HbA1c, FPG to 
be measured  at 
Week 12 
C-peptide 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Central lab 
 
Hematology, clinical 
chemistry 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See Appendix 2, 
Section 10.2 
Pregnancy test (WOCBP 
only) 
X 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Serum pregnancy test 
for screening; urine 
pregnancy test for 
subsequent 
monitoring (if positive 
to be confirmed by a 
serum test). 
AE/SAE 
To be assessed and reported if any throughout the study 
 
Hypoglycemia recording 
To be assessed and reported if any throughout the study 
 
DTSQs 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
DTSQc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
MOS-sleep 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 18 
Procedure 
Screening 
(weeks) 
Run-in (weeks) 
 
 
Intervention period (weeks) 
Follow up 
Notes 
-6/-5 
-4 
-3 
-2 
-1 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
EOTc 
2 to 4 
days after 
last IMP 
dose 
Visit Windows:  
Site visits : ±3 days  
Phone call visits : 
±1 day  
relative to Visit 6 
Visita 
1 
2 
3 
4 
 
5 
 
6 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
15 
16 
 
17 
 
18b 
 
19d 
 
 
Day 
-42/-35 
-28 
-20 
-14 
-7 
1 
7 
14 
21 
28 
35 
42 
48 
56 
64 
71 
78 
84 
 
86-88 
 
WPAI 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
a Telephone calls to monitor insulin titration should be scheduled by the Investigator for Weekly in between of site visits for all patients, unless the patient is attending the study site for sensor replacement. Option to 
come to site on D-10 and D74 for sensor replacement. 
b Visit 18 will occur at Week 12 regardless of the treatment end date, and procedures ticked below should be done 
c EOT (End Of Treatment) visit will occur in case of premature discontinuation of study treatment before Visit 18 at week 12 and related procedures ticked below should be applied. If at the time of such premature 
discontinuation there is ongoing CGM recording, it should be completed, and EoT vist done thereafter. Afterward, the patients should continue in the study up to the scheduled date of study completion. See 
Section 7.1 
d If EOT visit occurs beyond 2 to 4 days after last administration of study drug then Visit 8 will not be required. EOT and safety follow up can be done at the same time, if occurs within 2 to 4 days after last IMP dose. 
e The Investigator should contact IRT either at Visit 18 or  at EOT visit in case of premature end of treatment (whichever occurs first), to register end of treatment. 
f 
For each 20 day CGM period to be fully evaluable for CGM it is necessary to obtain a minimum of 10 days (not necessarily consecutive) of useable CGM data. Useable CGM data for a day/a 24-hour CGM profile 
are defined as: at least 80% time of records per 24 hours; no gap (missing data) lasting for ≥2 hours per 24 hours besides the warm-up time for the sensor after insertion. 
g SMPG to be performed by the patients from run-in period and throughout the study duration: 
1. 
Fasting (pre-breakfast/pre-injection) SMPG: daily until dose stabilization of basal insulin has been completed and fasting SMPG goal is reached. Thereafter, the number of fasting SMPG checks can be 
reduced according to the Investigator’s judgment, however at least 3 fasting (pre-breakfast) SMPG measurements per week should be done. 
2. 
SMPG values throughout the study, starting after Visit 2. Patients should test their SMPG following the Investigator’s instructions for mealtime insulin titration. 
3. 
2hPPG (post prandial plasma glucose); regularly as instructed by investigator to guide meal time insulin titration;  
4. 
7-point SMPG profile (before and 2 hours after breakfast, lunch and dinner, and at bedtime): at least ONE day during the week that precedes Visits 6  and 18 
Patients should be instructed to self-assess plasma glucose levels whenever they experience any symptoms of hypoglycemia; see ‘SMPG during symptomatic hypoglycemia’ in Section 8.1.4 for further 
instructions. 
 
Abbreviations: AE = adverse event, FPG = fasting plasma glucose, HbA1c = glycated hemoglobin, IMP = investigational medicinal product, IRT= interactive response technology, CGM = continuous glucose 
monitoring, EOT = end of treatment, PC = personal computer, R = randomization, SMPG = self-monitoring of plasma glucose, SAE = serious adverse event, WOCBP = women of childbearing potential.
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 19 
2 
INTRODUCTION 
The fluctuations in blood glucose, regular short-duration periods of hyperglycemia and 
hypoglycemia, which are not detected by the measurements of HbA1c, may possibly contribute to 
vascular pathological processes and diabetic complications. This association may be independent 
of average glucose exposure expressed by HbA1c. This hypothesis remains controversial, but 
stems from the observation that intensive (versus standard) glucose control in the diabetes control 
and complications trial (DCCT) was associated with reduced risk for retinopathy after correcting 
for HbA1c (4). Supportive observations report that the coefficient of variation (CV) of fasting 
plasma glucose (FPG) independently predicted mortality in type 2 diabetes mellitus (T2DM) (5). 
Potential mechanisms that might link oscillating blood glucose with vascular pathology include 
oxidative stress and inflammatory processes, with enhanced apoptosis of vascular endothelial 
cells (6). 
2.1 
STUDY RATIONALE 
In registration trials (EDITION and BEGIN), both Toujeo and Tresiba took Lantus as active 
comparator and demonstrated comparable efficacy and lower hypoglycemia risk. Toujeo and 
Tresiba are both described to have advantages over Lantus in their PK and PD profiles after once 
daily dosing regimens by providing a flatter fluctuation of PK exposure and a more evenly 
distributed GIR, which is considered desirable for a basal insulin. 
The present study LPS14947 is designed to further explore similarities and differences between 
Toujeo and Tresiba in terms of the effect on continuous glucose profile, while the conventional 
glycemic control as measured by HbA1c is anticipated to be similar between the 2 treatments. 
2.2 
BACKGROUND 
Insulin glargine U300 (HOE901-U300) is a more concentrated formulation of insulin glargine 
U100 (HOE901), 21A-Gly-31B-32B-Di-Arg human insulin, a recombinant analog of human 
insulin providing a 24 hour basal insulin supply after a single-dose SC injection. Insulin glargine 
U100 has been marketed as Lantus® for more than 15 years. Its efficacy and safety are 
well-known through extensive data collection involving over 100 000 patients in clinical studies, 
including randomized, controlled clinical trials and the results of post marketing surveillance 
arising from approximately 30 million patient-years of clinical experience. The more sustained 
release of insulin glargine Toujeo (insulin glargine U300) compared to insulin glargine 100 U/mL 
is attributable to the reduction of the injection volume by two thirds that results in a smaller 
precipitate surface area. Further information on Toujeo, including important clinical trials 
performed pre and post registration, can be found in the National Product Label (7). 
As observed in euglycemic clamp studies in patients with type 1 diabetes (PKD10086, PKD11627 
and TDR11626) after a single dose or multiple doses in healthy subjects or patients with T1DM, 
there are differences between Lantus and Toujeo in PK/PD profiles. The prolonged and flatter 
profile of the glucose-lowering activity of Toujeo (up to 36 hours) results in more constant 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 20 
glycemic control within a 24 hour injection interval and beyond, resulting in less circadian 
fluctuation in blood glucose levels and affording greater flexibility in dosing time (1). Given these 
features of the PK/PD profiles, Toujeo is considered to be well suitable for constant, peakless 
24-hour basal insulin supply in diabetes management, with the expectation of less hypoglycemic 
risk at equal to tighter blood glucose control. 
Clinical implication of Toujeo in management of type 1 diabetes was investigated in clinical 
studies in patients with T1DM. The EDITION-4 phase 3 trial in patients with T1DM showed 
similar therapeutic efficacy between Toujeo and Lantus with respect to glucose lowering, while a 
slightly lower risk of hypoglycemia was observed for Toujeo. Confirmed or severe nocturnal 
hypoglycemia was generally lower with Toujeo compared with Lantus, the incidence of 
confirmed or severe hypoglycemia at any time of day was equal or lower (8). 
PDY12777 was a small-scale (59 patients divided into 4-treatment arms) exploratory study using 
continuous glucose monitoring system (CGM), which provided sufficient data for diurnal glucose 
patterns associated with Toujeo or Lantus treatment. CGM analysis in participants with T1DM 
showed better glucose stability and lower intra-patient glucose variability with Toujeo than 
Lantus. These differences were more evident with the morning injection regimen. Moreover, the 
incidence of confirmed or severe hypoglycemic events was numerically lower with Toujeo than 
with Lantus. However, neither of the two studies was sufficiently powered to demonstrate reduced 
rates of hypoglycemia with Toujeo (9). 
Tresiba is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, 
resulting in a depot from which insulin degludec is continuously and slowly absorbed into the 
circulation leading to a flat and stable glucose-lowering-effect. During a period of 24 hours with 
once-daily treatment, the glucose-lowering effect of Tresiba, was evenly distributed between the 
first and second 12 hours. This recombinant analog of human insulin provides basal insulin supply 
beyond 42 hours after injection in euglycemic clamp conditions in type 1 diabetes (2).  
It has been approved in the US, European Union, Japan and other parts of the world. Further 
information on Tresiba can be found in the National Product Label (10). 
The efficacy and safety of Tresiba were demonstrated in BEGIN program. The impact of Tresiba 
on HbA1c was comparable with insulin Lantus but with reduced risk of hypoglycemia mainly 
during the protocol defined nocturnal period (11). 
A trial comparing the efficacy of insulin degludec with insulin glargine on glycemic control using 
CGM in patients with type 1 diabetes has shown that time within the glycemic target range 
(>70 mg/dL [>3.9 mmol/L] and <130 mg/dL [<7.2 mmol/L]) measured by CGM in the last 
4 hours of each dosing interval during the last 2 weeks of the 6-week treatment period was 
1.39 hours (SD 0.71) and 1.09 hours (0.77) respectively in insulin degludec and insulin glargine 
U100 arms respectively (12). 
Study LPS14585 compared the PD and PK properties of 0.4 and 0.6 U/kg/day insulin glargine 
(Toujeo) with the same dose levels of insulin degludec (Tresiba). At a dose level of 0.4 U/kg/day 
at steady state, the individual fluctuations of the glucose infusion rate (GIR) over the dosing 
interval of 24 hours (GIR-smFL0-24) were significantly lower following treatment with Toujeo 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 21 
compared to insulin degludec. The point estimate (90% CI) for the ratio of the PD parameter 
GIR-smFL0-24 for Toujeo versus insulin degludec was 0.80 (0.66 to 0.96) with a corresponding 
p-value of 0.047, indicating 20% less within-day variability of the glucodynamic profile for 
Toujeo versus insulin degludec in this clinically relevant dose (0.4 U/kg/day) for T1DM patients. 
In a recent comparative RCT (BRIGHT trial) where Toujeo was directly compared to Tresiba in 
previously insulin-naïve patients with T2DM, non-inferiority was shown in efficacy while 
hypoglycemia was found to be lower for Toujeo in the insulin titration period (week 0-12) with 
comparable rates in the maintenance period (week 13-24) (13). 
2.3 
BENEFIT/RISK ASSESSMENT 
Within the context of this Phase 4 study, a favorable risk-benefit assessment for the 
Investigational medicinal products (IMPs) (Toujeo and Tresiba) is already well established. The 
use of both drugs in this study is according to the approved National Product Label. 
With the exception of minimal laboratory assessments at screening, the study procedures 
(including the use of CGM) are consistent with the standard-of-care for these patients. The risks 
arising from the minimal blood sampling required by the protocol and also for the CGM sensor 
placement (limited to infrequent occurrence of local skin reaction) are low. 
Potential benefits to participants arise from the opportunity for treatment optimization and the 
availability of the CGM data following unblinding. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of Toujeo and Tresiba may be found in the Summary of Product Characteristics. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 22 
3 
OBJECTIVES AND ENDPOINTS 
Table 1 - Objectives and endpoints 
Objectives 
Endpoints 
Primary 
To demonstrate the noninferiority of insulin glargine 300 U/mL 
in comparison to insulin degludec 100 U/mL on glycemic 
control and variability in participants with diabetes mellitus 
Percent time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to 
≤10 mmol/L) at Week 12, obtained using continuous glucose 
monitoring (CGM) 
Secondary 
To evaluate the glycemic control and variability parameters in 
each treatment group at Week 12 using CGM 
At Week 12, the following endpoints will be assessed: 
 
Glucose total CV  
 
Glucose within-day and between-day CV  
Other secondary endpoints: 
 
Change from baseline to Week 12 in HbA1c 
 
Change from baseline to Week 12 in central lab FPG 
 
Percent time and mean hours per day with 
glucose<70mg/dL (on all time and during the night 
[00:00 to 05:59]) 
 
Percent time and mean hours per day with 
glucose>180mg/dL 
To evaluate the safety of insulin glargine 300 U/mL in 
comparison to insulin degludec 100 U/mL  
Number of participants with adverse events (see Section 8.3)  
Number of participants with at least one hypoglycemic event 
from baseline to Week 12 
Number of hypoglycemic events per participant year from 
baseline to Week 12 
Tertiary/exploratory 
To explore the glycemic control and variability parameters in 
each treatment group at Week 12 using CGM 
Mean hours per day in the glucose range of ≥70 to ≤180 mg/dL 
(≥3.9 to ≤10 mmol/L) 
Percent time and mean hours per day in the glucose range of 
≥70 to ≤140 mg/dL (≥3.9 to ≤7.8 mmol/L) (on all-time and 
during the night [00:00 to 05:59]) 
Nocturnal percent time in glucose range of ≥70 to ≤180 mg/dL 
(≥3.9 to ≤10 mmol/L) at Week 12, obtained using CGM 
Percent time and mean hours per day with glucose: <54 mg/dL, 
(on all time and during the night [00:00 to 05:59]) 
Percent time with glucose <70 mg/dL within the 12 hours after 
basal insulin injection 
Percent time and mean hours per day with glucose >250 mg/dL 
Mean glucose profile over 24-hour period 
24h-AUC 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 23 
Objectives 
Endpoints 
Daily insulin doses (total daily insulin, total basal insulin, total 
bolus insulin, ratio of basal to bolus insulin dose) in units and 
U/kg body weight 
Change from baseline to week 12 in patient-reported outcomes 
(treatment satisfaction, sleep quality and quantity, and 
productivity)  
7-point SMPG profiles (preprandial and 2-hour postprandial 
plasma glucose at breakfast, lunch dinner and bedtime) at 
Week 12 and change in 7-point SMPG profiles from baseline to 
Week 12 
3.1 
APPROPRIATENESS OF MEASUREMENTS 
The primary efficacy endpoint is based on the CGM recording to be collected during 
Weeks 10-12, representing the last 3 weeks of the 12 week IMP (either Toujeo or Tresiba) 
treatment period by which time stable doses are anticipated (ie, IMP titration phase expected to be 
up to Week 8, see Section 6.6.1.2). 
Secondary analyses will be performed to evaluate the therapeutic feature of a flatter and longer 
duration of Toujeo compared to Tresiba over at least 24 hours, which should result in more 
sustained glycemic control, and less hypoglycemia during nighttime. The assessment will be 
measured by the secondary and exploratory endpoints of: the incidence rate of nocturnal 
documented symptomatic hypoglycemia, and the variability analyses of CGM profiles. 
The CGM system allows frequent glucose measurements (every 5 minutes) and the ability to 
analyze glucose distributions in real time (14, 15). Use of this approach in a clinical study 
provides the opportunity to better understand glucose metabolism associated with the study IMP. 
This approach has been employed previously in studies of the efficacy of long-acting insulins in 
patients with diabetes. 
Mealtime insulin titration will also be implemented to achieve the postprandial SMPG targets. 
Thus, the glycemic control measured by laboratory HbA1c and FPG at Week 12 is expected to be 
similar between the two treatments.  
Frequent SMPG assessment values will be used to guide the insulin dose titration and to support 
the analyses of 7-point SMPG profile and hypoglycemia reports. At Visits 6, 14, 15 and 18 the 
SMPG data will be uploaded from the glucometer onto the site computer so that the Investigator 
and study staff are able to check the patient’s comprehension and compliance with dose 
adjustments and diary completion and to identify potential non-reported episodes of 
hypoglycemia. Safety analyses include a thorough hypoglycemia analysis on incidence rate, 
proportion of patients with hypoglycemia and the diurnal distribution of hypoglycemia. These 
analyses will be performed based on the SMPG and the hypoglycemic events reported by the 
patients. Patients will be instructed to measure SMPG whenever they feel hypoglycemic. This 
aims to detect and confirm as many hypoglycemic episodes as possible. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 24 
Sponsor will implement the monitoring of titration for both basal and meal time insulins to ensure 
optimal dosing.  
Patient-Reported Outcomes (PRO):  
Patients will complete self-reported questionnaires at designated time points in the study: 
The Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs and 
DTSQc, respectively) (16, 17) will be used to evaluate patient satisfaction with treatment and 
patient perception of blood glucose control over a several-week period.  
The MOS Sleep questionnaire will be used to measure patient perception on key aspects of sleep 
(18). The WPAI will be used to measure absenteeism, presenteeism and work productivity (19).  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 25 
4 
STUDY DESIGN 
4.1 
OVERALL DESIGN 
This is a multicenter, randomized, active-controlled, parallel-group, 12-week open-label study. 
The study consists of a 1- or 2–week screening period, followed by a 4-week run-in period, and a 
12-week randomized treatment period. 
During the first 2 weeks of the run-in period (Weeks -4 and -3), patients will undergo treatment 
stabilization of their current basal and mealtime insulin treatment, and will be trained and tested 
on how to perform study-related procedures. During the (-)3 – (-)1 weeks of run-in, patients will 
wear a CGM device, blinded both to patients and Investigators. This will be the baseline CGM 
period, when during 20 consecutive days, a minimum of (10 days, not necessarily consecutive) of 
useable CGM data must be generated, to be eligible for randomization. 
Patients satisfying the study inclusion/exclusion criteria (including CGM performance 
requirements) will be randomized in a 1:1 ratio to morning injections of either Toujeo or Tresiba, 
which will replace the patient’s current basal insulin. 
An interactive response technology (IRT) will be configured and randomization will be stratified 
by HbA1c at screening (<8.0%; ≥8.0%). 
During the randomized treatment period, CGM data (blinded to both patients and Investigators) 
will be collected during Weeks 9-12 during 20 consecutive days. 
The basal insulin injection will be once daily in the morning, defined as the time period between 
waking up and breakfast. The injection time will be discussed between the Investigators and 
patients at randomization and should be kept consistent at the same time each day. 
During the entire study starting after the screening period, patients will perform SMPG as 
specified in the study flow chart. The SMPG readings will be used to guide insulin dose titration 
for optimal glycemic control.  
Appropriate dose titration of basal and mealtime insulin will be implemented as described in the 
dose regimen section. 
At the end of the study, the patients will be followed-up from 2 to 4 days after last IMP dose to 
collect posttreatment safety information. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 26 
4.2 
SCIENTIFIC RATIONALE FOR STUDY DESIGN 
The fluctuations in blood glucose, regular short-duration periods of hyperglycemia and 
hypoglycemia, which are not detected by the measurements of HbA1c, may possibly contribute to 
vascular pathological processes and diabetic complications. This association may be independent 
of average glucose exposure expressed by HbA1c. This hypothesis remains controversial, but 
stems from the observation that intensive (versus standard) glucose control in the DCCT was 
associated with reduced risk for retinopathy after correcting for HbA1c (4). Supportive 
observations report that the coefficient of variation of FPG independently predicted mortality in 
T2DM (5). Potential mechanisms that might link oscillating blood glucose with vascular 
pathology include oxidative stress and inflammatory processes, with enhanced apoptosis of 
vascular endothelial cells (6). 
This is a randomized, active-controlled, 12-week open-label study to compare the efficacy of 
Toujeo with Tresiba using CGM glucose profiles, sampling ambulatory glucose level every 
5-minutes over a 20-day period at Week 12. The CGM during study period will be blinded to both 
the Investigators and patients. 
Eligible patients will be randomized to either Toujeo or Tresiba, both given once-daily by SC 
injection in the morning. Patients allocated to Toujeo or Tresiba groups will switch from their 
previous basal insulin. During 4 weeks of the run-in period, patients will be required to titrate 
their basal and mealtime insulin to optimize the fasting and 2-hour postprandial self-monitoring of 
plasma glucose (SMPG) targets. The baseline CGM will be performed during the last 3 weeks of 
run-in.  
The primary objective of the study is to explore the percent of time in target CGM glucose range 
of 70-180 mg/dL with Toujeo versus Tresiba treatment at 12 weeks of treatment. In addition, all 
hypoglycemia incidence and distribution (24 hours and nocturnal) will be analyzed according to 
the American Diabetes Association (ADA) classification (severe, documented symptomatic, 
asymptomatic, probable and relative) (20). Glucose stability and variability will be assessed 
between and within each group via measurements of glucose CV. 
A relatively homogenous patient population will be selected, reducing potential confounding 
effects, so that the true differences in the therapeutic effects of Toujeo versus Tresiba can be 
assessed. The study population includes patients 18-70 years of age with T1DM, on a basal plus 
mealtime insulin regimen for at least one year, and HbA1c level ≥7% and <10%. Patients must be 
on a stable dose of basal/bolus insulin regimen for 30 days before screening. 
Repeat assessments of selected PROs will be performed during the study as the exploratory 
analyses (including patient satisfaction with treatment and patient perception of blood glucose 
control assessed by Diabetes Treatment Satisfaction Questionnaire [status and change 
version - DTSQs and DTSQc], MOS Sleep Scale to measure key aspects of sleep and the Work 
Productivity and Activity Impairment Questionnaire [WPAI]- Diabetes; assessing the impairment 
on daily work and activities due to diabetes) in order to reveal any potential link between 
improvement in continues glucose profile and patient well-being. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 27 
4.3 
JUSTIFICATION FOR DOSE 
During the first 2 weeks of the run-in period (Weeks -4 and -3), patients will be required to titrate 
their basal and mealtime insulin to stabilize the fasting and 2-hour postprandial SMPG targets of 
≥70 to <100 mg/dL (≥3.9 to <5.6 mmol/L) while avoiding hypoglycemia episodes. 
At randomization, the initiation doses of Toujeo and Tresiba will be the patient’s current doses of 
their basal insulin on a unit-to-unit basis. 
Dose adjustments will be based on a median of fasting SMPG values from the last 3 days, which 
will include the value measured on the day of titration, measured by the patient using glucometers 
and accessories supplied by the Sponsor. Appropriate dose titration of IMP and mealtime insulin 
is expected to be up to Week 8. 
During the randomized treatment period, IMP injection will be administered once daily each 
morning at the same time. 
4.4 
END OF STUDY DEFINITION 
A participant is considered to have completed the study if he/she has completed all phases of the 
study including a 2 to 4 day follow-up period. 
The end of the study is defined as the date of the “last patient last visit” planned with the protocol, 
including the follow-up visit. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 28 
5 
STUDY POPULATION 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1 
INCLUSION CRITERIA 
Participants are eligible to be included in the study only if all of the following criteria apply: 
Age 
I 01. Participant must be 18 to 70 years of age inclusive, at the time of signing the informed 
consent. 
Type of participant and disease characteristics 
I 02. Participants with T1DM. 
I 03. Participants treated with multiple daily injections (MDI) using basal insulin analog once 
daily and rapid acting insulin analogs for at least one year. 
I 04. HbA1c ≥7% (48 mmol/mol) and ≤ 10% (86 mmol/mol) at screening. 
Sex 
I 05. Male or Female 
a) Female participants: A female participant is eligible to participate if she is not pregnant 
(see Appendix 4 [Section 10.4]), not breastfeeding, and at least one of the following 
conditions applies: 
- 
Not a woman of childbearing potential (WOCBP) as defined in Appendix 4 
(Section 10.4), 
OR 
b) A WOCBP who agrees to follow the contraceptive guidance in Appendix 4 (Section 10.4) 
during the intervention period. 
Informed Consent 
I 06. Capable of giving signed informed consent as described in Appendix 1 (Section 10.1.2) 
which includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 29 
5.2 
EXCLUSION CRITERIA  
Participants are excluded from the study if any of the following criteria apply: 
Medical conditions 
E 01. Any clinically significant abnormality identified either in medical history or during 
screening evaluation (eg, physical examination, laboratory tests, ECG, vital signs) , or any 
AE during screening period which, in the judgment of the investigator, would preclude 
safe completion of the study or constrains efficacy assessment. 
E 02. End stage renal disease defined as estimated glomerular filtration rate (GFR) modification 
of diet in renal disease (MDRD) <15 mL/min/1.73 m² or on renal replacement treatment. 
E 03. Laboratory findings at screening: 
 
ALT or AST >3 x ULN or total bilirubin >1.5 x ULN (except in case of documented 
Gilbert’s syndrome). 
 
Fasting C-peptide >0.2 nmol/L. 
E 04. Retinopathy or maculopathy with one of the following treatments, either recent (within 
3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy 
surgery. 
E 05. Body weight change ≥5 kg within 3 months prior to screening 
Prior/concomitant therapy 
E 06. Participants not on stable dose of basal insulin analog (±20% total daily dose) for at least 
30 days prior to screening. 
E 07. Participants having received Toujeo or Tresiba as basal insulin within 30 days prior to 
screening. 
E 08. Participants not using the same insulins (both basal and rapid) within 30 days prior to 
screening. 
E 09. Participants having received basal insulin dose ≥0.6 U/kg body weight within 30 days prior 
to screening. 
E 10. Participants having received any glucose lowering drugs (including any premixed insulins, 
human regular insulin as mealtime insulins, any others injectable or oral), other than basal 
and rapid insulin analogs, within 3 months prior to screening. 
E 11. Participants having received glucocorticoids (excluding topical application or inhaled 
form) for more than 10 days within 3 months prior to screening. 
E 12. Participants having used insulin pump within 6 months prior to screening. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 30 
E 13. Participants who will need real time, flash or implantable CGM for routine care any time 
during study participation. 
Prior/concurrent clinical study experience 
E 14. Exposure to any investigational drug in the last 4 weeks or 5 half-lives, whichever is 
longer, prior to screening or concomitant enrollment in any other clinical study involving 
an investigational study treatment. 
Diagnostic assessments 
Not applicable. 
Other exclusions 
E 15. Any contraindication to use of Toujeo, Tresiba and rapid insulin analogs according to the 
national product label. 
E 16. Sensitivity to any of the study interventions, or components thereof, or drug or other 
allergy that, in the opinion of the Investigator, contraindicates participation in the study. 
E 17. Night shift workers. 
E 18. Individuals accommodated in an institution because of regulatory or legal order; prisoners 
or subjects who are legally institutionalized. 
E 19. Participants dependent on the Sponsor or Investigator (in conjunction with section 1.61 of 
the ICH-GCP Ordinance E6). 
E 20. Participants are employees of the clinical study site or other individuals directly involved 
in the conduct of the study, or immediate family members of such individuals. 
Additional criteria at the end of the run-in period 
E 21. Participants unwilling or unable to comply with study procedures as outlined in the 
protocol. 
E 22. Participants who withdraw consent during the screening (starting from signed ICF). 
E 23. Inappropriate CGM use during run-in period evidenced by failure to obtain a minimum of 
(10 days, not necessarily consecutive) of useable CGM data by the end of run-in (see 
Section 8.1.1.2 for the definition of useable CGM data). 
5.3 
LIFESTYLE CONSIDERATIONS 
Lifestyle and diet therapy provided before the time of screening is to be continued during the 
study. Dietary and lifestyle counseling will be given by a healthcare professional and compliance 
will be checked as per SoA (Section 1.3) and should be consistent with international or local 
guidelines for patients with T1DM (with regard to the distribution of calories among 
carbohydrates, proteins, and fats, exercise, etc).  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 31 
5.4 
SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomly assigned to study intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond 
to queries from regulatory authorities. Minimal information includes demography, screen failure 
details, eligibility criteria, and any serious adverse event (SAE). 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened in cases where original screen failure was due to reasons expected to change at 
rescreening and based upon the Investigator’s clinical judgment. Rescreened patients will be 
subject to the screening visit procedures/assessments (see following paragraphs) including new 
informed consent signed and allocation of a new patient number. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 32 
6 
STUDY INTERVENTION 
Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study 
protocol. 
6.1 
STUDY INTERVENTION(S) ADMINISTERED 
Table 2 - Overview of study interventions administered 
Study 
intervention name 
Toujeo 
Tresiba 
Dosage formulation 
Toujeo (insulin glargine 300 U/mL) is supplied as 
a sterile, non-pyrogenic, clear, colorless solution 
for SC injection in the Toujeo SoloStar prefilled, 
disposable pen. 
Tresiba (insulin degludec 100 U/mL) is supplied 
as a sterile, non-pyrogenic, clear, colorless 
solution for SC injection in the marketed Tresiba 
FlexTouch prefilled, disposable pen. 
Unit dose 
strength(s)/Dosage 
level(s) 
Each Toujeo SoloStar contains in total 450 units 
of insulin glargine (1.5 mL of 300 U/mL insulin 
glargine solution). Mixing of Toujeo with other 
insulin products or dilution is not allowed 
Each Tresiba FlexTouch contains in total 
300 units of insulin degludec (3 mL of 100 U/mL 
insulin degludec solution). Mixing of Tresiba with 
other insulin products or dilution is not allowed. 
Route of administration 
SC self-injection 
SC self-injection 
Dosing instructions 
Toujeo will be self-administered by SC injection 
once daily in the morninga, which is defined as 
the time period between waking up and 
prebreakfast. The clock time for the morning 
injection (hh:mm) will be established at the 
discretion of the patient/Investigator at the time of 
randomization and will be maintained for the 
duration of the study. 
Injection site should be alternated between the 
left and right anterolateral and left and right 
posterolateral abdominal wall or thighs or upper 
armsb.  
Tresiba will be self-administered by SC injection 
once daily in the morninga, which is defined as 
the time period between waking up and 
prebreakfast. The clock time for the morning 
injection (hh:mm) will be established at the 
discretion of the patient/Investigator at the time 
of randomization and will be maintained for the 
duration of the study. 
Injection site should be alternated between the 
left and right anterolateral and left and right 
posterolateral abdominal wall or thighs or upper 
armsb.  
Packaging and labeling 
Toujeo SoloStar pens will be supplied as open 
label treatment kits containing 5 Toujeo SoloStar 
pens. Each SoloStar pen will be labeled as 
required per country requirement. Treatment 
labels will indicate the treatment number used for 
treatment allocation. The Investigator’s name, the 
patient number and visit number will be entered 
manually by the site staff on the treatment box 
label prior to dispensing. 
Tresiba FlexTouch pens will be supplied as open 
label treatment kits containing 5 Tresiba 
FlexTouch pens. Each FlexTouch pen will be 
labeled as required per country requirement. 
Treatment labels will indicate the treatment 
number used for treatment allocation. The 
Investigator’s name, the patient number and visit 
number will be entered manually by the site staff 
on the treatment box label prior to dispensing. 
a Patients taking their current basal insulin at any time (eg, evening) other than in the morning should switch their injection time to the morning 
at randomization. The instruction on changing injection time should be given by the Investigator in accordance with the National Product 
Label of the patient’s current basal insulin. On the day of switching injection time, the total dose of current basal insulin and the pre breakfast 
(if applicable) rapid action insulin may need to be reduced based on the physician’s medical judgment. For example, on the day before 
changing injection time, the dose of the current basal insulin may be changed to approximately 1/2 to 2/3 of the total daily dose, which would 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 33 
then be injected in the evening as the patient’s usual injection time. On the following day, the dose of randomly assigned basal insulin (IMP) 
will be equal to the total daily current basal insulin dose and injected in the morning before breakfast. 
b Within a given area, location should be changed (rotated) at each time to prevent injection site skin reactions.The injection sites for IMP and 
noninvestigational medicinal product (NIMP) should be different so that, if any, an injection site reaction can be attributed specifically either to 
IMP (Toujeo or Tresiba) or NIMP (mealtime insulin). 
INVESTIGATIONAL MEDICINAL PRODUCT(S) 
An instruction leaflet, which explains how to use the disposable pen and needles, will be provided 
for Toujeo and Tresiba. All patients will be trained by study staff at Visit 6 (randomization) on 
how to use the pen correctly, how to rotate injection site to avoid skin reactions, how to store the 
pen and how to change the needle. Training will be repeated as often as deemed necessary by 
study site staff during the treatment period. For the duration of the treatment, patients will be 
required to use the same type of study drug disposable pens and needles. Each patient will be 
supplied with the appropriate number of pens according to the dispensing scheme indicated in the 
SoA (see Section 1.2). 
Toujeo (insulin glargine 300 U/mL) 
Toujeo will be self-administered with the prefilled, disposable Toujeo SoloStar pen specifically 
labeled for use in the study. This pen allows dose setting in the range of 1–80 units with minimum 
of 1 unit increment. The dose of Toujeo is titrated according to the patient’s need for insulin 
glargine. 
The following pen needles will be provided for use with the disposable injection pen devices: 
 
BD Ultra Fine Needles 31 G x 5 mm. 
 
BD Ultra Fine Needles 31 G x 8 mm. 
Tresiba (insulin degludec 100 U/mL) 
Tresiba will be self-administered with the prefilled, disposable Tresiba FlexTouch pen specifically 
labeled for use in this study. This pen allows dose setting in the range of 1–80 units with 
minimum of 1 unit increment. The dose of Tresiba is titrated according to the patient’s need for 
insulin degludec 
The following pen needles will be provided for use with the disposable injection pen devices: 
 
BD Ultra Fine Needles 31 G x 5 mm. 
 
BD Ultra Fine Needles 31 G x 8 mm. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 34 
NONINVESTIGATIONAL MEDICINAL PRODUCT(S) 
The protocol-mandated background therapy is mealtime insulin analog, ie, rapid insulin analogs 
(eg, insulin glulisine, insulin lispro or insulin aspart). Patients in both treatment groups will 
continue with their short-acting mealtime insulin analogue which has been used for at least 
30 days before the screening visit and which will be continued throughout the study. The cost of 
the mealtime insulin analogue may be reimbursed if not covered by health insurance and if 
allowed by local regulations. Alternatively, the sponsor provided insulin glulisine may be offered. 
Dose adjustment of mealtime insulin can be based on a pattern of post-meal SMPG data from the 
prior 3 days (simple titration) OR the carbohydrate content of the meal. The injection sites should 
be different from the IMP (Toujeo or Tresiba) for the fast-acting mealtime insulin analogs so that 
any injection site reactions can be attributed specifically either to the fast-acting insulin or to the 
IMP. Changes in the body areas used for injection of basal (current during run-in or IMP during 
the randomized treatment period) and mealtime insulin should be avoided as far as possible during 
the study. 
6.1.1 Devices 
CGM  
Dexcom G6 device will be used for continuous glucose monitoring. 
 
Glucometers  
Roche Accucheck glucometers will be provided and used for SMPG measurements by patients.  
6.2 
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
Investigators or other authorized persons (eg, Pharmacists) are responsible for storing the 
IMP/NIMP in a secure and safe place in accordance with local regulations, labeling specifications, 
policies, and procedures. 
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported 
and resolved before use of the study intervention. 
Only participants enrolled in the study may receive study intervention and only authorized site 
staff may supply or administer study intervention. All study intervention must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance with 
the labeled storage conditions with access limited to the Investigator and authorized site staff. 
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records). 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 35 
Any quality issue noticed with the receipt or use of an IMP/NIMP/device (deficiency in condition, 
appearance, pertaining documentation, labeling, expiration date, etc) must be promptly notified to 
the Sponsor. Some deficiencies may be recorded through a complaint procedure (see  
Section 8.3.6). 
A potential defect in the quality of IMP/NIMP/device may be subject to initiation of a recall 
procedure by the Sponsor. In this case, the Investigator will be responsible for promptly 
addressing any request made by the Sponsor, in order to recall the IMP/NIMP/device and 
eliminate potential hazards. 
Under no circumstances will the Investigator supply IMP/NIMP/device to a third party (except for 
DTP shipment, for which a courier company has been approved by the Sponsor), allow the 
IMP/NIMP/device to be used other than as directed by this clinical trial protocol, or dispose of 
IMP/NIMP/device in any other manner. 
The expiry date is mentioned on the IMPs labels, and storage conditions are written on the IMPs 
labels and in the instruction leaflet. Patients are responsible for the correct storage of “not in-use” 
and “in-use” pens after it is dispensed at the site. 
All used, partially-used or unused treatments will be retrieved by the Sponsor. A detailed 
treatment log of the returned IMP will be established with the Investigator (or the Pharmacist) and 
countersigned by the Investigator and the monitoring team. 
The Investigator will not destroy any IMP unless the Sponsor provides written authorization.  
A potential defect in the quality of IMP may initiate a recall procedure by the Sponsor. In this 
case, the Investigator will be responsible for promptly addressing any request made by the 
Sponsor, in order to recall IMP and eliminate potential hazards. 
As NIMP will not be provided by the Sponsor, return and destruction will not be required. The 
cost of the mealtime insulin analogue may be reimbursed if not covered by health insurance and if 
allowed by local regulations. Alternatively, the sponsor provided insulin glulisine may be offered. 
6.3 
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING 
As Toujeo and the control drug Tresiba are distinguishable, this study is an open-label design, and 
no attempt will be made to blind the randomly assigned study treatment. 
The Clinical Supplies Trial Supply Operations Manager will provide the treatment kit number list 
and the Study Biostatistician will provide the randomization scheme to the IRT. IRT will then 
generate the patient randomization list according to which it will allocate patients to either 
treatment arm. 
The IMPs will be provided in open-label boxes and each type of kit is identified with a treatment 
number. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 36 
At the screening visit, the Investigator or designee will contact the IRT center to receive the 
patient number. This patient number is composed of a 12-digit number containing the 3-digit 
country code, 4-digit center code, and the 5-digit patient chronological number (which is 00001 
for the first patient screened in a center, 00002 for the second patient screened in the same center, 
etc).  
Patients can be re-screened once before randomization in case of non-eligibility or in cases where 
original screen failure was due to reasons expected to change at rescreening and based upon the 
Investigator’s clinical judgment. Re-screened patients will be subject to the screening visit 
procedures/assessments including new informed consent signed and allocation of a new patient 
number.  
Before randomization, baseline CGM results with accompanying CGM summary report certifying 
compliance with requirements MUST be available. In order for a patient to be randomized the 
baseline CGM performance (during Weeks -3 to -1) must reflect at least 10 days (not necessarily 
consecutive) of useable 24-hour CGM data (see Section 8.1.1.2 for the definition of useable data). 
At Visit 6, only after patient eligibility is confirmed, the Investigator or designee will call the IRT 
for patient randomization and first treatment kit(s) allocation. 
Only eligible patients will be randomized at a 1:1 ratio to receive Toujeo or Tresiba for 12 weeks. 
Randomization will be stratified by HbA1c at screening (<8.0%; ≥8.0%).  
A randomized patient is defined as a patient who is registered and assigned with a randomized 
treatment arm from the IRT, as documented from IRT log file, regardless of whether the treatment 
kit was used or not. 
The IRT will be contacted at each time a treatment kit(s) allocation is necessary, ie, at Visit 6 
(randomization) and also at Visit 14.  
A patient cannot be randomized more than once to the study. 
Complete details of potential instances requiring the site to contact the IRT are provided in 
Section 1.3. 
Compensation for lack of blinding 
Given the open-label administration of study treatments (basal insulin during the treatment 
period), the assessment of outcomes will be based on objectively collected data, which will be 
blinded for CGM (primary and secondary endpoints) and open for SMPG data (secondary 
endpoints). 
Neither the patient, the Investigator nor the Sponsor will have access to the individual data for the 
primary efficacy parameter (CGM records) obtained from each patient so as to avoid patients and 
Investigators making treatment decisions based on the data for the primary endpoint. The CGM 
receiver’s screen will be blocked of displaying data. The CGM data will be uploaded to a separate 
server which assures maintenance of the blind with vendor software and a report summary with 
daily CGM performance will be available immediately. Investigators will not be able to see the 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 37 
recorded glucose values, nor will the report include any real glucose data. However, transfers of 
CGM related to the Sponsor team will be performed during the study for data review purpose, 
with the name of the IMP treatment masked. 
The SMPG records in the patient diaries (and complete data at study visits where there is a 
download of SMPG data) enable Investigators to monitor the patients comprehension of the study 
requirements, identify unreported episodes of hypoglycemia, and also to guide the dose of basal 
(current during run-in, IMP during the randomized treatment period) and mealtime insulin dosage; 
hence these data are not blinded for the Investigator and the patient as they are required for 
managing the patient’s care during the study.  
The Sponsor study team, except individuals who have access to patients’ source documents (eg, 
local monitoring team, auditors) will remain blinded to the treatment arm of individual patients 
throughout the study up to the database lock. All analyses and data review before database lock 
will be performed blindly. Supplemental documentation will detail the exact measures to be kept 
in place to manage the risk of inadvertent unblinding of the study team. 
6.4 
STUDY INTERVENTION COMPLIANCE 
6.4.1 Drug accountability 
A Treatment Log Form for returned and dispensed IMP will be kept for each patient. Patients will 
return to the site with used and unused IMP at Visits 14 and 18. The Investigator or delegate will 
inspect IMP remaining in the returned packs and compare to dosing records documented in the 
patients’ diaries. Discrepancies will be addressed to the patient for clarification on treatment 
compliance. The Investigator will complete the appropriate Treatment Log Form based on the 
used/unused IMP (study drug pens) returned. 
6.4.2 Training to use injection devices 
An instruction leaflet, which explains how to use the disposable pen and needles, will be provided 
for Toujeo and Tresiba. All patients will be trained by study staff at Visit 6 (randomization) on 
how to use the pen correctly, how to rotate injection site to avoid skin reactions, how to store the 
pen and how to change the needle. Training will be repeated as often as deemed necessary by 
study site staff during the treatment period. For the duration of the treatment, patients will be 
required to use the same type of study drug disposable pens and needles. Each patient will be 
supplied with the appropriate number of pens according to the dispensing scheme indicated in the 
SoA (see Section 1.3). 
Patients must be reminded by study staff of the following instructions: ‘Injection pens should 
never be shared with others, even if the needle is changed. Always use a new needle for each 
injection to help ensure sterility and prevent blocked needles. Do not reuse or share needles with 
another person’.  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 38 
6.5 
CONCOMITANT THERAPY 
Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with: 
 
Reason for use. 
 
Dates of administration including start and end dates. 
 
Dosage information including dose and frequency. 
During the study, the following medications are prohibited. 
 
Any glucose-lowering agents other than: 
- 
 the IMP (Toujeo or Tresiba), 
- 
the patient’s current background basal insulin analog during the run-in period (which 
may not be changed during the study), 
- 
the patient’s existing mealtime insulin (which may not be changed during the study).  
This includes oral or injectable glucose lowering agents, other type of basal insulin 
(eg, NPH), pre-mixed insulin, and human regular insulin, 
 
Insulin pump therapy is not allowed during the course of the study. 
 
Initiation of any weight loss drugs is not allowed; previous treatment with weight loss 
drugs can be continued and doses must remain stable throughout the study. 
 
Systemic glucocorticoids for more than 10 consecutive days (topical or inhaled 
applications are allowed). 
Other medications which are unlikely to interfere with the IMP and the study variables are 
allowed as needed and discussed with the Investigator. However, doses of chronically 
administered medicines should be kept fixed during the trial if at all possible. 
6.6 
DOSE MODIFICATION 
Note: During the first 2 weeks of the run-in period, patients will be required to titrate their basal 
and mealtime insulin to stabilize the fasting and 2-hour postprandial self-monitoring of plasma 
glucose (SMPG) targets.  
6.6.1 Basal insulin 
The patient’s basal insulin dose will be titrated with the objective of reaching a target fasting 
SMPG of ≥70 to <100 mg/dL (≥3.9 to <5.6 mmol/L) while avoiding hypoglycemia episodes 
(ie, this is identical to the algorithm to be used for IMP see Section 6.6.1.2). Note: fasting SMPG 
should be taken within 30 minutes prior to injection of current basal insulin (if applicable) and 
before breakfast. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 39 
6.6.1.1 Starting dose 
At randomization, the initiation doses of Toujeo and Tresiba will be the patient’s current doses of 
their basal insulin on a unit-to-unit basis. 
The first injection of IMP should occur on the day of randomization (Visit 6) under the 
supervision of the Investigator or the designated study staff. If for any reason, the patient could 
not inject the first dose at the study site, the first dose can be administered in the morning of the 
next day and the date and time will be documented in the electronic case report form (eCRF) for 
randomized basal insulin (IMP). 
6.6.1.2 Dose adjustment 
6.6.1.2.1 Dose adjustments based on target fasting SMPG  
During the titration phase (expected to be up to Week 8), doses of IMP (either Toujeo or Tresiba) 
will be titrated to achieve glycemic targets without hypoglycemia according to the algorithm 
outlined in Table 3. 
The IMP dose will be titrated at least weekly (but no more often than every 3 days), until the 
patient reaches a target fasting SMPG of ≥70 to <100 mg/dL (≥3.9 to <5.6 mmol/L) while 
avoiding hypoglycemia episodes. 
Dose adjustments will be based on a median of fasting SMPG values from the last 3 days, which 
will include the value measured on the day of titration, measured by the patient using glucometers 
and accessories supplied by the Sponsor. 
Table 3 - Basal insulin dose adjustments 
Mediana fasting pre-breakfast SMPG values 
(last 3 days)  
Basal insulin dose adjustments (U/day)b 
≥140 mg/dL (≥ 7.8 mmol/L) 
+4 units 
≥100 and < 140 mg/dL (≥5.6 and <7.8 mmol/L) 
+2 units 
≥70 and <100 mg/dL (≥3.9 and 
<5.6 mmol/L) 
No change 
≥56 and <70 mg/dL (≥3.1 and <3.9 mmol/L) 
-2 units 
<56 mg/dL (<3.1 mmol/L) or occurrence of 2 (or more) 
symptomatic hypoglycemic episodes or 1 severe 
hypoglycemic episode 
-4 units or at the discretion of the Investigator or medically 
qualified designee 
Abbreviation: SMPG = self-monitoring of plasma glucose 
a Median refers to intermediate SMPG value (the value between the lowest and the highest SMPG values when the values are ranked in a 
growing order). 
b Prior to additional basal insulin titration, mealtime insulin should be titrated to achieve a bedtime and pre-breakfast glucose delta <50 mg/dL, 
if so considered helpful by the Investigator. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 40 
Regular SMPG is very important in order to achieve blood glucose targets. It is necessary to 
perform daily fasting/pre-breakfast SMPG and postprandial measurements (Section 8.1.4) to 
support the titration. More frequent SMPG at other time-point may be needed at the Investigator’s 
discretion. 
Patients will be familiarized with the adjustment schedule so that they will be able to monitor the 
dose adjustment with the assistance of the Investigator or medically qualified designee. During the 
study, contacts between the Investigator and patient are scheduled to assess the response to 
treatment and to decide on dose adjustment. During these visits, patients will report their SMPG 
data, insulin doses and hypoglycemia to the study site. 
If needed, additional contacts will be made available for patients to discuss dose adjustments 
in-between the scheduled visits. It is at the discretion of the Investigator to allow well-trained 
patients to make their IMP insulin dose adjustments in between the scheduled visits without prior 
consultation of the site personnel. 
The best efforts should be made to reach the target glucose by 8 weeks after randomization; 
thereafter, the dose should be maintained until the end of the study. If required, minimal dose 
adjustments may be considered at the discretion of the Investigator or medically qualified 
designee to achieve fasting SMPG target.  
6.6.1.2.2 Dose adjustment in cases of hypoglycemia 
Dose adjustment in cases of hypoglycemia will be as follows (refer to Section 8.2.4 for 
hypoglycemia definitions): 
 
Upward titration is to be stopped for 1 week after a case of severe hypoglycemia 
(requiring assistance) or ≥2 episodes of documented symptomatic hypoglycemia within a 
week, unless there was a manageable factor (eg, omission of a meal or overdosed insulin) 
for the event. 
 
Doses of basal insulin (IMP during the randomized treatment period and patient’s current 
medication during the run-in period) or mealtime insulin may be reduced or modified at 
any time for hypoglycemia during the study. 
 
Small decreases of the basal insulin dose (eg, 1 unit) are at the discretion of the 
Investigator or medically qualified designee, if SMPG is below 70 mg/dL (3.9 mmol/L) or 
if relevant hypoglycemia occurs.  
 
Patients who experienced mild to moderate hypoglycemia as a result of a missed meal, 
unusual exercise or alcohol use will be counseled on the correction of those behaviors and 
should not reduce their insulin dose.  
6.6.2 Mealtime insulin 
From Visit 2, the injection time (in relation to the meal intake) and frequency of mealtime insulin 
(ie, rapid-acting insulins: insulin glulisine, insulin lispro or insulin aspart) will be at the 
Investigator’s discretion, in accordance with the relevant National Product Labels. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 41 
The dose of the mealtime insulin analogs will be actively titrated to achieve a target of 2-hour 
postprandial plasma glucose. The dose adjustment regimen can be titrated based on a pattern of 
postprandial plasma glucose results of SMPG from the prior 3 days (simple titration based on a 
pattern of post-meal glucose median <130/>180 mg/dL) or based on the carbohydrate content of 
the meal (carb counting).  
The titration goal is a 2-hour postprandial SMPG in the range of ≥130 to ≤180 mg/dL (≥7.2 to 
≤10 mmol/L) while avoiding hypoglycemia. For the purpose of this protocol, 2-hour postprandial 
is defined as 2 hours after the start of the meal. 
Dose of mealtime insulin will be recorded in the patient’s diary and eCRF. Note: It is essential 
that this data is captured on the day of randomization. 
While basal insulin doses are increased, mealtime insulin doses may be reduced to avoid daytime 
hypoglycemia as deemed appropriate by the Investigator. 
Appropriate adjustment in mealtime insulin will continue throughout the study (Visits 2 to 18). 
The two regimens are described in Table 4 and Table 5. 
Table 4 - Rapid-acting insulin dose adjustment 
Mealtime dose of insulin 
Pattern of postprandial plasma 
glucose values <130 mg/dLa 
Postprandial plasma glucose 
values >180 mg/dLa 
≤10 units 
Decrease dose by 1 unit 
Increase dose by 1 unit 
≥11-19 units 
Decrease dose by 2 units 
Increase dose by 2 units 
≥20 units 
Decrease dose by 3 units 
Increase dose by 3 units 
a If more than half of the mealtime plasma glucose (2-hour postprandial plasma) values for the week were above target. 
Table 5 - Carb counting: insulin-to-carbohydrate ratio 
Mealtime dose of insulin 
Pattern of postprandial plasma 
glucose values <130 mg/dLa 
Pattern of postprandial plasma 
glucose values >180 mg/dLa 
1 unit/20 g 
Decrease to 1 unit/25 g 
Increase to 1 unit/15 g 
1 unit/15 g 
Decrease to 1 unit/20 g 
Increase to 1 unit/10 g 
1 unit/10 g 
Decrease to 1 unit/15 g 
Increase to 2 unit/15 g 
2 unit/15 g 
Decrease to 1 unit/10 g 
Increase to 3 unit/15 g 
3 unit/15 g 
Decrease to 2 unit/15 g 
Increase to 4 unit/15 g 
a If more than half of the mealtime plasma glucose values for the prior 3 days were above target 
Starting recommendation 1 unit to 15 grams carbs 
Consider calculating insulin to carb (I:C) ratio = 500/total daily dose (TDD) of insulin. 
Investigators will also be provided with an initial guideline of 1800/TDD as a correction factor to be used if applicable at the Investigators’ discretion. 
Dietary modifications (eg, snacks) will be made by the Investigator, dietician or other medically 
qualified person based on his/her best judgment. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 42 
6.6.3 Monitoring of insulin titration 
Sponsor will ensure the adequate monitoring of basal and mealtime insulin titration. The 
monitoring will be described in the Insulin-Dosing Supervision Manual. 
6.6.4 Evaluation of participants not meeting glycemic targets 
In case the target fasting glycemic goal cannot be achieved in spite of successive IMP dose 
titration over 8 weeks, the Investigator should ensure that no reasonable explanation exists for 
insufficient glucose control and in particular that: 
 
Plasma glucose was actually measured in fasting condition (eg, before breakfast within 
30 minutes window prior to injection). 
 
IMP and mealtime insulin are properly injected. 
 
There is no inter-current disease which may jeopardize glycemic control (eg, infectious 
disease). 
 
Compliance to diet and lifestyle is appropriate. 
 
If any of the above can reasonably explain the insufficient glycemic control, the 
Investigator should take appropriate action, eg,: 
- 
Adjust the IMP dose and mealtime insulin dose, 
- 
Check the compliance of IMP and mealtime insulin injection, 
- 
Evaluate and treat intercurrent disease (to be reported in AE)/ SAE/concomitant 
medication parts of the eCRF, 
- 
Organize a specific interview with a Registered Dietician or other medically qualified 
person to discuss with the patients on the absolute need to be compliant to diet and 
lifestyle recommendations. 
6.7 
INTERVENTION AFTER THE END OF THE STUDY 
Intervention after the end of the study treatment is at the discretion of the Investigator or other 
treating physician.  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 43 
7 
DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL 
7.1 
DISCONTINUATION OF STUDY INTERVENTION  
7.1.1 Definitive discontinuation 
The IMP should be continued whenever possible.  
In case the IMP is stopped, it should be determined whether the stop can be made temporarily; 
definitive IMP discontinuation should be a last resort. Any IMP discontinuation must be fully 
documented in the eCRF. In any case, the participant should remain in the study as long as 
possible. 
Definitive intervention discontinuation is any intervention discontinuation associated with the 
definitive decision from the Investigator not to re-expose the participant to the IMP at any time 
during the study, or from the participant not to be re-exposed to the IMP whatever the reason. 
List of criteria for permanent treatment discontinuation 
The patients may withdraw from treatment with the IMP if they decide to do so, at any time and 
irrespective of the reason, or this may be the Investigator’s decision. All efforts should be made to 
document the reason(s) for treatment discontinuation and this should be documented in the eCRF. 
The patients may withdraw from treatment with IMP in case of the following: 
 
At patient’s own request, ie, withdrawal of the consent for treatment. 
 
If, in the Investigator's opinion, continuation with the administration of IMP would be 
detrimental to the patient's well-being. 
 
At the specific request of the Sponsor. 
A patient must withdraw from treatment with IMP in either of the following cases: 
 
Intercurrent condition that requires discontinuation of IMP. 
 
Pregnancy in female participants. 
 
Necessity to use prohibited therapy (see Section 6.5) 
Any abnormal laboratory value will be immediately rechecked for confirmation before making a 
decision of permanent discontinuation of the IMP for the concerned patient. 
See the SoA for data to be collected at the time of intervention discontinuation and follow-up and 
for any further evaluations that need to be completed. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 44 
Handling of participants after definitive intervention discontinuation 
Participants will be followed-up according to the study procedures specified in this protocol up to 
the scheduled date of study completion, or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. 
If possible, and after the definitive discontinuation of intervention, the participants will be 
assessed using the procedure normally planned for the last dosing day with the IMP (Visit 18). If 
CGM assessment is ongoing it should be completed as planned for the ongoing 2-week period. 
After that patients should remain in the study and complete all relevant scheduled study 
assessments. Whenever possible, CGM should be performed on Weeks 10 - 12, and patient return 
for the planned Visit 18. 
All cases of definitive intervention discontinuation must be recorded by the Investigator in the 
appropriate pages of the e-CRF when considered as confirmed. 
7.1.2 Temporary discontinuation  
Temporary treatment discontinuation may be considered by the Investigator because of suspected 
AEs or for other reason.  
For all temporary treatment discontinuations, duration must be recorded by the Investigator in the 
appropriate pages of the eCRF. 
7.1.2.1 Rechallenge 
In case of treatment interruption due to an AE, reinitiation of treatment with the IMP will be done 
under close and appropriate clinical/and or laboratory monitoring once the Investigator will have 
considered according to his/her best medical judgment that the responsibility of the IMP(s) in the 
occurrence of the concerned event was unlikely and if the selection criteria for the study are still 
met (refer to Section 5.1 and Section 5.2).  
7.2 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY 
 A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, 
compliance, or administrative reasons. 
 If the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
 If a participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investigator must document this in the site study records. 
 See SoA for data to be collected at the time of study discontinuation and follow-up and for 
any further evaluations that need to be completed. 
If participants no longer wish to take the IMP, they will be encouraged to remain in the study. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 45 
The Investigators should discuss with them key visits to attend. The value of all their study data 
collected during their continued involvement will be emphasized as important to the public health 
value of the study. 
Participants who withdraw from the study intervention should be explicitly asked about the 
contribution of possible AEs to their decision, and any AE information elicited must be 
documented. 
All study withdrawals should be recorded by the Investigator in the appropriate screens of the 
e-CRF and in the participant’s medical records. In the medical record, at least the date of the 
withdrawal and the reason should be documented. 
In addition, a participant may withdraw his/her consent to stop participating in the study. 
Withdrawal of consent for intervention should be distinguished from withdrawal of consent for 
follow-up visits and from withdrawal of consent for non-participant contact follow-up, eg, 
medical record checks. The site should document any case of withdrawal of consent. 
Participants who have withdrawn from the study cannot be rerandomized (treated) in the study. 
Their inclusion and intervention numbers must not be reused.  
7.3 
LOST TO FOLLOW UP 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required study 
visit: 
 
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study. 
 
Before a participant is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant’s 
medical record. 
 
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 46 
8 
STUDY ASSESSMENTS AND PROCEDURES 
 
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed. 
 
Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study intervention. 
 
Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct. 
 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
 
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol-specified criteria and were performed 
within the time frame defined in the SoA. 
8.1 
EFFICACY ASSESSMENTS  
8.1.1 Continuous glucose monitoring (CGM) 
A CGM system is a device that records interstitial glucose levels continuously throughout the day 
and night via a subcutaneous sensor. During the study, patients will use the Dexcom G6® CGM 
system with software (DexCom, Inc., San Diego, CA), an approved device with single-use 
disposable electrochemical sensing elements designed for up to 10 days of continuous use with 
measurement of glucose levels in interstitial fluid in 5-minute intervals. 
All patients must use the CGM device provided by the Sponsor during the CGM collection 
periods. Additionally, patients cannot initiate personal (non-study) real time, flash or implantable 
CGM system during the study (see E 13). 
8.1.1.1 CGM performance 
Two (2) sets of CGM will be conducted by the study patients. Baseline CGM will start at Visit 3 
(Week -3) and stop at randomization visit (Visit 6). During the randomized treatment period, an 
endpoint CGM recording during Weeks 9, 10, 11 and 12 [Days 64 to 84]) will be done. Patients 
must be well trained to understand the importance of the CGM performance and compliance with 
the manufacture’s (DexCom) instructions. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 47 
All patients will undergo training, delivered by the investigational site personnel, at Visit 2 
regardless of previous experience with CGM. After the training, patients should understand the 
process of CGM and how to handle the CGM device at home, the distance of receiver and effect 
of temperature on the device etc. If the patient is not sufficiently compliant with the study 
procedures, all necessary training has to be repeated by the site staff. 
Patients, Investigators, and study personnel will be blinded to the CGM data. The CGM receiver’s 
screen will be blocked of displaying data. Neither patients nor Investigators will be able to see the 
glucose values. 
At Visit 3 and Visit 15, the insertion of CGM sensor will occur under the supervision of 
Investigators or designees. Patients will be instructed to insert the sensor into the belly (abdomen) 
at least 8 cm (3 inches) away from the insulin injection sites.  
After the CGM sensor being inserted, and the transmitter being attached, patients will stay in the 
study site as long as needed to explain the use of CGM. During the next 19 days when the patients 
are operating the CGM, they must: 
 
Carry the CGM receiver with them all the time; the receiver must be placed within 20 feet 
(6 meters) from the patients’ body in order to capture the data measured by the device. 
 
After 10 days of wearing the device, patients must remove and replace the sensor 
themselves. Note: If required, Investigators can arrange for patients to attend the site after 
the first 10 days of CGM for the sensor to be replaced at the study site. 
Patients will receive a user guide of instruction included in the DexCom G6 device kit. Technique 
support via a 24/7 help-line service for trouble shooting will be provided by the manufacturer, 
DexCom. The patients should immediately contact the sites if they encounter any device 
malfunction or device related events eg, sensor fracture. The Investigator or a site staff will help 
patients contact the DexCom service line for problem solving.  
After the end of the study, the patients and their Investigator will receive a standardized analysis 
(eg, Ambulatory Glucose Profile) of their personal two 20-day CGM-periods.  
8.1.1.2 CGM qualification and data transfer 
CGM qualification 
There are 2 periods of CGM in this study. During each CGM period, patients will wear the CGM 
for 20 consecutive days to generate a minimum of (10 days, not necessarily consecutive) of 
useable CGM records. Useable CGM data for a day/a 24-hour CGM profile are defined as:  
 
At least 80% time of records per 24 hours.  
 
No gap (missing data) lasting for ≥2 hours per 24 hours besides the warm-up time for the 
sensor after insertion. 
Note: Only patients with 10 days out of 20 of qualified CGM records will proceed to 
randomization and other CGM recording periods. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 48 
CGM data transfer 
The CGM data will be uploaded to a separate server which assures maintenance of the blind with 
vendor software (QuintilesIMS Study Management Suite) and a data acceptability report with 
daily CGM performance will be available immediately. This will be performed at the end of the 
20-day CGM period and may additionally be generated in the event of a patient returning to the 
site for replacement of the sensor after the first 10 days of CGM. Investigators will not be able to 
see the recorded glucose values, nor will the report include any real glucose data. The CGM 
summary will be used for the Investigators to review the patient’s daily performances and 
determine the quality of CGM and will be considered as source documents). 
Use of CGM data for future analysis 
After the database lock anonymized CGM data may be transferred to a third party for future 
analysis and modeling of glycemic values.  
8.1.2 Glycated hemoglobin A1c 
Glycated hemoglobin A1c is assayed at screening (Visit 1; Week -6/-5), randomization Visit 6 
and Visit 18 (Week 12). For the eligibility and efficacy assessments of the study, HbA1c is 
measured by a certified level I “National Glycohemoglobin Standardization Program”, or 
equivalent certification as per specific country regulations, central laboratory. The screening value 
will be transferred into the IRT for stratification purpose during the patient randomization at the 
Visit 6. 
8.1.3 Fasting plasma glucose 
Fasting plasma glucose is measured at a central laboratory. Blood samples for FPG measurement 
are taken at screening (Week -6/-5), randomization Visit 6 and at Visit 18 (Week 12). 
8.1.4 Self-monitoring of plasma glucose 
Plasma glucose values will be self-measured by the patients using the Sponsor-provided 
glucometers and corresponding supplies (lancet, control solutions, test strips, etc). Patients should 
not use their own glucometers during the study period starting after Visit 2 (Week -4). 
Self-monitoring plasma glucose performance 
At Visit 2, the patients will be shown how to accurately measure plasma glucose values with the 
blood glucometers. The Investigator or a member of the investigational staff will explain the need 
to measure glucose at the times requested for profiles and how to correctly record the values and 
times. Training will be repeated as often as necessary at the study visits and the investigational 
staff will review the study diary at each visit. 
The schedule for performing SMPG is specified in Section 1.3. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 49 
Self-monitoring of plasma glucose readings will be used to guide the basal and mealtime insulin 
titration to reach glucose targets. The Investigators should review the SMPG records at each visit 
and also ask the pattern of fasting and postprandial SMPG so that they can provide instruction to 
the patients for appropriate insulin dose adjustment. Investigators may request more frequent 
blood glucose test and/or at specific time eg, midnight, if needed, to help the patients optimize 
insulin dosage. The SMPG records will be the patient’s study diary entries (available at each 
visit). The SMPG summary report downloaded at Visits 6, 14, 15 and 18 will also be available to 
Investigators. 
Investigators will record SMPG values and insulin doses during weekly telephone contacts as 
well.  
Fasting self-monitoring of plasma glucose 
After randomization, before breakfast SMPG = Pre-injection SMPG 
Pre-injection SMPG: Within 30 minutes prior to injection of Toujeo or Tresiba before breakfast 
on the day of the first injection of the IMP (Day 1/Visit 6) and daily until uptitration has been 
completed and fasting pre-breakfast SMPG is stable in the target range, and then, at least 3 fasting 
measurements per week. 
2 hours PPG will be measured by patient regularly as instructed by investigator to guide the 
dosing of meal time insulin.  
7-point SMPG profiles 
Before (pre-injection after randomization) and 2 hours after breakfast; lunch; dinner, and at 
bedtime: at least 1 day during the week that precedes Visits 6 and 18. Note: 7-point SMPG profile 
should also be pre-injection during the run-in period in cases where the patient’s current basal 
insulin is administered in the morning. 
SMPG during symptomatic hypoglycemia 
Whenever the patients feel hypoglycemic symptoms, plasma glucose should be measured by the 
patient (or others, if applicable), if possible. Patients should be instructed to self-assess plasma 
glucose levels prior to carbohydrate intake/administration of glucose whenever symptomatic 
hypoglycemia is suspected, unless safety considerations necessitate immediate 
carbohydrate/glucose rescue prior to confirmation with the SMPG. 
Patients have to document hypoglycemic events appropriately in their diaries and contact the 
Investigator as soon as possible following severe events for review and for decision on any 
necessary actions to be taken. 
All hypoglycemia episodes will be documented on the “hypoglycemia specific form” in the eCRF. 
This includes all symptomatic hypoglycemia events and asymptomatic hypoglycemia. 
Investigators should review the SMPG diary entries (and when available also data stored in the 
glucometer) to assess data for episodes of hypoglycemia, ie, to confirm episodes reported by 
patients in the diary and also to identify any episodes that were not reported in the diary). 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 50 
Hypoglycemia events fulfilling the criteria of a SAE will also be documented on the AE and SAE 
form in the eCRF. 
Recording of SMPG data 
Patients will document their SMPG values with the testing times in the Sponsor-provided diary. If 
for any reason, SMPG is recorded by the patient in a non-Sponsor provided diary, the Investigator 
(or designee) and patient will sign/initial the data so that the diary can be kept in the study source 
documents. 
At on-site Visits 6, 14, and 18, SMPG data stored in the individual’s glucometer will be uploaded 
to the site’s computer. A summary including all measured glucose values will be promptly 
available for the Investigator (or designee) to review. SMPG data will be uploaded to site’s PC 
(server independent from eCRF). At a minimum, for SMPG data that are captured in the eCRF, 
including the values recorded during weekly telephone contacts, the Investigators or study staff 
must verify the accuracy with the data that are uploaded from the glucometer. Once an error is 
identified, only the corrected data should be entered in the eCRF and erroneous data in the diary 
will be corrected by the patient and initialed. 
Use of SMPG data for future analysis 
The SMPG data from the glucometer will be uploaded to an independent server and will not be 
captured in the clinical database (which will comprise SMPG data that is transcribed from the 
study diary).  
The downloaded SMPG data will not be analyzed or reported in the clinical study report. 
After the database lock anonymized SMPG data may be transferred to third party for future 
analysis and modeling of glycemic values. 
8.1.5 Insulin dose (including IMP during the treatment period) 
Insulin dose and injection time for both basal insulin (ie, patient’s current basal insulin prior to 
randomization or IMP [Toujeo or Tresiba] after randomization) and mealtime insulin will be 
documented in the study diary on a daily basis. All doses of mealtime insulin analog during the 
day as taken for all meals and all snacks must be recorded. 
 
At Weeks 4, 8, and 12, the following data will be entered in the eCRF: 
- 
The dose the patient was taking prior to the visit and the dose taken after the visit (so 
as to reveal any dose adjustments made at the visit), 
- 
All available data on the injection time and doses administered will be entered in the 
eCRF, 1 week before on site visit, including missed injection, 
- 
Missed injections. 
 
In case of symptomatic hypoglycemia, the dose and injection time should be entered in the 
eCRF on the specific hypoglycemia form. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 51 
 
All available data of dose and injection time on the last 3 days before permanently IMP 
treatment discontinuation. 
 
Data on SMPG values and dose of basal and rapid acting insulin, obtained verbally during 
weekly telephone contacts. 
8.1.6 Patient-reported Outcomes (PROs) 
The patient-reported outcome (PRO) questionnaires in this study are the Treatment Satisfaction 
Questionnaire (DTSQs and DTSQc versions), the MOS Sleep and the Work Productivity and 
Activity Impairment Questionnaire (WPAI).  
The patients will be requested to complete all the questionnaires by themselves during selected 
clinical visits (see study SoA), independently from investigator, site staff and any help from 
friends or relatives. For validity purposes, patients will be asked to answer all the questions of the 
questionnaires at the start of the visit in a quiet place, and while on site to return the completed 
questionnaires on the same day. 
In case of premature discontinuation of study treatment, all the PRO questionnaires will be 
completed by the patients as normally planned at 12 weeks.  
8.1.6.1 DTSQs 
The Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs) will be used to 
evaluate patient satisfaction with treatment and patient perception of blood glucose control over a 
several week period (16). The DTSQs is a validated questionnaire comprised of 8 questions which 
are answered on a Likert scale from 0 to 6.  Responses to 6 of the items will be summed to 
produce a Total Treatment Satisfaction score ranging from 0 (no satisfaction) to 36 (high 
satisfaction with treatment). The 2 items of ‘perceived frequency of ‘hyperglycemia’ (Item 2) and 
‘perceived frequency of hypoglycemia’ (Item 3) are scored separately ranging from 0 (none of the 
time) to 6 (most of the time). The DTSQs will be completed by the patients at baseline and 
Week 12. Mean differences in scores from baseline and between groups will be evaluated to 
understand the impact of treatment on patient satisfaction. 
The DTSQs is available in appendix 5 (Section 10.5). 
8.1.6.2 DTSQc 
The Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) was developed 
from the original DTSQ to evaluate the change in treatment satisfaction at a specific time point. 
The DTSQc instructions and response options differ from those of the DTSQs to produce 
measures of relative change in satisfaction rather than measures of absolute satisfaction.  
It will be used to measure patient perception of change in treatment satisfaction at 12 weeks. 
Scores for DTSQc treatment satisfaction items range from −3 to +3, and the sum of the treatment 
satisfaction score range from −18 to +18. Positive scores are indicative of improvement in 
treatment satisfaction, whereas negative scores are indicative of deterioration in treatment 
satisfaction since start of the study. Perceived frequency of hyperglycemia and hypoglycemia 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 52 
scores range from −3 to +3, with negative scores indicating fewer problems with blood glucose 
levels and positive scores indicating more problems than before. DTSQc will be completed by the 
patients at 12 weeks after the DTSQs (status version). To control for baseline scores, DTSQs will 
be used as a measure of treatment satisfaction at baseline. 
The DTSQc is available in appendix 5 (Section 10.5). 
8.1.6.3 MOS Sleep 
Originally developed for use in the Medical Outcomes Study (MOS), the MOS Sleep Scale is a 
brief, self-administered generic assessment designed to measure key aspects of sleep, such as 
disturbance, adequacy, somnolence, and quantity. 
The 12-item acute revised version of the MOS Sleep will be used in this study with a past week 
recall period and 5-point likert response options (appendix 5 in Section 10.5.3). 
The 12-item MOS Sleep Scale assessment yields scores on six subscales (18, 21):  
 
Sleep Disturbance (4-item subscale on sleep initiation problems, and sleep maintenance 
problems). 
 
Snoring (single-item subscale). 
 
Shortness of Breath or Headache (single-item subscale asking about the frequency of 
awakening with shortness of breath or with a headache). 
 
Sleep Adequacy (2-item subscale asking about frequency of awakening fresh and rested in 
the morning and getting the amount of sleep needed). 
 
Daily Somnolence (3-item subscale). 
 
Sleep Quantity (single-item subscale representing the average number of hours slept). 
 
One Sleep Problems Index is also calculated based on 9 of the items. 
Responses to all but the open-ended sleep quantity item are transformed to scores on a 
0-100 metric, with higher item scores reflecting more of the attribute implied by the scale name. 
Scores on the multi-item subscales and indexes also range from 0 to 100. 
The MOS Sleep will be completed by the patients at baseline and Week12. 
8.1.6.4 WPAI  
The WPAI is a 6-item validated questionnaire assessing the amount of absenteeism, presenteeism 
and daily activity impairment attributable to a specific health problem (WPAI:SHP version V2.0) 
(19). An adapted version of the WPAI:SHP will be used where the term PROBLEM was replaced 
by DIABETES, as requested by the authors.  
The WPAI:Diabetes will be completed by the patients at baseline and Week 12. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 53 
8.2 
SAFETY ASSESSMENTS  
Planned time points for all safety assessments are provided in the SoA. 
8.2.1 Physical examinations 
A complete physical examination will include, at a minimum, assessments of the [Cardiovascular, 
Respiratory, Gastrointestinal and Neurological] systems. Height and weight will also be measured 
and recorded. 
Investigators should pay special attention to clinical signs related to previous serious illnesses. 
Any new finding or worsening of previous finding should be reported as a new AE. 
8.2.2 Vital signs 
Vital signs will be measured in a semi-supine position after 5 minutes rest and will include 
systolic and diastolic blood pressure and pulse. 
Blood pressure (mmHg) should be measured when the patient is quiet and seated and with their 
arm outstretched in line with mid-sternum and supported. Measurement should be taken under 
standardized conditions, approximately at the same time of the day, on the same arm, with the 
same device and the values are to be recorded in the eCRF. Devices for blood pressure 
measurement should be regularly recalibrated according to manufacturers’ instructions. 
Heart rate (bpm) will be measured at the time of the measurement of blood pressure. 
8.2.3 Clinical safety laboratory assessments 
See Appendix 2 (Section 10.2) for the list of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency.  
The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged 
by the Investigator to be more severe than expected for the participant’s condition. 
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by the Investigator or medical monitor. 
 
If such values do not return to normal/baseline within a period of time judged reasonable 
by the Investigator, the etiology should be identified and the Sponsor notified. 
 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2), 
must be conducted in accordance with the laboratory manual and the SoA.  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 54 
 
If laboratory values from non-protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically significant by the Investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.  
8.2.4 Hypoglycemia 
Hypoglycemia will be reported on the specific hypoglycemia event information form of the 
e-CRF. Hypoglycemia fulfilling the seriousness criteria will be documented in addition on the 
SAE form in the e-CRF. 
The SMPG values will be used for the confirmation of hypoglycemia (ie, episodes both reported 
and not-reported by patients in the diary).  
Hypoglycemic events will be categorized (20, 22, 23, 24) as follows: 
 
Severe hypoglycemia: Severe hypoglycemia is an event requiring assistance of another 
person to actively administer carbohydrate, glucagon, or other resuscitative actions. These 
episodes may be associated with sufficient neuroglycopenia to induce seizure, 
unconsciousness or coma. Plasma glucose measurements may not be available during such 
an event, but neurological recovery attributable to the restoration of plasma glucose to 
normal is considered sufficient evidence that the event was induced by a low plasma 
glucose concentration. The definition of severe symptomatic hypoglycemia includes all 
episodes in which neurological impairment was severe enough to prevent self-treatment 
and which were thus thought to place participants at risk for injury to themselves or others. 
Note that “requiring assistance of another person” means that the participant could not 
help himself or herself. Assisting a participant out of kindness, when assistance is not 
required, should not be considered a “requiring assistance” incident.  Severe hypoglycemia 
will qualify as an SAE only if it fulfills SAE criteria (see Section 10.3). For example, 
events of seizure, unconsciousness or coma must be reported as SAEs. 
 
Documented symptomatic hypoglycemia: Documented symptomatic hypoglycemia is an 
event during which typical symptoms of hypoglycemia are accompanied by a measured 
plasma glucose concentration less than 3.9 mmol/L (70 mg/dL). Clinical symptoms that 
are considered to result from a hypoglycemic episode are, eg, increased sweating, 
nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, 
headache, sleep disorder, confusion, seizures, unconsciousness, or coma. 
 
Asymptomatic hypoglycemia: Asymptomatic hypoglycemia is an event not accompanied 
by typical symptoms of hypoglycemia but with a measured plasma glucose concentration 
less than 3.9 mmol/L (70 mg/dL). 
In addition to the threshold of plasma glucose of less than  3.9 mmol/L (70 mg/dL), documented 
hypoglycemia with a measured plasma glucose concentration less than 3.0 mmol/L (54 mg/dL) 
will also be analyzed (20, 24). 
Hypoglycemic events will be evaluated regardless the time of onset during the study and time of 
the day. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 55 
In addition, hypoglycemia events will be evaluated at the following time periods defined by time 
of the day: 
 
Nocturnal hypoglycemia: any hypoglycemia of the above categories that occurs between 
00:00 and 05:59, regardless of whether participant was awake or woke up because of the 
event. 
 
Daytime hypoglycemia: any hypoglycemia of the above categories that occurs between 
06:00 and 23:59. 
Note: CGM values will not be taken into account for the purpose of hypoglycemia. 
8.3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
Adverse event of special interest 
An adverse event of special interest (AESI) is an AE (serious or nonserious) of scientific and 
medical concern specific to the Sponsor’s product or program, for which ongoing monitoring and 
immediate notification by the Investigator to the Sponsor is required. Such events may require 
further investigation in order to characterize and understand them. Adverse events of special 
interest may be added, modified or removed during a study by protocol amendment. 
The AESIs are listed below: 
 
Pregnancy of a female subject entered in a study as well as pregnancy occurring in a 
female partner of a male subject entered in a study with IMP/NIMP;  
- 
Pregnancy occurring in a female participant entered in the clinical trial or in a female 
partner of a male participant entered in the clinical trial. It will be qualified as an SAE 
only if it fulfills one of the seriousness criteria (see Appendix 3 [Section 10.3]), 
- 
In the event of pregnancy in a female participant, IMP should be discontinued, 
- 
Follow-up of the pregnancy in a female participant or in a female partner of a male 
participant is mandatory until the outcome has been determined (See Appendix 4 
[Section 10.4]). 
 
Symptomatic overdose (serious or non-serious) with IMP/NIMP 
- 
An overdose (accidental or intentional) with the IMP/NIMP is an event suspected by 
the Investigator or spontaneously notified by the participant (not based on systematic 
drug count) and defined as any dose administration which, in the Investigator’s 
opinion based on clinical judgment is considered significantly greater than the 
prescribed dose of insulin. 
Of note, asymptomatic overdose has to be reported as a standard AE. 
The definitions of an AE or SAE can be found in Appendix 3 (Section 10.3). 
AE will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant’s legally authorized representative).  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 56 
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to discontinue the study intervention or the study (see Section 7).  
8.3.1 Time period and frequency for collecting AE and SAE information  
All SAEs will be collected from the signing of the informed consent form (ICF) until the 
follow-up visit at the time points specified in the SoA (Section 1.3). 
All AE will be collected from the signing of the ICF until the follow-up visit at the time points 
specified in the SoA (Section 1.3). 
All SAEs and AESI will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix 3 (Section 10.3). The Investigator will submit any updated SAE data to the 
Sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the Investigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the Investigator must promptly notify the 
Sponsor. 
8.3.2 Method of detecting AEs and SAEs 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3). 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.3.3 Follow-up of AEs and SAEs 
After the initial AE/AESI/SAE report, the Investigator is required to proactively follow each 
participant at subsequent visits/contacts.  At the pre-specified study end-date, all SAEs, [and non-
serious AEs of special interest (as defined in Section 8.3)], will be followed until resolution, 
stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in 
Section 7.3). Further information on follow-up procedures is given in Appendix 3 (Section 10.3). 
8.3.4 Regulatory reporting requirements for SAEs 
 
Prompt notification by the Investigator to the Sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 57 
 
The Sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and Investigators. 
 
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and Sponsor policy and 
forwarded to Investigators as necessary. 
 
Adverse events that are considered expected will be specified in the product prescribing 
information. 
 
An Investigator who receives an Investigator safety report describing a SAE or other 
specific safety information (eg, summary or listing of SAEs) from the Sponsor will review 
and then file it along with the Investigator’s Brochure and will notify the IRB/IEC, if 
appropriate according to local requirements.  
8.3.5 Pregnancy 
 
Details of all pregnancies in female participants and female partners of male participants 
occurring after the start of study intervention and until the end of the study will be 
collected and followed until the outcome. 
 
If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section 10.4). 
 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
8.3.6 Guidelines for reporting product complaints 
Any defect in the IMP/NIMP/device must be reported as soon as possible by the Investigator to 
the monitoring team that will complete a product complaint form within required timelines. 
Appropriate information (eg, samples, labels or documents like pictures or photocopies) related to 
product identification and to the potential deficiencies may need to be gathered. The Investigator 
will assess whether or not the quality issue has to be reported together with an AE or SAE. 
8.4 
TREATMENT OF OVERDOSE 
Sponsor does not recommend specific treatment for an overdose. 
In the event of an overdose, the Investigator should: 
1. Contact the Medical Monitor immediately. 
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 58 
3. Document the quantity of the excess dose as well as the duration of the overdose in the 
eCRF. 
Decisions regarding dose interruptions or modifications will be made by the Investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the participant. 
8.5 
PHARMACOKINETICS 
PK parameters are not evaluated in this study. 
8.6 
PHARMACODYNAMICS 
Pharmacodynamic parameters are not evaluated in this study. 
8.7 
GENETICS 
Genetics are not evaluated in this study. 
8.8 
BIOMARKERS 
Biomarkers are not evaluated in this study. 
8.9 
HEALTH ECONOMICS 
Health economics are not evaluated in this study. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 59 
9 
STATISTICAL CONSIDERATIONS  
9.1 
STATISTICAL HYPOTHESES 
The objective is to show non-inferiority of Toujeo versus Tresiba in patients with type 1 diabetes 
on the percent time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to ≤10 mmol/L) at Week 12 
obtained using CGM. 
9.2 
SAMPLE SIZE DETERMINATION  
The sample size calculation is based on the percent time spent in glucose range of ≥70 to 
≤180 mg/dL (≥3.9 to ≤10 mmol/L) at Week 12, assessed from CGM measurements obtained 
during Weeks 10, 11 and 12. 
For this criterion of percent time in range, there is no predefined non-inferiority margin. A relative 
non-inferiority margin of 10% is considered. 
Let m1 and m0 be the true means for the Toujeo and Tresiba groups, respectively.  
The non-inferiority null hypothesis would be H0: m1-m0 ≤ -0.1*m0 or H0: m1-0.9*m0 ≤0 and the 
alternative hypothesis (H1): m1=m0. 
Toujeo would be considered non-inferior to Tresiba if the lower limit of the 95% CI for the 
adjusted difference estimate of m1-0.9*m0 at Week 12 is >0. 
To ensure 90% power, the sample size should satisfy: 
1.96 −(0.1 ∗𝑚0)
√1.81 ∗𝑆𝐷2
𝑛
= − 1.282 
Where -1.282 is the 10th percentile of a standard normal distribution and SD the common SD. 
Which leads to: 
𝑛= (1.96 + 1.282)2 ∗1.81 ∗𝑆𝐷2
(0.1 ∗𝑚0)2
 
Assuming a common SD of 14.7%, an average percent time in range in the Tresiba treatment 
group of 56% (value from LPS14587), no true difference between both arms under H1, and a 
relative non-inferiority of 10%, a sample size of 131 evaluable patients per treatment group would 
provide at least 90% power to show non-inferiority of Toujeo with respect to Tresiba on the 
percentage of time plasma glucose within the range of ≥70 to ≤180 mg/dL at Week 12. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 60 
With the assumption of a non-evaluability rate of 22% 338 participants (169 per treatment arm) 
will have to be randomized.  
Patient is evaluable for the primary endpoint if he/she as at least 10 days of useable CGM data 
(not necessarily consecutives) at Week 12 (see Section 8.1.1.2 for definition of useable data). 
9.3 
POPULATIONS FOR ANALYSES 
For purposes of analysis, the following populations are defined (Table 6): 
Table 6 - Populations for analyses 
Population 
Description 
ITT 
All randomized (patients who signed ICF and with a treatment arm allocated before first IMP and 
recorded in the IRT database) participants, irrespective of the treatment actually being received, 
analyzed according to the treatment group allocated by randomization. 
PP 
The PP population is a subset of ITT population with no major protocol deviations. Participants included 
in this population will fulfill at least the criteria below: 
 
randomized and received only the treatment allocated at the randomization 
 
did not permanently discontinue treatment 
The PP population will be fully defined in the SAP. 
Safety 
All randomized participants who received at least one dose of IMP, regardless of the amount of 
treatment administered. Patients will be analyzed according to the treatment actually received. 
ICF: informed consent form; IRT: interactive response technology; ITT: intent to treat; PP: per protocol; SAP: statistical analysis plan 
9.4 
STATISTICAL ANALYSES 
The SAP will be developed and finalized before database lock and will describe the participant 
populations to be included in the analyses, and procedures for accounting for missing, unused, and 
spurious data. This section is a summary of the planned statistical analyses of the primary and 
secondary endpoints. 
9.4.1 Efficacy analyses 
All efficacy analyses will be performed on the ITT population. Sensitivity analyses will be 
performed on the PP population on a selection of endpoints. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 61 
Table 7 - Efficacy analyses 
Endpoint 
Statistical Analysis Methods 
Primary: Percent time in glucose 
range of ≥70 to ≤180 mg/dL (≥3.9 to 
≤10 mmol/L) at Week 12, obtained 
using CGM 
Primary endpoint using available data from the 12-week randomized period will be 
analyzed using an ANCOVA model including the fixed categorical effects of treatment 
group (Toujeo, Tresiba), randomization stratum of screening HbA1c (<8.0% versus 
≥8.0%), as well as, the continuous fixed covariate of baseline percent time in range value. 
This procedure will provide baseline adjusted least-squares means estimates at Week 12 
for both treatment groups, as well as, the differences of these estimates, with their 
corresponding standard errors (SEs) and 95% CIs. 
To assess non-inferiority, the lower bound of the two-sided 95% CI for the adjusted 
difference estimate of m1 - 0.9*m0 at Week 12 will be compared to 0. 
Non-inferiority will be demonstrated if the lower bound of the two-sided 95% CI of the 
adjusted difference estimate of m1 - 0.9*m0 at Week 12 on the ITT population is >0. 
A sensitivity analysis will be performed using the PP population. 
Let m1 and m0 be the true means for the Toujeo and Tresiba groups, respectively. 
To assess non-inferiority, the lower bound of the two-sided 95% CI for the adjusted 
difference estimate of m1 - 0.9*m0 at Week 12 will be compared to 0. 
Non-inferiority will be demonstrated if the lower bound of the two-sided 95% CI of the 
adjusted difference estimate of m1 - 0.9*m0 at Week 12 on the ITT population is >0. 
A sensitivity analysis will be performed using the PP population. 
Secondary: CGM endpoints at 
Week 12 (see Section 3) 
CGM endpoints will be analyzed using the same model as described for the primary 
endpoint using the ITT population. 
Exploratory analysis will be performed on within day glucose CV to summarize the 
treatment effects across subgroup defined by within day CV<36% vs. >=36% at baseline. 
Secondary 
 
 
Change from baseline to 
Week 12 in HbA1c 
Change in HbA1c will be analyzed using an analysis of covariance (ANCOVA) model 
including fixed categorigal effect of treatment group (Toujeo, Tresiba), as well as, the 
continuous fixed covariate of baseline HbA1c value.  
 
Change from baseline to 
Week 12 in central lab FPG 
Change in FPG will be analyzed using ANCOVA model including the randomization 
stratum of HbA1c at screening (<8.0%, ≥8.0%), treatment group (Toujeo, Tresiba), as 
well as, the continuous fixed covariate of baseline FPG value. 
Exploratory 
[Will be described in the statistical analysis plan finalized before database lock] 
 
To control the type I error, a hierarchical step-down testing procedure described by Hochberg and 
Tamhane (3) will be applied for the primary efficacy endpoint and the main secondary endpoint: 
 
Step 1 proceeds to assess non-inferiority of Toujeo versus Tresiba on the percent time in 
range in 70-180 mg/dl. 
 
Step 2: only if step 1 is demonstrated, then non-inferiority of Toujeo versus Tresiba  on the 
glucose total CV will be tested with a relative non-inferiority margin of 10%. 
 
Step 3: only if step 2 is demonstrated, then difference between Toujeo and Tresiba on the 
percent time in range in 70-180 mg/dl will be tested. 
No multiplicity adjustment will be made on other secondary/other efficacy variables; 95% CI and 
P-values presented for these endpoints will be done for descriptive purpose only. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 62 
9.4.2 Safety analyses 
All safety analyses will be performed on the Safety Population.  
The summary of safety results will be presented by treatment group.  
The baseline value is defined generally as the last available value before randomization. 
For all safety data, the observation period will be divided as follows: 
 
The pre-treatment phase is defined as the time from when the patients sign the informed 
consent to randomization. 
 
The on-treatment phase is defined as the time from the first injection of the open label 
IMP (included) up to 2 days after the last injection of IMP. 
 
The post-treatment phase is defined as the time after the on-treatment phase until the end 
of the study (Follow up Visit).  
Treatment-emergent AEs (TEAEs) are AEs that developed or worsened or became serious during 
the on-treatment phase. 
Table 8 - Safety analyses 
Endpoint 
Statistical Analysis Methods 
Secondary: 
 
 
Number of 
participants with AEs 
TEAEs, treatment-emergent SAEs, TEAEs leading to death, and TEAEs leading to treatment 
discontinuation will be summarized by treatment group for the 12-week on-treatment period. 
All adverse events will be coded to a “preferred term” (PT) and “high-level group term” (HLGT), 
“high level term” (HLT) and associated primary “system organ class” (SOC) using the version of 
MedDRA currently in use by the Sponsor at the time of database lock. 
Adverse event incidence tables will present by SOC (sorted by internationally agreed order), 
HLGT, HLT and PT sorted in alphabetical order, and for each treatment group, the number (n) 
and percentage (%) of patients experiencing at least one AE. 
Multiple occurrences of the same event in the same patient will be counted only once in the 
tables within a treatment period. The denominator for computation of percentages is the safety 
population within treatment group. 
 
Number of 
participants with at 
least one 
hypoglycemic event 
from baseline to 
Week 12 
The number and incidence of patients experiencing at least one hypoglycemic event will be 
presented per treatment group and type of hypoglycemic event (see Section 8.2.4) and 
according to time of occurrence (nocturnal [ie, 00:00 to 05:59], any time of day and daytime 
[ie, 06:00 to 23:59]) during the 12-week on treatment period. The Odds Ratio and its 
corresponding 95% CI of Toujeo arm over Tresiba arm for each hypoglycemic event (nocturnal 
and any time of the day) will be estimated by a logistic regression model. 
 
Number of 
hypoglycemic events 
per participant year 
from baseline to 
Week 12. 
The rate of hypoglycemic events (in patient-year of exposure) will be determined per treatment 
group and type of hypoglycemic event (see Section 8.2.4), and according to time of occurrence 
(nocturnal [ie, 00:00 to 05:59], any time of the day) during the 12-week on treatment period. 
Exploratory 
Not applicable 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 63 
9.4.3 Other analyses  
Not applicable. 
9.5 
INTERIM ANALYSES  
No interim analysis is planned during the study. 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 64 
10 
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1 
APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS 
10.1.1 Regulatory and Ethical Considerations 
 
This study will be conducted in accordance with the protocol and with the following: 
- 
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and the applicable amendments and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, 
- 
Applicable ICH Good Clinical Practice (GCP) Guidelines, 
- 
Applicable laws and regulations. 
 
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by the Investigator and 
reviewed and approved by the IRB/IEC before the study is initiated.  
 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
 
The Investigator will be responsible for the following: 
- 
Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC, 
- 
Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures, 
- 
Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations. 
10.1.2 Informed Consent Process 
 
The Investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions regarding 
the study.  
 
Participants must be informed that their participation is voluntary. Participants or their 
legally authorized representative will be required to sign a statement of informed consent 
that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health 
Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, 
and the IRB/IEC or study center.  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 65 
 
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF. 
 
Participants must be re-consented to the most current version of the ICF(s) during their 
participation in the study.  
 
A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative.  
 
Participants who are rescreened are required to sign a new ICF. 
10.1.3 Data Protection 
All personal data collected related to participants, Investigators, or any person involved in the 
study, which may be included in the Sponsor’s databases, shall be treated in compliance with all 
applicable laws and regulations including the GDPR (Global Data Protection Regulation).  
Data collected must be adequate, relevant and not excessive, in relation to the purposes for which 
they are collected. Each category of data must be properly justified and in line with the study 
objective. 
Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names or 
any information which would make the participant identifiable will not be transferred.  
The participant must be informed that his/her personal study-related data will be used by the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.  
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities. 
When archiving or processing personal data pertaining to the Investigator and/or to the 
participants, the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by any unauthorized third party. 
10.1.4 Committees Structure 
The steering committee is composed of scientists with clinical and methodological expertise in 
diabetes and conduct of clinical trials. This committee, led by a chairman, is responsible for 
producing and conducting a scientifically sound study and for ensuring accurate reporting of the 
study. In that capacity, the steering committee must address scientific issues encountered during 
the study. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 66 
10.1.5 Dissemination of Clinical Study Data 
Sanofi shares information about clinical trials and results on publically accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other 
clinical trial disclosure commitments established by pharmaceutical industry associations.  These 
websites include clinicaltrials.gov, EU clinicaltrialregister (eu.ctr), and sanofi.com, as well as 
some national registries. 
In addition, results from clinical trials in patients are required to be submitted to peer-reviewed 
journals following internal company review for accuracy, fair balance and intellectual property. 
For those journals that request sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directed to submit their request to 
clinicalstudydatarequest.com. 
Individual participant data and supporting clinical documents are available for request at 
clinicalstudydatarequest.com. While making information available we continue to protect the 
privacy of participants in our clinical trials.  Details on data sharing criteria and process for 
requesting access can be found at this web address: clinicalstudydatarequest.com. 
10.1.6 Data Quality Assurance 
 
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The 
Investigator is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF.  
 
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
 
The Investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
 
Monitoring details describing strategy (eg, risk-based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk-Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) 
are provided in separate study documents. 
 
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
 
The Sponsor assumes accountability for actions delegated to other individuals 
(eg, Contract Research Organizations). 
 
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 67 
 
Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator for 25 years after the signature of the final study 
report unless local regulations or institutional policies require a longer retention period. No 
records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor.  
10.1.7 Source documents 
 
Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the Investigator’s site. 
 
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The Investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available. 
10.1.8 Study and Site Closure 
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed. 
The Investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the Sponsor or Investigator may include but are 
not limited to: 
 
Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the Sponsor's procedures, or GCP guidelines. 
 
Inadequate recruitment of participants by the Investigator. 
 
Discontinuation of further study intervention development. 
10.1.9 Publication Policy 
 
The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor 
before submission. This allows the Sponsor to protect proprietary information and to 
provide comments.  
 
The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In 
this case, a coordinating Investigator will be designated by mutual agreement. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 68 
 
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements. 
10.2 
APPENDIX 2: CLINICAL LABORATORY TESTS 
The tests detailed in Table 9 will be performed by the central laboratory.  
 
Protocol-specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol. 
 
Additional tests may be performed at any time during the study as determined necessary 
by the Investigator or required by local regulations. 
Table 9 - Protocol-required laboratory assessments 
Laboratory 
assessments 
 
Parameters 
Hematology 
Platelet count  
Red blood cell (RBC) count 
Hemoglobin 
Hematocrit 
White blood cell (WBC) count  
 
Clinical chemistry 
Uric acid 
Potassium 
Aspartate 
aminotransferase (AST)/ 
Serum glutamic-
oxaloacetic transaminase 
(SGOT) 
Total bilirubin (in case 
of values above the 
normal range, 
differentiation in 
conjugated and non-
conjugated bilirubin) 
 
Creatinine 
 
 
Sodium 
Alanine 
aminotransferase 
 (ALT)/ Serum glutamic-
pyruvic transaminase 
(SGPT) 
Estimated creatinine 
clearance 
 
FPG 
HbA1c 
Blood urea nitrogen 
(BUN) 
Alkaline phosphatase 
 
 
 
Other screening tests 
 
C peptide 
 
Serum human chorionic gonadotropin (hCG) pregnancy test (for 
women of childbearing potential at screening) 
 
Urine hCG pregnancy test for WOCBP at Visit-6 and 18 (to be 
confirmed with serum test if positive) 
 
The results of central laboratory tests will be uploaded to the clinical database. Investigators will 
receive the reports from central laboratory and must document their review of each laboratory 
safety report. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 69 
10.3 
APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING 
DEFINITION OF AE 
AE definition 
 
An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered related 
to the study intervention. 
 
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention. 
Events meeting the AE definition 
 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the Investigator (ie, not related to progression of underlying 
disease), eg: 
- 
Symptomatic and/or,  
- 
Requiring either corrective treatment or consultation, and/or,  
- 
Leading to IMP discontinuation or modification of dosing, and/or,  
- 
Fulfilling a seriousness criterion, and/or,  
- 
Defined as an AESI. 
 
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
 
New conditions detected or diagnosed after study intervention administration even though 
it may have been present before the start of the study. 
 
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. 
 
"Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfil the definition of an AE or SAE.  
 
The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfil the definition of an AE or SAE. Also, "lack of 
efficacy" or "failure of expected pharmacological action" also constitutes an AE or SAE. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 70 
Events NOT meeting the AE definition 
 
Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
Investigator to be more severe than expected for the participant’s condition. 
 
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition. 
 
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE. 
 
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
 
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
DEFINITION OF SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease). 
A SAE is defined as any untoward medical occurrence that, at any dose: 
a) Results in death 
b) Is life-threatening 
The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe. 
c) Requires inpatient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE 
should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE. 
d) Results in persistent disability/incapacity 
- 
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 71 
- 
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption. 
e) Is a congenital anomaly/birth defect 
f) Other situations: 
- 
Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize 
the participant or may require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition. These events should usually be 
considered serious. 
- 
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse. 
RECORDING AND FOLLOW-UP OF AE AND/OR SAE 
AE and SAE recording 
 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event. 
 
The Investigator will then record all relevant AE/SAE information in the CRF. 
 
It is not acceptable for the Investigator to send photocopies of the participant’s medical 
records to the Sponsor’s representative in lieu of completion of the AE/SAE CRF page. 
 
There may be instances when copies of medical records for certain cases are requested by 
the Sponsor’s representative. In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copies of the medical records before 
submission to the Sponsor’s representative. 
 
The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE. 
Assessment of intensity 
The Investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories: 
 
Mild: An event that is easily tolerated by the participant, causing minimal discomfort and 
not interfering with everyday activities. 
 
Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 72 
 
Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe. 
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe. 
Assessment of causality 
 
The Investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. 
 
A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
 
The Investigator will use clinical judgment to determine the relationship. 
 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated. 
 
The Investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment. 
 
For each AE/SAE, the Investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality. 
 
There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to the Sponsor’s representative. However, it is 
very important that the Investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the Sponsor’s 
representative. 
 
The Investigator may change his/her opinion of causality in light of follow-up information 
and send a SAE follow-up report with the updated causality assessment. 
 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
Follow-up of AEs and SAEs 
 
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the Sponsor’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals. 
 
If a participant dies during participation in the study or during a recognized follow-up 
period, the Investigator will provide the Sponsor’s representative with a copy of any post-
mortem findings including histopathology. 
 
New or updated information will be recorded in the originally completed CRF. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 73 
 
The Investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information. 
REPORTING OF SAES 
SAE reporting to the Sponsor’s representative via an electronic data collection tool 
 
The primary mechanism for reporting an SAE to the Sponsor’s representative will be the 
electronic data collection tool. 
 
If the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see next section) in order to report the event within 24 hours. 
 
The site will enter the SAE data into the electronic system as soon as it becomes available. 
 
After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data. 
 
If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off-
line, then the site can report this information on a paper SAE form (see next section) or to 
the Sponsor’s representative by telephone. 
 
Contacts for SAE reporting can be found in a separate document. 
SAE reporting to the Sponsor’s representative via paper CRF 
 
Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor’s representative. 
 
In rare circumstances and in the absence of facsimile equipment, notification by telephone 
is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier 
service. 
 
Initial notification via telephone does not replace the need for the Investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames. 
 
Contacts for SAE reporting can be found in a separate document. 
10.4 
APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION 
DEFINITIONS: 
Woman of childbearing potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below). 
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019
Version number: 1
Property of the Sanofi group - strictly confidential 
Page 74 
Women in the following categories are not considered WOCBP 
1. Premenarchal
2. Premenopausal female with 1 of the following:
-
Documented hysterectomy,
-
Documented bilateral salpingectomy,
-
Documented bilateral oophorectomy.
For individuals with permanent infertility due to an alternate medical cause other than
the above, (eg, mullerian agenesis, androgen insensitivity), Investigator discretion
should be applied to determining study entry.
Note:  Documentation can come from the site personnel’s: review of the participant’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female
-
A postmenopausal state is defined as no menses for 12 months without an alternative
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal
range may be used to confirm a postmenopausal state in women not using hormonal
contraception or hormonal replacement therapy (HRT). However, in the absence of
12 months of amenorrhea, confirmation with more than one FSH measurement is
required,
-
Females on HRT and whose menopausal status is in doubt will be required to use one
of the non-estrogen hormonal highly effective contraception methods if they wish to
continue their HRT during the study. Otherwise, they must discontinue HRT to allow
confirmation of postmenopausal status before study enrollment.
CONTRACEPTION GUIDANCE 
Female participants 
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE: 
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when 
used consistently and correctly. 

Implantable progestogen-only hormone contraception associated with inhibition of ovulationb

Intrauterine device (IUD)

Intrauterine hormone-releasing system (IUS) b

Bilateral tubal occlusion

Vasectomized partner
(Vasectomized partner is a highly effective contraceptive method provided that the partner is the
sole sexual partner of the woman of childbearing potential and the absence of sperm has been
confirmed. If not, an additional highly effective method of contraception should be used.
Spermatogenesis cycle is approximately 90 days.)
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 75 
Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when used 
consistently and correctly. 
Combined (estrogen- and progestogen-containing ) hormonal contraception associated with inhibition 
of ovulationc 
 oral 
 intravaginal 
 transdermal 
 injectable 
Progestogen-only hormone contraception associated with inhibition of ovulationc 
 oral 
 injectable 
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.) 
ACCEPTABLE METHODSd 
 Progestogen-only oral hormonal contraception where inhibition of ovulation is not the primary 
mode of action 
 Male or female condom with or without spermicidee 
 Cervical cap, diaphragm, or sponge with spermicide 
 A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide 
(double-barrier methods)c 
a) Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for those participating in clinical studies. 
b) Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those 
when used consistently and correctly. 
c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action. 
d) Considered effective, but not highly effective - failure rate of ≥1% per year.  Periodic abstinence (calendar, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational 
amenorrhoea method (LAM) are not acceptable methods of contraception.  
e) Male condom and female condom should not be used together (due to risk of failure with friction). 
COLLECTION OF PREGNANCY INFORMATION:  
Male participants with partners who become pregnant  
 
The Investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive study intervention. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 76 
 
After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor. 
Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
Female participants who become pregnant  
 
The Investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours of learning of a 
participant's pregnancy. The participant will be followed to determine the outcome of the 
pregnancy. The Investigator will collect follow-up information on the participant and the 
neonate and the information will be forwarded to the Sponsor. Generally, follow-up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or absence 
of anomalies) or indication for the procedure. 
 
Any pregnancy complication or elective termination of a pregnancy will be reported as an 
AE or SAE. A spontaneous abortion is always considered to be an SAE and will be 
reported as such. Any post-study pregnancy related SAE considered reasonably related to 
the study intervention by the Investigator will be reported to the Sponsor as described in 
Section 8.3.4. While the Investigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention. 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 77 
10.5 
APPENDIX 5: QUESTIONNAIRE 
10.5.1 The Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs)  
 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 78 
10.5.2 The Diabetes Treatment Satisfaction Questionnaire Change Version  
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 79 
10.5.3 MOS Sleep 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 80 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 81 
10.5.4 WPAI 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 82 
 
10.6 
APPENDIX 6: ADA HYPOGLYCEMIA DEFINITIONS 
In this study, hypoglycemia is categorized according to the American Diabetes Association 
workgroup on hypoglycemia classification:  
 
Defining and Reporting Hypoglycemia in Diabetes: A Report from American diabetes 
Association Workgroup on hypoglycemia Diabetes Care. 2005 May;28(5):1245-9.  
 
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and The 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95. 
In addition to the threshold of ≤70 mg/dL (≤3.9 mmol/L), hypoglycemia episodes with a plasma 
glucose of <54 mg/dL (<3.0 mmol/L) will be analyzed separately:  
International Hypoglycemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L 
(54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American 
Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 
2017; 40(1): 155-157. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 83 
10.7 
APPENDIX 7: COUNTRY-SPECIFIC REQUIREMENTS  
Not applicable. 
10.8 
APPENDIX 8: ABBREVIATIONS 
 
AE: 
adverse event 
AESI: 
adverse event of special interest 
ANCOVA: 
analysis of covariance 
CGM: 
continuous glucose monitoring 
CI: 
confidence interval 
CV: 
coefficient of variation 
DCCT: 
Diabetes Control and Complications Trial 
eCRF: 
electronic case report form 
FPG: 
fasting plasma glucose 
GIR: 
glucose infusion rate 
HbA1c: 
glycated hemoglobin A1c 
IMP: 
investigational medicinal product 
IRT: 
interactive response technology 
ITT: 
intent to treat 
PD: 
Pharmacodynamics 
PK: 
Pharmacokinetics 
SAE: 
serious adverse event 
SC: 
subcutaneous 
SD: 
standard deviation 
SE: 
standard errors 
SMPG: 
self-monitoring of plasma glucose 
T1DM: 
type 1 diabetes mellitus 
 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 84 
11 
REFERENCES 
 
1. Sanofi. Data on file. 
2. Heise T, Hövelmann U, Nosek L, Hermanski L, Bøttcher SG, Haahr H. Comparison of the 
pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. 
Expert Opin Drug Metab Toxicol. 2015;11(8):1193-201. 
3. Hochberg Y, Tamhane AC. Multiple comparison procedures. John Wiley & Sons (print 1987).  
Published online: 27 May 2008. 
4. The Diabetes Control and Complications Trial Research Group. The Relationship of Glycemic 
Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the 
Diabetes Control and Complications Trial. Diabetes 1995;44(8):968-83. 
5. Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P et al. Fasting plasma 
glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes 
Study. Diabetes Care. 2000 Jan;23(1):45-50. 
6. Vora J, Heise T. Variability of glucose-lowering effect as a limiting factor in optimizing basal 
insulin therapy: a review. Diabetes Obes Metab. 2013 Aug;15(8):701-12. 
7. Toujeo Summary of product characteristics -EMEA/H/C/000309 -II/0095/G 
8. Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. New Insulin 
Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A 
Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015;38 
(12):2217–25. 
9. Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, et al. 
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 
Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening 
Injections. Diabetes Care. 2017;40(4):554–60. 
10. Tresiba Sumary of Product Characteristics -EMEA/H/C/002498 -N/0016 
11. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. BEGIN Basal-Bolus Type 1 
Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine 
in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus 
Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 
Apr 21;379(9825):1489-97. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 85 
12. NCT01569841. 
https://clinicaltrials.gov/ct2/show/results/NCT01569841?term=01569841&rank=1&sect=X87
0156. Accessed April 20, 2017. 
13. Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, et al. More Similarities 
Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 
Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. 
Diabetes Care. 2018 Oct;41(10):2147-54. 
14. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. 
Continuous glucose monitoring and intensive treatment of type 1 diabetes. Juvenile Diabetes 
Research Foundation Continuous Glucose Monitoring Study Group.  N Engl J Med. 
2008;359(14):1464-76. 
15. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 Dec;40(12):1631-
40. 
16. Bradley C. The Diabetes Treatment Satisfaction Questionnaire (DTSQ). In: Bradley C, ed. 
Handbook of psychology and diabetes: a guide to psychological measurement in diabetes 
research and practice. Chur (Switzerland): Harwood Academic Publishers; 1994:111-132 
17. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside 
status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999 
Mar;22(3):530-2. 
18. Hays RD, Stewart AL. In: Stewart AL, Ware JE, editors. Sleep measures. Measuring 
functioning and well-being: the Medical Outcomes Study approach. Durham, NC: Duke 
University Press; 1992. p. 235-59. 
19. 
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work 
productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5):353-65. 
 
20. American Diabetes Association Standards of Medical Care in Diabetes-2019. Diabetes care. 
January 2019 Volume 42, Supplement 1. 
21. Hays, RD, Martin, SA, Sesti, AM, Spritzer, KL (2005). Psychometric properties of the 
Medical Outcomes Study Sleep measure. Sleep Medicine, 6, 41-44. 
22. American Diabetes Association Workgroup on Hypoglycemia. Defining and Reporting 
Hypoglycemia in Diabetes: a report from the American Diabetes Association Workgroup on 
Hypoglycemia. Diabetes Care. 2005 May;28(5):1245-9. 
23. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and 
diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine 
Society. Diabetes Care. 2013 May;36(5):1384-95. 
VV-CLIN-0514702 2.0


Clinical Trial Protocol 
LPS14947 - insulin glargine 300 U/mL 
31-May-2019 
Version number: 1 
 
Property of the Sanofi group - strictly confidential 
Page 86 
24. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L 
(54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American 
Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 
2017 Jan;40(1):155-157. 
 
 
VV-CLIN-0514702 2.0


Signature Page for VV-CLIN-0514702 v2.0
lps14947-16-1-1-protocol
Approve & eSign
Approve & eSign
VV-CLIN-0514702 2.0

SAP_001.pdf: 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity 
According to template: QSD-002643 VERSION 7.0 (20-FEB-2019) 
Page 1 
STATISTICAL ANALYSIS PLAN 
A 12-week randomized controlled trial to compare TOUJEO® and TRESIBA® in 
terms of glucose values in target range and variability during continuous glucose 
monitoring (CGM) in patients with type 1 diabetes mellitus  
HOE901-U300-LPS14947 
STATISTICIAN: 
 
STATISTICAL PROJECT LEADER: 
 
DATE OF ISSUE:  01-Jul-2021 
Total number of pages: 
64 
VV-CLIN-0612739 1.0
NCT04075513


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 2 
TABLE OF CONTENTS 
STATISTICAL ANALYSIS PLAN ................................................................................................................... 1 
TABLE OF CONTENTS .................................................................................................................................. 2 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS .......................................................................... 5 
1 
OVERVIEW AND INVESTIGATIONAL PLAN ................................................................................ 6 
1.1 
STUDY DESIGN AND RANDOMIZATION ...................................................................................... 6 
1.2 
OBJECTIVES ................................................................................................................................... 6 
1.2.1 
Primary objectives ............................................................................................................................ 6 
1.2.2 
Secondary objectives ....................................................................................................................... 6 
1.2.3 
Tertiary/exploratory objectives ......................................................................................................... 6 
1.3 
DETERMINATION OF SAMPLE SIZE ............................................................................................. 6 
1.4 
STUDY PLAN ................................................................................................................................... 7 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL .................................. 8 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN ....................... 9 
2 
STATISTICAL AND ANALYTICAL PROCEDURES .................................................................... 10 
2.1 
ANALYSIS ENDPOINTS ............................................................................................................... 10 
2.1.1 
Demographic and baseline characteristics .................................................................................... 10 
2.1.2 
Prior or concomitant medications ................................................................................................... 12 
2.1.3 
Efficacy endpoints .......................................................................................................................... 12 
2.1.3.1 
Primary efficacy endpoint(s) .......................................................................................................... 13 
2.1.3.2 
Secondary efficacy endpoint(s) ...................................................................................................... 13 
2.1.3.3 
Tertiary/exploratory efficacy endpoint(s) ........................................................................................ 13 
2.1.4 
Safety endpoints ............................................................................................................................ 14 
2.1.4.1 
Adverse events variables ............................................................................................................... 15 
2.1.4.2 
Deaths ............................................................................................................................................ 16 
2.1.4.3 
Laboratory safety variables ............................................................................................................ 16 
2.1.4.4 
Vital signs variables ....................................................................................................................... 17 
2.1.4.5 
Electrocardiogram variables .......................................................................................................... 17 
2.1.4.6 
Hypoglycemia events ..................................................................................................................... 17 
2.1.5 
Pharmacokinetic variables ............................................................................................................. 18 
2.1.6 
Pharmacodynamic/genomics endpoints ........................................................................................ 18 
2.1.7 
Quality-of-life endpoints ................................................................................................................. 18 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 3 
2.1.7.1 
DTSQs ........................................................................................................................................... 18 
2.1.7.2 
DTSQc ........................................................................................................................................... 19 
2.1.7.3 
MOS Sleep ..................................................................................................................................... 19 
2.1.7.4 
WPAI .............................................................................................................................................. 20 
2.1.8 
Health economic endpoints ............................................................................................................ 20 
2.2 
DISPOSITION OF PATIENTS ....................................................................................................... 20 
2.2.1 
Randomization and drug dispensing irregularities ......................................................................... 21 
2.3 
ANALYSIS POPULATIONS ........................................................................................................... 22 
2.3.1 
Efficacy populations ....................................................................................................................... 22 
2.3.1.1 
Intent–to-treat population ............................................................................................................... 22 
2.3.1.2 
Per-protocol population .................................................................................................................. 22 
2.3.1.3 
Population without trial impact (disruption) due to COVID-19 ....................................................... 23 
2.3.2 
Safety population ........................................................................................................................... 24 
2.4 
STATISTICAL METHODS ............................................................................................................. 24 
2.4.1 
Demographics and baseline characteristics .................................................................................. 24 
2.4.2 
Prior or concomitant medications ................................................................................................... 25 
2.4.2.1 
Non-antidiabetic medications ......................................................................................................... 25 
2.4.2.2 
Antidiabetic medications ................................................................................................................ 25 
2.4.3 
Extent of investigational medicinal product exposure and compliance ......................................... 26 
2.4.3.1 
Extent of investigational medicinal product exposure .................................................................... 26 
2.4.3.2 
Daily insulin doses ......................................................................................................................... 27 
2.4.3.3 
Compliance .................................................................................................................................... 27 
2.4.4 
Analyses of efficacy endpoints ....................................................................................................... 27 
2.4.4.1 
Analysis of primary efficacy endpoint(s) ........................................................................................ 28 
2.4.4.2 
Analyses of secondary efficacy endpoints ..................................................................................... 31 
2.4.4.3 
Multiplicity issues ........................................................................................................................... 32 
2.4.4.4 
Additional efficacy analysis(es) ...................................................................................................... 33 
2.4.5 
Analyses of safety data .................................................................................................................. 33 
2.4.5.1 
Analyses of hypoglycemia events .................................................................................................. 33 
2.4.5.2 
Analyses of adverse events ........................................................................................................... 34 
2.4.5.3 
Deaths ............................................................................................................................................ 36 
2.4.5.4 
Analyses of laboratory variables .................................................................................................... 36 
2.4.5.5 
Analyses of vital sign variables ...................................................................................................... 37 
2.4.5.6 
Analyses of electrocardiogram variables ....................................................................................... 37 
2.4.6 
Analyses of pharmacokinetic and pharmacodynamic variables .................................................... 37 
2.4.7 
Analyses of quality of life/health economics variables ................................................................... 37 
2.5 
DATA HANDLING CONVENTIONS .............................................................................................. 38 
2.5.1 
General conventions ...................................................................................................................... 38 
2.5.2 
Data handling conventions for secondary efficacy variables ......................................................... 39 
2.5.2.1 
CGM secondary and tertiary endpoints ......................................................................................... 39 
2.5.2.2 
Absolute change ............................................................................................................................ 40 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 4 
2.5.2.3 
HbA1c and FPG ............................................................................................................................. 40 
2.5.2.4 
WPAI .............................................................................................................................................. 41 
2.5.2.5 
MOS Sleep ..................................................................................................................................... 41 
2.5.3 
Missing data ................................................................................................................................... 41 
2.5.4 
Windows for time points ................................................................................................................. 44 
2.5.5 
Unscheduled visits ......................................................................................................................... 45 
2.5.6 
Pooling of centers for statistical analyses ...................................................................................... 45 
2.5.7 
Statistical technical issues ............................................................................................................. 45 
3 
INTERIM ANALYSIS ..................................................................................................................... 46 
4 
DATABASE LOCK ........................................................................................................................ 47 
5 
SOFTWARE DOCUMENTATION ................................................................................................. 48 
6 
REFERENCES ............................................................................................................................... 49 
7 
LIST OF APPENDICES ................................................................................................................. 50 
APPENDIX A: SUMMARY OF STATISTICAL ANALYSES .......................................................................... 51 
APPENDIX B: QUESTIONNAIRES (PROS) ................................................................................................. 59 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 5 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
 
ADA: 
American Diabetes Association 
AE: 
Adverse Event 
AESI: 
Adverse Event of Special Interest 
ANCOVA: 
Analysis of Covariance 
ATC: 
Anatomical Therapeutic Chemical 
AUC: 
Area Under the Curve 
CDG: 
Customised Drug Grouping 
CGM: 
Continuous Glucose Monitoring 
CI: 
Confidence Interval 
CV: 
Coefficient of Variation 
DTSQc: 
Diabetes Treatment Satisfaction Questionnaire (Change) 
DTSQs: 
Diabetes Treatment Satisfaction Questionnaire (Status) 
eCRF: 
Electronic Case Report Form 
EOS: 
End of Study 
GMI: 
Glucose Management Indicator 
HLT: 
High-Level Term 
ICF: 
Informed Consent Form 
IMP: 
Investigational Medicinal Product 
IRT: 
Interactive Response Technology 
ITT: 
Intent-to-Treat 
LLT: 
Lower-Level Term 
LS Means: 
least squares means 
MAR: 
Missing at Random 
MDI: 
Multiple Daily Injections 
MedDRA: 
Medical Dictionary for Regulatory Activities 
MI: 
Multiple Imputation 
MNAR: 
Missing not at Random 
NIMP: 
Non-investigational Medicinal Product 
PRO: 
Patient-Reported Outcomes 
PT: 
Preferred Term 
SAE: 
Serious Adverse Events 
SAP: 
Statistical Analysis Plan 
SD: 
Standard Deviation 
SE: 
Standard Error 
SMPG: 
Self-Monitoring of Plasma Glucose 
SOA: 
Schedule of Activities 
SOC: 
System Organ Class 
TEAE: 
Treatment-Emergent Adverse Event 
WHO-DD: 
World Health Organization-Drug Dictionary 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 6 
1 
OVERVIEW AND INVESTIGATIONAL PLAN  
1.1 
STUDY DESIGN AND RANDOMIZATION  
This is a multicenter, randomized, active-controlled, parallel-group, 12-week open-label study to 
compare the efficacy of TOUJEO® (HOE901-U300) with TRESIBA® using 20-day continuous 
glucose monitoring (CGM) glucose profiles at Week 12 in patients with type 1 diabetes mellitus.  
Patients satisfying the study inclusion/exclusion criteria (including CGM performance 
requirements) will be randomized via an Interactive Response Technology (IRT) in a 1:1 ratio to 
1 of the 2 treatment groups and treated for 12 weeks. Randomization will be stratified by HbA1c 
at screening (<8.0% versus ≥8.0%). 
Approximately 338 patients will be randomly assigned to study intervention for an estimated total 
of 131 evaluable patients per treatment within approximately 50 sites. 
1.2 
OBJECTIVES  
1.2.1 Primary objectives  
The primary objective of this study is to demonstrate the non-inferiority of insulin glargine 
300 U/mL (Toujeo®) in comparison to insulin degludec 100 U/mL (Tresiba®) on glycemic 
control and variability in patients with diabetes mellitus. 
1.2.2 Secondary objectives  
The secondary objectives are 
• 
To evaluate the glycemic control and variability parameters in each treatment group at 
Week 12 using CGM 
• 
To evaluate the safety of insulin glargine 300 U/mL in comparison to insulin degludec 
100 U/mL 
1.2.3 Tertiary/exploratory objectives  
The tertiary objective is to further explore the glycemic control and variability parameters in each 
treatment group at Week 12 using CGM. 
1.3 
DETERMINATION OF SAMPLE SIZE  
The sample size calculation is based on the percent time spent in glucose range of ≥70 to 
≤180 mg/dL (≥3.9 to ≤10 mmol/L) at Week 12, assessed from CGM measurements obtained from 
Weeks 10 to 12.  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 7 
For this criterion of percent time in range, there is no predefined non-inferiority margin. A relative 
non-inferiority margin of 10% is considered. 
Let m1 and m0 be the true means for the Toujeo® and Tresiba® groups, respectively.  
The non-inferiority null hypothesis would be H0: m1-m0 ≤-0.1*m0 or H0: m1-0.9*m0 ≤ 0 and the 
alternative hypothesis would be H1: m1=m0.  
Toujeo would be considered non-inferior to Tresiba if the lower limit of the 95% confidence 
interval (CI) for the adjusted difference estimate of m1-0.9*m0 at Week 12 is > 0. 
To ensure 90% power, the sample size should satisfy: 
1.96 −(0.1 ∗𝑚0)
√1.81 ∗𝑆𝐷2
𝑛
= −1.282 
where −1.282 is the 10th percentile of a standard normal distribution and standard deviation (SD) 
the common SD, which leads to: 
𝑛=
(1.96 + 1.282)2 ∗1.81 ∗𝑆𝐷2
(0.1 ∗𝑚0)2
 
Assuming a common SD of 14.7%, an average percent time in range in the Tresiba treatment 
group of 56% (value from LPS14587), no true difference between both arms under H1, and a 
relative non-inferiority of 10%, a sample size of 131 evaluable patients per treatment group would 
provide at least 90% power to show non-inferiority of Toujeo with respect to Tresiba on the 
percentage of time plasma glucose within the range of ≥70 to ≤180 mg/dL at Week 12. 
With the assumption of a non-evaluability rate of 22%, 338 patients (169 per treatment group) 
will be randomized. 
1.4 
STUDY PLAN  
The study consists of a 1- or 2-week screening period, followed by a 4-week run-in period, and a 
12-week randomized treatment period. 
During the first 2 weeks of the run-in period (Weeks -4 and -3), patients will undergo treatment 
stabilization of their current basal and mealtime insulin treatment and will be trained and tested on 
how to perform study-related procedures. During the (-3) – (-1) weeks of run-in, patients will 
wear a CGM device, blinded to both patients and Investigators. During these 20 consecutive days, 
CGM readings will be collected as CGM assessment at baseline. 
During the randomized treatment period, CGM readings will also be collected in the same fashion 
as in the run-in period during Weeks 10-12. This will be the CGM assessment at Week 12. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 8 
During the entire study starting after the screening period, patients will perform Self-Monitoring 
of Plasma Glucose (SMPG) as specified in the study flow chart. The SMPG readings will be used 
to guide insulin dose titration for optimal glycemic control. 
At the end of the study, the patients will be followed-up for between 2 to 4 days after the last 
Investigational Medicinal Product (IMP) dose to collect post-treatment safety information. 
Figure 1 is a representation of the study schema. 
 
The schedule of activities (SOA) for the study is presented in Section 1.3 of the protocol. 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL  
Following the updated version of ‘Clinical Targets for Continuous Glucose Monitoring Data 
Interpretation: Recommendations From the International Consensus on Time in Range’ in 2019 
(1), some exploratory endpoints were added related CGM  
• Mean glucose 
• Glucose Management Indicator (GMI) (2) as defined by GMI (%) = 3.31+0.02392*(mean 
glucose in mg/dL) 
• Percent time and mean hours per day in the glucose range of ≥54 to <70 mg/dL (≥3.0 to 
<3.9 mmol/L) (on all-time and during the night [00:00 to 05:59]), 
• Percent time and mean hours per day in the glucose range of >180 to ≤250 mg/dL (>10 to 
≤13.9 mmol/L) (on all-time and during the night [00:00 to 05:59]), 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 9 
Following a misprint in ‘International Consensus on Use of Continuous Glucose Monitoring’ in 
2017 (3) , corrected in CGM consensus in 2019, an update of threshold for glucose within-day CV 
was done: ≤ 36 % instead of < 36%  
For consistency between CGM endpoints and safety endpoints, the following endpoints related to 
hypoglycemia were added: 
• Hypoglycemia (symptomatic or asymptomatic) documented by a measured plasma 
glucose concentration of <3.9 mmol/L (< 70 mg/dL) and ≥3.0 mmol/L (≥54 mg/dL), on 
all-time and during the night [00:00 to 05:59] 
As per FDA & EMA guidelines provided during COVID-19 pandemic situation, several 
considerations (new population set call “Population without trial impact (disruption) due to 
COVID-19” and sensitivity analyses) were considered during the Statistical Analysis Plan (SAP) 
finalization. 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN  
Not applicable. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 10 
2 
STATISTICAL AND ANALYTICAL PROCEDURES  
2.1 
ANALYSIS ENDPOINTS  
2.1.1 Demographic and baseline characteristics  
The baseline value is the last available value obtained up to the date and time of randomization or 
up to the time of first injection of the treatment if the measurement occurred on the same day as 
randomization. 
All baseline safety and efficacy parameters (apart from those listed below) are presented along 
with the summary statistics in the safety and efficacy sections (Section 2.4.5 and Section 2.4.4). 
Demographic characteristics 
Demographic variables are:  
• 
Gender (Male, Female),  
• 
Age in years at date of informed consent (quantitative and qualitative variable: from 
18 – 64 and 65 years and over),  
• 
Weight in kg (quantitative),  
• 
BMI in kg/m2 (quantitative and qualitative variable: <25, ≥25 < 30, ≥30 <35, and 
≥35 kg/m2),  
• 
Randomization strata of screening HbA1c categories (<8.0 and ≥8.0%). 
Medical or surgical history 
Medical (or surgical) history includes any past and/or concomitant diseases or past surgeries.  
This information will be coded using the version of Medical Dictionary for Regulatory Activities 
(MedDRA) currently in effect at Sanofi at the time of database lock. 
Disease characteristics at baseline  
Specific disease history includes: 
• 
Time from diagnosis to randomization (years) and age at diagnosis (years),  
• 
History of gestational diabetes (yes, no),  
• 
Time from first intake of basal insulin analog and of rapid acting insulin analog to 
randomization (years),  
• 
Screening basal insulin analog (treatment preferred name according to the World Health 
Organization-Drug Dictionary [WHO-DD]). Distinction between insulin glargine U100 
and insulin glargine U300 will be provided, 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 11 
• 
Screening basal insulin dose, as reported on screening visit and in case of several lines 
reported the last available will be used (total daily dose in IU, total daily dose adjusted for 
body weight, in IU/kg), 
• 
Screening mealtime insulin analog (Insulin glulisine, Insulin lispro, Insulin aspart), 
• 
Screening mealtime insulin dose, as reported on screening visit and in case of several lines 
reported the last available will be used (total daily dose in IU, total daily dose adjusted for 
body weight, in IU/kg), 
• 
Screening total daily insulin dose, ie, the day of screening visit (basal + mealtime) in IU 
and adjusted for body weight in IU/kg, 
• 
Run-in basal insulin analog (treatment preferred name according to the WHO-DD). 
Distinction between insulin glargine U100 and insulin glargine U300 will be provided, 
• 
Run-in basal insulin dose (total daily dose [in IU], total daily dose adjusted for body 
weight [in IU/kg]), as mean of previous basal daily dose during the 3 last days prior to the 
first IMP (or prior to randomization for not treated patients), in case of less than 3 days, 
the last dose will be used, 
• 
Run-in mealtime insulin analog (Insulin glulisine, Insulin lispro, Insulin aspart), 
• 
Run-in mealtime insulin dose (total daily dose, total daily dose adjusted for body weight) 
as mean of previous mealtime insulin total daily dose during the 3 last days prior to the 
first IMP (or prior to randomization for not treated patients), in case of less than 3 days, 
the last dose will be used. Of note, this will be considered as baseline mealtime insulin 
dose, 
• 
Run-in total daily insulin doses (basal + mealtime) (total daily dose, total daily dose 
adjusted for body weight),  
• 
Diabetes complications (at least one, Diabetic Retinopathy, Non-Proliferative Diabetic 
Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Neuropathy, Diabetic 
Nephropathy),  
• 
Method of mealtime insulin titration (Pattern of postprandial plasma glucose results of 
SMPG from the prior 3 days or Carbohydrate content of the meal [carb counting]). 
Vital signs  
Vital signs at baseline are:  
• 
Systolic Blood Pressure (mmHg),  
• 
Diastolic Blood Pressure (mmHg),  
• 
Heart Rate (Beats/min). 
Any technical details related to computation, dates, and imputation for missing dates are described 
in Section 2.5. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 12 
2.1.2 Prior or concomitant medications  
All medications taken since enrollment and until the end of the study are to be reported in the case 
report form. 
Non-antidiabetic and antidiabetic medications will be considered separately. 
All medications will be coded using the WHO-DD version currently in effect at Sanofi at the time 
of database. 
• Prior medications are those the patient used prior to first injection of IMP intake. Prior 
medications can be discontinued before first administration or can be ongoing during 
treatment phase.  
• Concomitant medications are any treatments received by the patient concomitantly to the 
IMP from first injection of IMP to the last injection of IMP + 2 days (0 day for 
anti-diabetic therapy). A given medication can be classified both as a prior medication and 
as a concomitant medication.  
• Post-treatment medications are those the patient took in the period running from the 3rd 
day (1 day for anti- diabetic therapy) after last IMP intake up to the end of the study. 
Any technical details related to computation, dates, imputation for missing dates are described in 
Section 2.5. 
2.1.3 Efficacy endpoints  
Observation period for efficacy endpoints 
The 12–week randomized period for efficacy variables is defined as the time from randomization 
until Week 12 (Visit 18) for randomized patients, regardless of study treatment discontinuation. 
CGM data 
A patient is eligible for randomization if a minimum of 10 days (not necessarily consecutive) of 
useable CGM data are generated during 20 consecutive days at run-in period. 
At Week 12, CGM is evaluable if there is at least 10 days of useable CGM data (not necessarily 
consecutives) within the analysis time windows (see Section 2.5.4) at Week 12 evaluation. 
Useable CGM data for a day/a 24-hour CGM profile are defined as having: 
• At least 80% time of records per 24 hours (ie, 231 data points among the 288 recorded in  
24 hours). 
• No gap (missing data) lasting for a total of ≥ 2 hours per 24 hours besides the warm-up 
time for the sensor after insertion. 
For CGM endpoints, details on derivations are available in Section 2.5. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 13 
2.1.3.1 Primary efficacy endpoint(s)  
The primary efficacy endpoint is the percent time in the glucose range of  ≥70 to ≤180 mg/dL 
(≥3.9 to ≤10 mmol/L) at Week 12, obtained using CGM (for derivation see Section 2.5.1). 
For any gap of less than 2 hours between two available CGM measurements, linear interpolation 
will be performed to impute the unobserved values at the time points (Section 2.5.1). 
2.1.3.2 Secondary efficacy endpoint(s)  
To address the secondary objective of evaluating the glycemic control and variability parameters 
in each treatment group, efficacy endpoints will be assessed using CGM, HbA1c, and FPG. 
At Week 12 the following main secondary endpoints will be assessed using CGM (see 
Section 2.5.2.1). 
• 
Glucose total coefficient of variation (CV) (%), main secondary endpoint, 
• 
Glucose within-day and between-day CV (%).  
Other secondary endpoints to be assessed are: 
Based on central lab 
• 
Change from baseline to Week 12 in HbA1c (% and mmol/mol), 
• 
Change from baseline to Week 12 in FPG (mmol/L and mg/dL). 
Based on CGM 
• 
Percent time and mean hours per day with glucose <70 mg/dL (on all time [00:00 to 
23:59] and during the night [00:00 to 5:59] obtained from CGM, 
• 
Percent time and mean hours per day with glucose >180 mg/dL obtained from CGM. 
2.1.3.3 Tertiary/exploratory efficacy endpoint(s)  
To address the tertiary objective of exploring the glycemic control and variability parameters in 
each treatment group at Week 12 using CGM, the following endpoints will be assessed: 
• 
Mean hours per day in the glucose range of ≥70 to ≤180 mg/dL (≥3.9 to ≤10 mmol/L), 
• 
Percent time and mean hours per day in the glucose range of ≥70 to ≤140 mg/dL (≥3.9 to 
≤7.8 mmol/L) (on all-time and during the night [00:00 to 05:59]), 
• 
Nocturnal [00:00 to 05:59] percent time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to 
≤10 mmol/L), 
• 
Day time [06:00 to 23:59] percent time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to 
≤10 mmol/L), 
• 
Percent time and mean hours per day with glucose <54 mg/dL (<3.0 mmol/L) (on all time 
and during the night [00:00 to 5:59]), 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 14 
• 
Percent time with glucose <70 mg/dL (<3.9 mmol/L) within the 12 hours after basal 
insulin injection, 
• 
Percent time and mean hours per day with glucose >250 mg/dL (>13.9 mmol/L), 
• 
Mean glucose profile over a 24-hour period, 
• 
24-hour Glucose Area Under the Curve (AUC mg/dL*minutes), derived using the 
trapezoidal rule. The derivation will be adjusted to be an hourly average (Section 2.5.2.1), 
• 
Mean glucose, 
• 
GMI,  
• 
Percent time and mean hours per day in the glucose range of ≥54 to <70 mg/dL (≥3.0 to 
<3.9 mmol/L) (on all-time and during the night [00:00 to 05:59]), 
• 
Percent time and mean hours per day in the glucose range of >180 to ≤250 mg/dL (>10 to 
≤13.9 mmol/L) (on all-time and during the night [00:00 to 05:59]). 
 
Other tertiary/exploratory endpoints than those related to CGM: 
• Daily insulin doses (total daily insulin, basal insulin, mealtime insulin, ratio of basal to 
mealtime insulin dose) in units and U/kg body weight at each visit. Change at Week 8 and 
Week 12 from baseline will be derived.  
• Change from baseline to Week 12 in patient-reported outcomes (treatment satisfaction, 
sleep quality and quantity, and productivity) (for detail on PROs, see Section 2.1.7). 
• 7-point SMPG profiles (pre-prandial and 2-hour postprandial plasma glucose at breakfast, 
lunch, dinner, and bedtime) at Week 12 and change in 7-point SMPG profiles from 
baseline to Week 12. 
2.1.4 Safety endpoints  
To address the secondary objective of evaluating the safety of insulin glargine 300 IU/mL in 
comparison to insulin degludec 100 IU/mL, the following endpoints will be observed 
• 
Number of patients with adverse events (see Section 8.3 of the protocol). 
• 
Number of patients with at least one hypoglycemic event from baseline to Week 12. 
• 
Number of hypoglycemic events per participant-year from baseline to Week 12. 
The safety analysis will be based on the reported adverse events (AEs) and other safety 
information, such as vital signs. The specific safety parameter of interest for insulin treatment is 
hypoglycemia. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 15 
Observation period  
For all safety data, the observation period will be divided as follows:  
• 
The pre-treatment phase is defined as the time from when the patients sign the informed 
consent to first injection of IMP (excluded).  
• 
The on-treatment phase is defined as the time from the first injection of IMP (included) up 
to 2 days after the last injection of IMP. 
• 
The post-treatment phase is defined as the time after the on-treatment phase until the end 
of the study (Follow up Visit).  
On-study observation period is defined as the time from start of treatment until the end of the 
study (defined as last protocol planned visit or the resolution/stabilization of all serious adverse 
events (SAEs) and AEs of specific interest (AESI) as defined in the protocol). 
2.1.4.1 Adverse events variables  
All AEs and SAEs will be collected from the signing of the informed consent form (ICF) until the 
follow-up visit (defined as patient’s last visit planned per protocol or the resolution/stabilization 
of all SAEs and AESI). All events will be managed and reported in compliance with all applicable 
regulations and included in the final clinical study report. 
Adverse event observation period  
• 
Pre-treatment AEs are AEs that developed or worsened or became serious from the signed 
informed consent date up to first administration of IMP 
• 
Treatment-emergent adverse events (TEAEs) are AEs that developed or worsened or 
became serious during the on-treatment period 
• 
Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period 
All AEs (including SAEs and AESIs) will be coded to a lower-level term (LLT), preferred term 
(PT), high-level term (HLT), high-level group term (HLGT), and associated primary system organ 
class (SOC) using the version of MedDRA currently in effect at Sanofi at the time of database 
lock. 
AESI include the following terms, as defined by the protocol: 
• 
Symptomatic overdose: Symptomatic overdose (serious or non-serious) with IMP and/or 
non-investigational medicinal product (NIMP) will be identified through a specific 
question on the AE page in the eCRF. 
• 
Pregnancy: Pregnancy occurring, either in a female subject or in a female partner of a male 
subject entered in the study will be identified through a dedicated AE page in the e-CRF. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 16 
2.1.4.2 Deaths  
The deaths observation period is per the observation periods defined above.  
• Death on-study: deaths occurring during the on-study observation period 
• Death on-treatment: deaths occurring during the on-treatment period  
• Death poststudy: deaths occurring after the end of the study  
2.1.4.3 Laboratory safety variables  
Clinical laboratory data consist of blood analysis, including hematology, clinical chemistry, and 
serum pregnancy tests.  
Blood samples for clinical laboratories will be taken at Visit 1 (screening, Week -6/-5). Additional 
urine samples will be collected on Visit 6 (randomization) and 18 (Week 12) in WOCBP for urine 
pregnancy test (to be confirmed by a serum test, if positive). The laboratory parameters will be 
classified as follows: 
• Hematology (Conventional Units and SI units):  
- 
Platelet count (×10^3/uL and GI/L),  
- 
Hemoglobin (g/dL and g/L),  
- 
Hematocrit (%),  
- 
Red blood cell count (×10^6/uL and TI/L),  
- 
White blood cell count × x10^3/uL and GI/L). 
• Clinical chemistry (Conventional Units and SI units):  
- 
Uric acid (mg/dL and µmol/L),  
- 
Potassium (mEq/L and mmol/L),  
- 
Aspartate aminotransferase/Serum glutamicoxaloacetic transaminase (AST/SGOT, 
U/L), 
- 
 Alanine aminotransferase/Serum glutamicpyruvic transaminase (ALT/SGPT, U/L),  
- 
Total bilirubin (in case of values above the normal range, differentiation in conjugated 
and nonconjugate bilirubin mg/dL and umol/L),  
- 
Creatinine (mg/dL and umol/L),  
- 
Sodium (mEq/L and mmol/L),  
- 
Estimated creatinine clearance (Glomerular Filtration Rate, MDRD, 
mL/min/1.73m^2),  
- 
Blood urea nitrogen (BUN, mg/dL, and mmol/L),  
- 
Alkaline phosphatase (U/L). 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 17 
• Other tests (Conventional Units and SI units): 
- 
C peptide (ng/mL and pmol/L),  
- 
Serum β-human chorionic gonadotropin (for women of childbearing potential at 
screening, mIU/mL),  
- 
Urine hCG pregnancy test for WOCBP at Visit 6 and 18 (to be confirmed with serum 
test, if positive). 
2.1.4.4 Vital signs variables  
Vital signs will be assessed according to the defined visit window (see Section 2.5.4). 
The following vital signs will be assessed: 
• Weight (Kg), 
• Systolic blood pressure (mmHg) in sitting position, 
• Diastolic blood pressure (mmHg) in sitting position, 
• Heart rate (beats/min) in sitting position. 
2.1.4.5 Electrocardiogram variables  
Not applicable to the study. 
2.1.4.6 Hypoglycemia events  
Hypoglycemia events will be evaluated during pre-treatment and on-treatment period (see 
Section 2.1.4). 
All reported hypoglycemia events will be classified according to American Diabetes Association 
(ADA) classification as follows: 
• 
Severe hypoglycemia: an event that ‘Required Assistance Because Subject Was Not 
Capable of Helping Self’.  
• 
Documented symptomatic hypoglycemia: an event during which typical symptoms are 
accompanied by a measured plasma glucose concentration less than 3.9 mmol/L 
(<70 mg/dL).  
• 
Asymptomatic hypoglycemia: an event with no symptoms of hypoglycemia but a 
documented measured plasma glucose concentration less than 3.9 mmol/L (<70 mg/dL). 
In addition, the following events will be also considered:  
• 
Documented symptomatic hypoglycemia with measured plasma glucose concentration less 
than 3.0 mmol/L (<54 mg/dL).  
• 
Asymptomatic hypoglycemia with measured plasma glucose concentration less than 
3.0 mmol/L (<54 mg/dL). 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 18 
• 
Hypoglycemia (symptomatic or asymptomatic) documented by a measured plasma 
glucose concentration less than 3.9 mmol/L (<70 mg/dL). 
• Hypoglycemia (symptomatic or asymptomatic) documented by a measured plasma 
glucose concentration of <3.9 mmol/L (< 70 mg/dL) and ≥3.0 mmol/L (≥54 mg/dL). 
• 
Hypoglycemia (symptomatic or asymptomatic) documented by a measured plasma 
glucose concentration less than 3.0 mmol/L (<54 mg/dL). 
• 
Severe and/or symptomatic hypoglycemia documented by plasma glucose concentration 
less than 3.9 mmol/L (<70 mg/dL). 
• 
Severe and/or symptomatic hypoglycemia documented by plasma glucose concentration 
less than 3.0 mmol/L (<54 mg/dL). 
In addition to anytime of the day (00:00 to 23:59), hypoglycemia events will be evaluated at the 
following time periods: 
• 
Nocturnal hypoglycemia: any hypoglycemic event that occurs between 00:00 and 05:59. 
• 
Diurnal hypoglycemia: any hypoglycemic event that occurs between 06:00 and 23:59. 
Note: CGM values will not be considered for identifying hypoglycemia. 
2.1.5 Pharmacokinetic variables  
Not applicable to the study. 
2.1.6 Pharmacodynamic/genomics endpoints  
Not applicable to the study. 
2.1.7 Quality-of-life endpoints  
Several patient-reported outcomes (PROs) endpoints will be evaluated using the following 
questionnaires: Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change 
(DTSQc) versions, MOS Sleep, and Work Productivity and Activity Impairment Questionnaire 
(WPAI). 
Details on handling of missing data for PROs are available in Section 2.5.2.4. 
2.1.7.1 DTSQs  
The DTSQs is used to assess patient satisfaction with treatment and patient perception of blood 
glucose control; it is a validated questionnaire comprised of the 8 questions answered on a Likert 
scale from 0 to 6. It will be completed at baseline and Week 12.  
Responses to questions 1, 4, 5, 6, 7, and 8 will be summed to produce a Total Treatment 
Satisfaction score ranging from 0 (no satisfaction) to 36 (high satisfaction with treatment).  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 19 
The 2 items of ‘perceived frequency of hyperglycemia’ (question 2) and ‘perceived frequency of 
hypoglycemia’ (question 3) are scored separately ranging from 0 (none of the time) to 6 (most of 
the time).  
2.1.7.2 DTSQc  
The Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) was developed 
from the original DTSQ to evaluate the change in treatment satisfaction at a specific time point. It 
contains 8 questions answered on a Likert scale from -3 to 3. The DTSQc instructions and 
response options differ from those of the DTSQs to produce measures of relative change in 
satisfaction rather than measures of absolute satisfaction. The DTSQc will be completed at 
Week 12. 
Responses to questions 1, 4, 5, 6, 7, and 8 will be summed to produce a Total Treatment 
Satisfaction score ranging from -18 to 18. Positive scores are indicative of improvement in 
treatment satisfaction, whereas negative scores are indicative of deterioration in treatment 
satisfaction since start of the study.  
The 2 items of ‘perceived frequency of hyperglycemia’ (question 2) and ‘perceived frequency of 
hypoglycemia’ (question 3) are scored separately ranging from -3 (much less of the time) to 3 
(much more of the time), meaning negative scores indicate fewer problems with blood glucose 
levels and positive scores indicate more problems than before.  
2.1.7.3 MOS Sleep  
The MOS Sleep used to measure patient perception on key aspects of sleep, consisting of 
12 questions that will be completed by the patients at baseline and Week 12. The MOS Sleep 12 
items acute revised version with the ‘past week’ recall period will be used to collect information.  
The 12-item MOS Sleep Scale assessment yields scores on six subscales: Sleep Disturbance 
(4-item subscale on sleep initiation problems, and sleep maintenance problems), Snoring (single-
item subscale), Shortness of Breath or Headache (single-item subscale asking about the frequency 
of awakening with shortness of breath or with a headache), Sleep Adequacy (2-item subscale 
asking about frequency of awakening fresh and rested in the morning and getting the amount of 
sleep needed), Daily Somnolence (3-item subscale), and Sleep Quantity (single-item subscale 
representing the average number of hours slept). 
The Sleep Problems Index is also calculated based on 9 of the items. 
Responses to all but the open-ended sleep quantity item are transformed to scores on a 0-100 
metric, with higher item scores reflecting more of the attribute implied by the scale name. 
Scores on the multi-item subscales and indexes also range from 0 to 100. 
MOS-sleep scores will be calculated automatically via the electronic system provided by the 
owner of this questionnaire.  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 20 
2.1.7.4 WPAI  
The WPAI SHP assesses the amount of absenteeism, presenteeism and daily activity impairment 
attributable to a specific health problem (WPAI:SHP version V2.0). An adapted version of the 
WPAI:SHP will be used with the term PROBLEM replaced by DIABETES, as requested by the 
author. 
The WPAI:SPH consists of 6 questions which will be completed by the patients at baseline and 
Week 12.  
The 6 questions will be used to derive 4 scores (see Section 2.5.2.4) and scores are multiplied by 
100 to express in percentages. 
2.1.8 Health economic endpoints  
Not applicable to the study. 
2.2 
DISPOSITION OF PATIENTS  
Screened patients are defined as any patients who signed the informed consent.  
Randomized patients consist of all patients with a signed informed consent form who have been 
allocated a treatment kit based on a randomization process, regardless of whether the treatment kit 
was used.  
Patient study status 
For patient study status, the total number of patients in each of the following categories will be 
presented in the clinical study report using a flowchart diagram or summary table: 
• 
Screened patients 
• 
Screen failure patients and reasons for screen failure  
• 
Treated but not randomized 
• 
Randomized patients 
• 
Randomized but not treated patients 
• 
Randomized and treated patients 
• 
Patients who completed the 12-week on-treatment period (patients who have performed 
Visit 18, who did not permanently discontinue) 
• 
Patients who discontinued IMP by main reason for permanent treatment discontinuation 
• 
Patients who did not complete the study  
• 
Patients who discontinued the study by main reason for study discontinuation 
• 
Status at last study contact (Alive/Death) 
• 
Lost to follow-up  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 21 
For all categories of patients (except for the screened and non-randomized categories) percentages 
will be calculated using the number of randomized patients as the denominator for each treatment 
group.  
Reasons for treatment discontinuation will be supplied in tables giving numbers and percentages 
by treatment group.  
Lost to follow-up will be based on the End of Study [EOS] page as ‘Other’ with specify ‘Lost to 
Follow Up’.      
All critical or major deviations potentially impacting efficacy analyses, randomization, and 
drug-dispensing irregularities, and other major or critical deviations will be summarized in tables 
giving numbers and percentages of deviations by treatment group. 
Same summary as above will be displayed for any critical or major deviation due to COVID-19 
pandemic. Patients excluded from Population without trial impact (disruption) due to COVID-19 
will be listed. 
The patients with any visit impacted by COVID-19 crisis will be summarized in a separate table 
giving numbers and percentages by treatment group. 
Additionally, the analysis populations for safety and efficacy, will be summarized in a table by 
number of patients in the randomized population:  
• 
Efficacy population: intent-to-treat (ITT) population, per-protocol population and 
Population without trial impact (disruption) due to COVID-19, 
• 
Safety population. 
2.2.1 Randomization and drug dispensing irregularities  
Randomization and drug-dispensing irregularities occur whenever: 
• 
A randomization is not in accordance with the protocol-defined randomization method, 
such as a) an ineligible patient is randomized, b) a patient is randomized based on an 
incorrect stratum, c) a patient is randomized twice, or d) in a dynamic randomization 
scheme the treatment assignment is, in fact, not random, due to a computer program error. 
OR 
• 
A patient is dispensed an IMP kit not allocated by the protocol-defined randomization, 
such as a) a patient at any time in the study is dispensed a different treatment kit than as 
randomized (which may or may not contain the correct-as-randomized IMP), or b) a 
non-randomized patient is treated with IMP reserved for randomized patients. 
Randomization and drug-dispensing irregularities will be monitored throughout the study and 
reviewed on an ongoing basis.  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 22 
All randomization and drug-dispensing irregularities will be documented in the clinical study 
report. If the number of irregularities is large enough to make a tabular summary useful, the 
irregularities will be categorized and summarized among randomized patients (number and 
percentages). Nonrandomized, treated patients will be described separately. 
Randomization and drug-dispensing irregularities to be prospectively identified as protocol 
deviations include but are not limited to: 
• 
IMP dispensed without randomization, 
• 
IMP dispensed prior to randomization, 
• 
Patient randomized twice, 
• 
IMP kit number actually dispensed to the patient is different from the IMP kit number 
allocated, 
• 
Wrong stratum of randomization, 
• 
IMP dispensed without allocation at re-supply visit, 
• 
Non-existing patient randomized by error. 
2.3 
ANALYSIS POPULATIONS  
Patients who are dispensed study drug without calling the IRT or before calling the IRT are 
considered non-randomized patients. They are excluded from any population for analysis, 
including safety. 
2.3.1 Efficacy populations  
The primary efficacy analysis population will be the ITT population. 
2.3.1.1 Intent–to-treat population  
The ITT population consists of all randomized patients, irrespective of the treatment received. 
Randomized patients are patients who signed the ICF and with a treatment group allocated before 
the first IMP administration and recorded in the IRT database.  
Patients will be analyzed in the treatment group to which they are randomized.  
2.3.1.2 Per-protocol population  
The per-protocol population (PP) is a subset of the ITT population which will comprise all 
randomized patients, who are exposed, who do not permanently discontinued IMP allocated by 
IRT, who completed the study as per protocol (as reported in the EOS page) and who do not 
present any major protocol deviations that potentially impact the primary efficacy results, as 
presented below: 
• 
Major or critical deviation linked to inclusion criteria: 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 23 
- 
From inclusion criterion I02: Patients without T1DM. 
- 
From inclusion criterion I03: Not treated with multiple daily injections (MDI) using 
basal insulin analog once daily and rapid acting insulin analogs for at least one year 
- 
From inclusion criterion I04: HbA1c <7% or >10% 
• 
Major or critical deviation linked to exclusion criteria:  
- 
With E09: Patients having received basal insulin dose ≥0.6 U/kg body weight within 
30 days prior to screening. 
- 
With E13: Patients who will need real time, flash or implantable CGM for routine care 
any time during study participation. 
- 
With E23: Inappropriate CGM use during run-in period evidenced by failure to obtain 
a minimum of 10 days (not necessarily consecutive) of useable CGM data by the end 
of run-in. 
• 
Other major or critical deviation potentially impacting primary efficacy results: 
- 
Not taken only the treatment allocated by IRT (ie, wrong treatment taken at 
randomization or switch during the study) 
- 
Wrong stratum of randomization  
- 
Taken any prohibited medications for more than 10 consecutive days during the study 
as follows: 
- 
Any glucose-lowering agents other than IMP, the patient’s current background 
basal insulin analog during the run-in period (which may not be changed during the 
study), or the patient’s existing mealtime insulin (which may not be changed 
during the study). This includes oral or injectable glucose lowering agents, other 
type of basal insulin (eg, NPH), pre-mixed insulin, and human regular insulin  
- 
Insulin pump therapy. 
- 
Systemic glucocorticoids (topical or inhaled applications are allowed). 
- 
Patient who did not receive the CGM at Week 9, or for whom there are issues with 
uploading the CGM data at Week 12. This will be evaluated for patients who 
completed the treatment period and the study 
Of note: in case of CGM performed as planned in the protocol (20-days during Week 10, Week 11 
and Week 12) but not evaluable (ie, less 10 days, [not necessarily consecutive] of useable CGM 
data among the 20-days of CGM), the patient is not excluded from PP population. 
2.3.1.3 Population without trial impact (disruption) due to COVID-19  
The “Population without trial impact (disruption) due to COVID-19” is defined as patient without. 
• Premature treatment discontinuation due to COVID-19 
• Premature end of study due to COVID-19 
• Critical or major protocol deviations due to COVID-19  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 24 
For the primary efficacy endpoint, analysis based on Population without trial impact (disruption) 
due to COVID-19 will be performed as sensitivity analysis. 
2.3.2 Safety population  
The safety population is defined as all randomized patients who received at least 1 dose or part of 
a dose of the IMP. Patients in the safety population will be analyzed according to the actual 
treatment received. In the event that different treatments are administrated to the same patient, the 
patient is to be analyzed using the treatment that he/she is on for the most time. 
In addition  
• Non-randomized but treated patients will not be part of the safety population; however, 
their safety data will be presented separately 
• Randomized patients for whom it is unclear whether they took the IMP will be included in 
the safety population as randomized 
2.4 
STATISTICAL METHODS  
2.4.1 Demographics and baseline characteristics  
Continuous data will be summarized using the number of available data, mean, standard deviation 
(SD), median, minimum, first quartile (Q1), third quartile (Q3), and maximum for each treatment 
group.  
Categorical and ordinal data will be summarized using the number and percentage of patients in 
each treatment group.  
Parameters will be summarized on the ITT population analyzed in the treatment group to which 
they were randomized. Analyses for the safety population (respectively, PP population) will be 
included in the appendices if the size of the safety population (respectively PP population) is 
different (>10%) from the size of that in the primary analysis population (ie, ITT population) for 
any treatment group. 
Parameters described in Section 2.1.1 will be summarized by treatment group using descriptive 
statistics.  
For medical and surgical history, non-prespecified diagnoses will be summarized by treatment 
group according to the MedDRA dictionary. Incidence tables will present by SOC and HLT – 
sorted by SOC internationally agreed order and by decreasing frequency of HLT based on 
incidence in the overall treatment group – the number (n) and percentage (%) of patients 
experiencing an event. Multiple occurrences of the same event in the same patient will be counted 
only once in the tables. The denominator for computation of percentages will be the randomized 
population within each treatment group. 
P-values on demographic and baseline characteristic data will not be calculated. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 25 
2.4.2 Prior or concomitant medications  
The prior, concomitant and post-treatment medications will be presented for the ITT population 
separately for anti-diabetic medications and other (ie, non-anti-diabetic) medications.  
2.4.2.1 Non-antidiabetic medications  
Non antidiabetic medications will be summarized by treatment group according to the WHO-DD 
dictionary, considering the first digit of the anatomical therapeutic chemical (ATC) class 
(anatomic category) and the first 3 digits of the ATC class (therapeutic category).  
All ATC codes corresponding to a medication will be summarized, and patients will be counted 
once in each ATC category (anatomic or therapeutic) linked to the medication. Therefore, patients 
may be counted several times for the same medication.  
The table for prior non-antidiabetic medications will be sorted by decreasing frequency of ATC 
followed by all other therapeutic classes based on the overall incidence across treatment group. In 
case of equal frequency regarding ATCs (anatomic or therapeutic categories), alphabetical order 
will be used. 
The tables for concomitant and post-treatment medications will be sorted by decreasing frequency 
of anatomic class followed by therapeutic classes based on the incidence in the Toujeo group. In 
case of equal frequency regarding ATCs (anatomic or therapeutic categories), alphabetical order 
will be used. 
2.4.2.2 Antidiabetic medications  
The table for prior anti-diabetic medications other than basal and mealtime insulin analogs 
(permitted or not permitted per protocol) will be summarized per pre-defined  and standardized 
medication name based on the overall incidence across treatment group. In case of equal 
frequency, alphabetical order will be used. 
The table for concomitant anti-diabetic medications other than basal and mealtime insulin analogs 
(permitted or not permitted per protocol) will be summarized per pre-defined and standardized 
medication name based on the incidence in the Toujeo group. In case of equal frequency, 
alphabetical order will be used. 
The following predefined classes (customised drug grouping [CDG]) will be considered for prior 
and concomitant:  
At least one non-insulin therapy 
• Biguanides  
• Sulfonylureas  
• Glinides  
• Thiazolidinedione  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 26 
• DPP-4 inhibitors  
• SGLT-2 inhibitors  
• GLP1-RA  
• Alpha-glucosidase inhibitors  
• Other blood glucose lowering drugs  
At least one insulin therapy different from insulin analog (even if not permitted in prior or 
concomitant) 
• Insulin NPH 
• Premixed insulin 
• Short acting regular human insulin 
The table for post anti-diabetic medications will be summarized per pre-defined class and 
standardized medication name based on the incidence in the Toujeo group. In case of equal 
frequency, alphabetical order will be used. Insulin therapy could include insulin analog. 
A list of codes to be used in determining these pre-defined classes is in a separate operational 
document. 
Of note, basal and mealtime insulin analogs as prior medications are described in Section 2.1.1 
Frequency statistics including number of patients and percentage will be provided. 
2.4.3 Extent of investigational medicinal product exposure and compliance  
The extent of IMP exposure and compliance will be assessed and summarized by actual treatment 
within the safety population (Section 2.3.2). 
2.4.3.1 Extent of investigational medicinal product exposure  
The extent of IMP exposure will be assessed by the duration of IMP exposure over the study 
period.  
The duration of treatment exposure will be the total number of days of administration of the 
open-label IMP, regardless of unplanned intermittent discontinuations (see Section 2.5.3 for 
calculation in case of missing or incomplete data). The duration of IMP exposure will be 
calculated as:  
• 
(date of the last open-label IMP injection – date of the first open-label IMP injection) + 1. 
Duration of IMP exposure will be summarized descriptively as a quantitative variable (number, 
mean, SD, median, minimum, and maximum). In addition, duration of treatment exposure will 
also be summarized categorically by numbers and percentages for each of the following categories 
and cumulatively according to these categories 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 
84 days and >84 days.  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 27 
Additionally, the cumulative duration of treatment exposure will be provided, defined as the sum 
of the duration of treatment exposure for all patients, and will be expressed in patient years. 
2.4.3.2 Daily insulin doses  
Daily insulin dose will be summarized descriptively (number, mean, SD, median, Q1, Q3, 
minimum, and maximum) at each visit (baseline, and post baseline: Week 8 and Week 12). 
Basal insulin daily dose (U and U/kg) at baseline is defined as the actual starting IMP dose of 
basal insulin as reported by the Investigator into the e-CRF (first IMP intake). 
Mealtime insulin (ie, rapid acting insulin analog) daily dose (U and U/kg) at baseline is defined as 
the actual mealtime total daily dose in run-in (see Section 2.1.1) .  
At each postbaseline visit, the daily basal, mealtime, and total (basal plus mealtime) insulin doses 
(U and U/kg) will be calculated as the mean of total daily insulin doses (as reported in the CRF) 
collected in the week before the corresponding visit. 
The change from baseline daily doses variable at Week 8 and Week 12 will also be summarized 
descriptively. 
2.4.3.3 Compliance  
A given administration will be considered noncompliant if the patient did not take the IMP as 
required by the protocol, meaning one injection per day. No imputation will be made for patients 
with missing or incomplete data.  
The percentage of compliance for a patient will be defined as the number of days with at least one 
administration divided by the duration of IMP exposure. 
Treatment compliance will be summarized descriptively as quantitative variables (number, mean, 
SD, median, minimum, and maximum) by treatment group for the safety population. In addition, 
numbers and percentages of patients whose compliance is <80% will be summarized by treatment 
group. 
2.4.4 Analyses of efficacy endpoints  
For each patient, the number of days with useable CGM data within the analysis time window 
(see Section 2.5.4) will be derived in the following categories: < 10 days, 10 days, 11 days, 
12 days, 13 days, 14 days, ≥14 days at baseline and at Week 12. The categories could be updated 
based on real data. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 28 
2.4.4.1 Analysis of primary efficacy endpoint(s)  
2.4.4.1.1 Primary efficacy analysis  
The primary efficacy endpoint is the percent time in glucose range is defined as the proportion of 
CGM readings falling into the range of ≥70 to ≤180 mg/dL [≥3.9 to ≤10 mmol/L] at the Week 12 
evaluation. 
The primary efficacy endpoint will be analyzed using available data from the 12-week 
randomized period in ITT population via an analysis of covariance (ANCOVA) including the 
fixed categorical effects of treatment group (Toujeo versus Tresiba), randomization stratum of 
screening HbA1c (<8.0% versus ≥8.0%), as well as, the continuous fixed covariate of baseline 
percent time in range value. 
Multiple imputation (MI) assuming missing at random (MAR) will be used to replace missing 
data of percent time in glucose range at Week 12 and at baseline. The MAR assumption means 
that the missingness depends only on observed variables and not on the data that would have been 
observed (in the present case, the percent time in glucose range that would have been observed).  
Moreover, the imputation procedure will also depend on the observed pattern of missingness: 
A) Monotone Pattern: Patients with missing baseline CGM and missing Week 12 CGM, or 
patients with baseline CGM but without a Week 12 value.  
B) Non-Monotone Pattern: Patients with missing baseline CGM but with a Week 12 CGM. 
Baseline CGM evaluable being used as a criterion to allow the randomization, this pattern 
is not expected to be represented in the study. 
In order to explore missing data patterns for the primary efficacy analysis, number and percentage 
of patients in each of the following categories will be presented by treatment group.  
- 
Pattern 1: patients with missing baseline CGM and missing Week 12 CGM, 
- 
Pattern 2: patients with baseline CGM but missing Week 12 CGM, 
- 
Pattern 3: patients with missing baseline CGM but with Week 12 CGM, 
- 
Pattern 4: patients with baseline CGM and Week 12 CGM 
Once missing data pattern will be assessed, the three-step programming process described in 
Section 2.5.3 will provide baseline-adjusted least-squares means estimates at Week 12 for both 
treatment groups, as well as, the differences of these estimates, with their corresponding standard 
errors (SEs), 95% CI, and one-sided P-values (H0: m1 - 0.9 × m0 ≤ 0, with m1 = true mean of 
Toujeo and m0 = true mean of Tresiba). 
Toujeo would be considered non-inferior to Tresiba if the lower limit of the 95% CI for the 
adjusted difference estimate of m1-0.9*m0 at Week 12 is > 0 (with m1=true means of Toujeo and 
m0=true means of Tresiba).  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 29 
In addition to the non-inferiority testing that is the primary analysis, and only if non-inferiority of 
Toujeo in comparison to Tresiba on the percent time in the range of 70-180 mg/dL is 
demonstrated and if non-inferiority of Toujeo versus Tresiba on the glucose total CV is 
demonstrated (see Section 2.4.4.3 for multiplicity issues), superiority of Toujeo over Tresiba on 
the percent time in the range of 70-180 mg/dL will be tested. 
The point estimate of difference in mean of percent time in range and the corresponding 95% CI 
will also be estimated using the following ESTIMATE statement in PROC GLM (in Step 2, See 
Section 2.5.3). 
ESTIMATE “TOUJEO-TRESIBA” TREAT 1 -1 
and the Step 3 will be done to obtain baseline-adjusted least-squares means estimates at Week 12 
for both treatment groups as well as, the differences of these estimates, with their corresponding 
standard errors (SEs), 95% CI. The lower bound of the two-sided 95% CI for the adjusted 
difference estimate of m1 - m0 at Week 12 will be compared to 0 and subjected to a superiority 
test (if lower limit of 95% CI is >0). 
The superiority comparison is considered as a secondary analysis of the primary efficacy variable. 
Assumption assessment 
The studentized residuals from the 1000 ANCOVA models described in Step 2 above with 
imputed data will be inspected and plotted against the predicted values, all in the same graph, for 
a visual assessment to detect any homoscedasticity. 
2.4.4.1.2 Sensitivity analyses  
First sensitivity analysis: MI on the PP population  
A first sensitivity analysis will be performed on the PP population (see Section 2.3.1.2) with the 
same multiple imputation process as for primary analysis.  
Second sensitivity analysis: MI under missing not at random (MNAR) assumption on ITT 
population  
In addition, to investigate possible violations of the MAR assumption, a second sensitivity 
analysis with multiple imputation in conjunction with MNAR assumption based on patient status 
at Week 12 will be performed for ITT population. 
Under the MNAR assumption, patients with study treatment discontinuation without any CGM 
done at Week 12 and patients with missing CGM endpoints at Week 12 due to other reasons (ie, 
non-evaluable CGM) will be imputed differently.  
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 30 
This MI process for the missing data can be carried out in two parts: 
1. For patients who prematurely discontinue the study treatment, as it is not expected to have 
enough patient who discontinued with CGM at Week 12 done, hypothesis of return to 
baseline will be used. The imputation for Week 12 will be from the following model 
~ N (BASE, SD) (BASE is the baseline value for the patient, SD estimated for all patients 
at baseline) 
2. For patients who did not prematurely discontinue the study treatment, the multiple 
imputation method described as the primary efficacy analysis under MAR assumption will 
be used. 
Missing values will be imputed 1,000 times. For each imputation, the two completed datasets 
from the two parts detailed above will be combined into one single completed dataset. Each 
completed dataset will then be analyzed though an ANCOVA model which will include fixed 
categorical effects of treatment group, randomization stratum screening HbA1c value [<8.0% 
versus ≥8.0%], as well as fixed continuous fixed covariate of baseline percent time in range 
value. The final results will be obtained by combining the least squares (LS Means) means and 
LS mean differences from these 1,000 analyses, using Rubin’s formula. 
 
Third sensitivity analysis: MI on Population without trial impact (disruption) due to 
COVID-19  
A third sensitivity analysis will be performed on Population without trial impact (disruption) due 
to COVID-19 (see Section 2.3.1.3) with the same multiple imputation process as for primary 
analysis. 
2.4.4.1.3 Subgroup analyses  
Where appropriate for the size of a subgroup (at least 30 patients in each category), exploratory 
analyses will be performed on the primary endpoint to summarize the treatment effects across 
subgroups defined by the following baseline and screening factors: 
• 
Duration of diabetes (<10/>= 10 years),  
• 
Gender, 
• 
Randomization strata of screening HbA1c categories (<8.0% versus ≥8.0%), 
• 
BMI (<30 and ≥30 kg/m²). 
Categories for subgroup analyses may be adapted according to data. 
For each subgroup, the primary efficacy endpoint using available data from the 12-week 
randomized period in ITT population will be analyzed via an analysis of covariance (ANCOVA) 
including the fixed categorical effects of treatment group (Toujeo, Tresiba), randomization 
stratum of screening HbA1c (<8.0% versus ≥8.0%), the continuous fixed covariate of baseline 
percent time in range value, and adding the corresponding subgroup factor and subgroup 
factor-by-treatment interaction. LSmeans treatment difference (with the corresponding SEs and 
95% CI) will be presented for each subgroup. The P-value for the interaction fixed term will be 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 31 
obtained in order to evaluate whether the corresponding subgroup is behaving as a response 
modifier. 
The ESTIMATE statement in PROC GLM, which reflects the subgroup analyses by baseline and 
screening factors, will be used. An example of SAS code for the subgroup analysis by gender is 
provided below:  
Female group: 
ESTIMATE “TOUJEO-TRESIBA” ARM 1 -1 SEX*ARM 1 0 -1 0; 
Male group: 
ESTIMATE “TOUJEO-TRESIBA” ARM 1 -1 SEX*ARM 0 1 0 -1; 
Forest plot will be provided.  
Further subgroup analyses may be performed if deemed necessary for the interpretation of results. 
2.4.4.2 Analyses of secondary efficacy endpoints  
Secondary efficacy endpoints analysis will be done on the ITT population, with no multiple 
imputation except for the main secondary endpoint ‘Glucose total CV’, for which a similar 
procedure as for the primary endpoint applies as it is part of the multiplicity procedure. No 
sensitivity analyses are planned for secondary endpoints. 
2.4.4.2.1 CGM secondary endpoints  
The CGM endpoints will be analyzed using an ANCOVA model  
• 
Glucose total CV (main secondary endpoint) 
• 
Glucose within-day and between-day CV 
• 
Percent time and mean hours per day with glucose <70 mg/dL (on all time and during the 
night [00:00 to 05:59]) 
• 
Percent time and mean hours per day with glucose >180 mg/dL 
The ANCOVA model to perform the analysis includes the fixed categorical effects of treatment 
group (Toujeo, Tresiba), randomization stratum of screening HbA1c (<8.0% versus ≥8.0%), as 
well as the continuous fixed covariate of baseline value for the corresponding endpoints. 
For glucose total CV (main secondary endpoint), and if the non-inferiority on the primary 
endpoint is demonstrated, the non-inferiority will be tested. But, unlike TIR, for CV the lower the 
better. Therefore, the non-inf comparison will be based on: 
H0: m1 − 1.1 × m0 ≥ 0 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 32 
For the other secondary endpoints, LSmeans treatment difference (with the corresponding SEs 
and 95% CI) will be provided and the p-value (of the difference between the two treatments) will 
be provided for descriptive purpose only (see Section 2.4.4.4). 
2.4.4.2.2 HbA1c  
Change in HbA1c will be analyzed using an ANCOVA model including the fixed categorical 
effects of treatment group (Toujeo, Tresiba) as well as the continuous fixed covariate of baseline 
HbA1c value; LSmeans treatment difference (with the corresponding SEs and 95% CI) will be 
provided and p-value (of the difference between the two treatments) will be provided for 
descriptive purpose. 
2.4.4.2.3 FPG  
Change in FPG will be analyzed using an ANCOVA model including the fixed categorical effects 
of treatment group (Toujeo, Tresiba) and the randomization stratum of HbA1c at screening 
(<8.0%, ≥8.0%) as well as the continuous fixed covariate of baseline FPG value. LSmeans 
treatment difference (with the corresponding SEs and 95% CI) will be provided and p-value (of 
the difference between the two treatments) will be provided for descriptive purpose. 
2.4.4.2.4 Subgroups analyses of secondary efficacy endpoints  
Subgroup analyses will be performed on glucose within-day CV to summarize the treatment 
effects across subgroup defined by glucose within day CV≤36% vs. >36% at baseline. The 
ANCOVA model will be used, the randomization stratum of HbA1c at screening, CV subgroup at 
baseline, as well as the interaction of treatment group by CV subgroup at baseline are included as 
fixed effects. LS means treatment difference (with the corresponding SEs and 95% CI) will be 
presented for each subgroup. The p-value for the interaction fixed term will be obtained in order 
to evaluate whether the corresponding subgroup is behaving as a response modifier. 
2.4.4.3 Multiplicity issues  
To control the type I error, a hierarchical step-down testing procedure described by Hochberg and 
Tamhane (4) will be applied for the primary efficacy endpoint and the main secondary endpoint: 
• 
Step 1 assesses non-inferiority of Toujeo versus Tresiba on the percent time in the range of 
70-180 mg/dL, 
• 
Step 2: only if Step 1 is demonstrated, then non-inferiority of Toujeo versus Tresiba on the 
glucose total CV will be tested with a relative non-inferiority margin of 10%, 
• 
Step 3: only if Step 2 is demonstrated, then the difference between Toujeo and Tresiba on 
the percent time in the range of 70-180 mg/dL will be tested. 
No multiplicity adjustment will be made on other secondary/other efficacy variables; 95% CI and 
p-values presented for these endpoints will be done for descriptive purpose only. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 33 
2.4.4.4 Additional efficacy analysis(es)  
The tertiary/exploratory variables (see Section 2.1.3.3) will be summarized by treatment group, 
using descriptive statistics for continuous variables for ITT population, except for PROs. 
A plot with the mean glucose profile over 24-hour period will be presented. For each patient, the 
data will be summarized for each 1-hour interval over 24-hour period, eg, [00:00, 01:00), [01:00, 
2:00), …, [23:00, 24:00) taking the average of CGM readings from usable CGM days. Then, the 
mean profile will be calculated taking the average across all patients at each interval and plotted at 
the midpoint of each 1-hour interval. 
For PRO, the analyses are described in Section 2.4.7. 
Change from baseline in 7-point SMPG profiles (pre-prandial and 2-hour postprandial plasma 
glucose at breakfast, lunch and dinner, and at bedtime) to Week 12 will be described by treatment 
group using mean and SD. 
A figure representing the mean (+/- SE) at baseline and Week 12 per time point as well as change 
from baseline at Week 12 will be produced by treatment group. 
2.4.5 Analyses of safety data  
The summary of safety results will be presented by treatment group classifying each patient in the 
group corresponding to the actual treatment received.  
General common rules 
All safety analyses will be performed on the safety population by actual treatment received as 
defined in Section 2.3.2, unless otherwise specified, using the following common rules: 
• 
Safety data in patients who do not belong to the safety population (eg, exposed but not 
randomized) will be listed separately, 
• 
The baseline value is defined as the last available value before the first injection of 
open-label IMP, 
• 
The analysis of the safety variables will be essentially descriptive. 
2.4.5.1 Analyses of hypoglycemia events  
 
Incidence of patients with at least one hypoglycemia event  
A frequency table showing the number and % of patients experiencing at least one hypoglycemic 
event will be presented for any hypoglycemia and for each type of hypoglycemia (see 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 34 
Section 2.1.4.6), overall and according to time of occurrence (nocturnal [ie, 00:00 to 05:59], for 
any time of day and daytime [ie, 06:00 to 23:59] during the on-treatment period.  
The Odds Ratio and its corresponding 95% CI for the Toujeo arm over the Tresiba arm for each 
hypoglycemic event (nocturnal and any time of the day) during the on treatment period will be 
estimated by a logistic regression model adjusted on randomization strata of screening HbA1c. 
Number and rate of hypoglycemia event  
The number and rate of hypoglycemic events (in patient-year of exposure) will be determined for 
any hypoglycemia and for each type of hypoglycemic event, overall and according to time of 
occurrence (nocturnal [ie, 00:00 to 05:59], any time of the day) during the on treatment period and 
in the pre-treatment period. 
For each type of hypoglycemic event during the on treatment period, the rate ratio, and its 
corresponding 95% CI, for the Toujeo arm over the Tresiba arm will be estimated using an 
over-dispersed Poisson regression model adjusted on randomization strata of screening HbA1c. 
2.4.5.2 Analyses of adverse events  
Generalities 
The primary focus of AE reporting will be on TEAEs. Pre-treatment and post-treatment AEs will 
be described separately.  
If an adverse event date/time of onset (occurrence, worsening, or becoming serious) is incomplete, 
an imputation algorithm will be used to classify the adverse event as pre-treatment, 
treatment-emergent, or post-treatment. The algorithm for imputing date/time of onset will be 
conservative and will classify an adverse event as treatment emergent unless there is definitive 
information to determine if it is pre-treatment or post-treatment. Details on classification of 
adverse events with missing or partial onset dates are provided in Section 2.5.4. 
Adverse event incidence tables will be presented by SOC, HLGT, HLT, and PT, sorted in 
alphabetical order for each treatment group, showing the number (n) and percentage (%) of 
patients experiencing an adverse event. Multiple occurrences of the same event in the same patient 
will be counted only once in the tables within a treatment phase. The denominator for 
computation of percentages is the safety population within each treatment group. 
Sorting within tables ensures the same presentation for the set of all adverse events within the 
observation period (pre-treatment, treatment-emergent, and post-treatment). For that purpose, the 
table of all treatment-emergent adverse events presented by SOC and PT sorted by the 
internationally agreed SOC order and decreasing frequency of PTs within SOCs will define the 
presentation order for all other tables unless otherwise specified. Sorting will be based on results 
for the Toujeo treatment group. 
A listing of SAEs and listing of withdrawals due to AEs will be presented. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 35 
Analysis of all treatment-emergent adverse events 
The following treatment-emergent adverse event (TEAE) summaries will be generated for the 
safety population. 
• 
Overview of TEAEs, summarizing the number (%) of patients with any 
- 
TEAE 
- 
Serious TEAE 
- 
TEAE leading to death 
- 
TEAE leading to permanent treatment discontinuation 
- 
TEAE related to IMP 
• 
The number (%) of patients experiencing TEAE(s) presented by PT, sorted by decreasing 
incidence of PT in the Toujeo treatment arm. 
• 
All TEAEs by primary SOC, HLGT, HLT, and PT, showing number (%) of patients with 
at least 1 treatment-emergent adverse event sorted by the SOC internationally agreed 
order.  The other levels (HLGT, HLT, PT) will be presented in alphabetical order. 
• 
All TEAEs by primary SOC and PT, showing the number (%) of patients with at least 
1 treatment-emergent adverse event, sorted by the internationally agreed SOC order and 
by decreasing incidence of PTs in the Toujeo treatment arm within each SOC.  
• 
All TEAEs related to IMP by primary SOC and PT, showing the number (%) of patients 
with at least 1 treatment-emergent adverse event, sorted by the internationally agreed SOC 
order and by decreasing incidence of PTs in the Toujeo treatment arm within each SOC.  
Analysis of all treatment emergent serious adverse event(s) 
• All treatment-emergent serious adverse events by primary SOC, HLGT, HLT, and PT, 
showing the number (%) of patients with at least 1 serious treatment-emergent adverse 
event, sorted by the internationally agreed SOC order.  The other levels (HLGT, HLT, PT) 
will be presented in alphabetical order. 
• 
All treatment-emergent serious adverse events by primary SOC and PT, showing the 
number (%) of patients with at least 1 serious treatment-emergent adverse event, sorted by 
the internationally agreed SOC order and by decreasing incidence of PTs in Toujeo 
treatment arm within each SOC. 
• 
All treatment-emergent serious adverse events related to IMP, by primary SOC and PT, 
showing the number (%) of patients with at least 1 treatment-emergent serious adverse 
event, sorted by the internationally agreed SOC order and by decreasing incidence of PTs 
in Toujeo treatment arm within each SOC.  
• 
All treatment-emergent serious adverse events leading to treatment discontinuation, by 
primary SOC and PT, showing the number (%) of patients sorted by the internationally 
agreed SOC order and by decreasing incidence of PTs in Toujeo treatment arm within 
each SOC. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 36 
Analysis of all treatment-emergent adverse event(s) leading to treatment discontinuation 
• 
All treatment-emergent adverse events leading to treatment discontinuation, by primary 
SOC and PT, showing the number (%) of patients sorted by the internationally agreed 
SOC order and by decreasing incidence of PTs in the Toujeo treatment arm within each 
SOC. 
Analysis of adverse events of special interest 
• 
A listing of patients with symptomatic overdose with IMP/NIMP. Pregnancy will be listed 
separately. 
Analysis of pre-treatment and post-treatment adverse events  
An overview of pre-treatment and/or post-treatment adverse events will be presented as a listing if 
only a few, otherwise as a summary (presenting number of patients with any pre-/post-treatment 
adverse events, serious pre-/post-treatment adverse events, pre-/post-treatment adverse events 
leading to death). 
• 
All pre-treatment adverse events by primary SOC and PT, showing the number (%) of 
patients with at least 1 pre-treatment adverse event, sorted by the internationally agreed 
SOC order and PT will be presented by alphabetical order. 
• 
All post-treatment adverse events by primary SOC and PT, showing the number (%) of 
patients with at least 1 post-treatment adverse event, sorted by the internationally agreed 
SOC order and PT will be presented by alphabetical order. 
In case of a low number of events (pre-treatment and post-treatment), a only listing will be 
provided. 
2.4.5.3 Deaths  
The following summaries of deaths will be generated for the safety population. 
• 
Number (%) of patients who died by study period (on-study, on-treatment, poststudy). 
• 
TEAEs leading to death (death as an outcome on the adverse event case report form page 
as reported by the Investigator) by primary SOC and PT showing number (%) of patients 
sorted by internationally agreed SOC order and by decreasing incidence of PTs in the 
Toujeo treatment arm within each SOC. In case of a low number of events, only a listing 
will be provided. 
Deaths in non-randomized patients or randomized but not treated patients will be also presented. 
2.4.5.4 Analyses of laboratory variables  
As most of safety laboratory parameters are only collected at screening and not during the study 
(see Section 2.1.4.3), no analyses will be performed. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 37 
2.4.5.5 Analyses of vital sign variables  
The summary statistics (including number, mean, median, Q1, Q3, standard deviation, minimum 
and maximum) of all vital signs variables as well as changes from baseline will be calculated for 
each study assessment (baseline, Week 8 and Week 12, see Section 2.5.4) by treatment group. 
2.4.5.6 Analyses of electrocardiogram variables  
Not applicable to the study. 
2.4.6 Analyses of pharmacokinetic and pharmacodynamic variables  
Not applicable to the study 
2.4.7 Analyses of quality of life/health economics variables  
The analyses will be done on ITT population. 
For DTSQs, MOS-Sleep, and WPAI, a descriptive summary of each score (see Section 2.1.7) will 
be done at baseline and at Week 12. 
Change in DTSQs, MOS-Sleep, and WPAI scores from baseline to Week 12 will be analyzed 
using an ANCOVA model including the fixed categorical effects of treatment group (Toujeo, 
Tresiba), and the randomization stratum of HbA1c at screening (<8.0%, ≥8.0%), as well as, the 
continuous fixed covariate of baseline score.  
LS means and the corresponding SEs and 95% confidence interval by treatment for the change 
from baseline will be presented for descriptive purposes. 
The DTSQc score will be analyzed using descriptive statistics at Week 12. 
The DTSQc scores at Week 12 will be analyzed using an ANCOVA model including the fixed 
categorical effects of treatment group (Toujeo, Tresiba), DTSQs score at baseline, and the 
randomization stratum of HbA1c at screening (<8.0%, ≥8.0%). 
LS means differences in scores between treatment groups and its SEs and their corresponding 
95% confidence interval of will also be evaluated. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 38 
2.5 
DATA HANDLING CONVENTIONS  
The following formulas will be used for computation of parameters: 
2.5.1 General conventions  
CGM days will be defined as starting/ending at 00:00/23:59 on the 24-hour clock. Only useable 
CGM days within the time windows (see Section 2.5.4) are used for derivation of CGM endpoints 
(primary and secondary). 
Percentage time in range 
The proportion of CGM readings falling into the range of ≥70 to ≤180 mg/dL [≥3.9 to≤10 
mmol/L] from useable CGM (at least 10 useable days among the 20-day CGM within the time-
window, see Section 2.5.4). 
If there is missing data between two available measurements, linear interpolation will be 
performed to impute the time points with missing data. For example, if a glucose value is less than 
70 mg/dL at 5 min, missing at 10 and 15 min then higher than 180 mg/dL at 20 min, the data at 10 
and 15 minutes will be imputed using linear interpolation. Missing data at the start of the day and 
end of day will not be imputed. 
Demographic formulas 
• 
If the date of T1DM diagnosis is not missing, age at diagnosis will be calculated extracting 
the year from the date of the T1DM diagnosis and the year of birth:  
a) Age at diagnosis (years) = YEAR (date of diagnosis) – year of birth. 
• 
Time since diabetes diagnosis will be derived: 
a) Time since diabetes diagnosis (years) = Integer [(date of Informed Consent – Date of 
Diagnosis + 1)/365.25]. 
Disease characteristics at baseline formulas 
• 
Total daily insulin dose adjusted for body weight: Total daily dose (IU) / body weight in 
kg. 
Physical examination formulas 
• BMI (Quetelet index formula):  
a) Weight (kg) / (Height (m) × Height (m)) 
where using height assessed at Screening Visit and body weight collected over the study. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 39 
2.5.2 Data handling conventions for secondary efficacy variables  
2.5.2.1 CGM secondary and tertiary endpoints  
• 
mean hours per day = percent time × 24 hours 
24-hour Area under the Curve (AUC24), derived using the trapezoidal rule based on AUCt 
(AUC over the CGM assessment period) and then divided by the number of days with 
usable CGM data. Trapezoidal rule:  
a) 0.5 × (glucose reading at time i + glucose reading at time i-1) × (time i - time i-1). 
Note: Missing values for calculation of AUC will be treated as not collected. 
The following main secondary endpoints will be calculated as follows: 
• 
Glucose total CV = 100% times square root of 𝑠2
𝑡𝑜𝑡𝑎𝑙 divided by the mean glucose 𝑦̅. That 
is: 
CV𝑡𝑜𝑡𝑎𝑙=  100 × 𝑠𝑡𝑜𝑡𝑎𝑙
2
𝑦̅
 
with 
𝑠2
𝑡𝑜𝑡𝑎𝑙=
∑
∑
(𝑦𝑖𝑗−𝑦̅)
2
𝑛𝑖
𝑗=1
 
𝑘
𝑖=1
𝑁−1
 
and  
𝑦̅ =
∑
∑
𝑦𝑖𝑗
𝑛𝑖
𝑗=1
𝑘
𝑖=1
𝑁
  , 
where 𝑁 is the number of total useable CGM data for each patient; 𝑘 is the number of CGM 
assessment days; 𝑦𝑖𝑗 is the 𝑗𝑡ℎ CGM data from the Day 𝑖 and 𝑛𝑖 is the number of total useable 
CGM data within the Day 𝑖. 
• 
Glucose between days CV = 100% times square root of 𝑠2
𝑏𝑒𝑡𝑤𝑒𝑒𝑛 divided by the mean 
glucose 𝑦̅. That is:  
CV𝑏𝑒𝑡𝑤𝑒𝑒𝑛=  100 × 𝑠𝑏𝑒𝑡𝑤𝑒𝑒𝑛
2
𝑦̅
 
with  
𝑠2
𝑏𝑒𝑡𝑤𝑒𝑒𝑛= ∑
(𝑦̅𝑖−𝑦̅)2 
𝑘
𝑖=1
𝐾−1
 
where 𝑦̅𝑖 is the mean glucose for Day 𝑖: 
𝑦̅𝑖=
∑
𝑦𝑖𝑗
𝑛𝑖
𝑗=1
𝑛𝑖
 . 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 40 
• 
Glucose within days CV = 100% times square root of 𝑠2
𝑤𝑖𝑡ℎ𝑖𝑛 divided by the mean 
glucose 𝑦̅. That is:  
CV𝑤𝑖𝑡ℎ𝑖𝑛=  100 × 𝑠𝑤𝑖𝑡ℎ𝑖𝑛
2
𝑦̅
 
with  
𝑠2
𝑤𝑖𝑡ℎ𝑖𝑛= 1
𝐾∑ 
𝑘
𝑖=1
∑
(𝑦𝑖𝑗−𝑦̅𝑖)
2
𝑛𝑖
𝑗=1
𝑛𝑖−1
 . 
A Proc Varcomp procedure will be used to compute Glucose within days CV and Glucose 
between days CV for each patient where time point variability within each day is also accounted 
for 
proc varcomp data =dsn;  
 by USUBJID avisit; 
 class ADY TIMEBIN; 
 model AVAL = ADY TIMEBIN; 
 ods output estimates=outstat; 
run; 
where: 
AVAL: glucose value 
AVISIT: Analysis visit including Baseline and Week 12 
ADY: Analysis day 
TIMEBIN: Timepoints 
The CGM secondary/exploratory endpoints related to percent in time in range whatever the 
threshold(s) will be derived on a similar way as the primary endpoint. 
• GMI (%) = 3.31 + 0.02392 × (mean glucose in mg/dL) 
2.5.2.2 Absolute change  
Absolute change from baseline for all secondary endpoints will be calculated as follows: 
• 
Absolute change from baseline on 𝑋 at Visit 𝑖 = (𝑋 at Visit 𝑖) – (𝑋 at baseline) 
where 𝑋 is a given secondary endpoint value, 𝑖 is the post-baseline visit 𝑖 and baseline is the last 
assessment before first administration of IMP. 
2.5.2.3 HbA1c and FPG  
HbA1c (mmol/mol) = (HgbA1C% − 2.15) × 10.929 
FPG (mmol/mol) = FPG mg/dL × 0.0555 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 41 
2.5.2.4 WPAI  
Employment status will be derived based on the coding rules for self-administration. That is, if 
Q1 = YES or Q1 = NO or missing and hours missed or worked > 0, then employed. If Q1 is 
missing and hours missed and worked = 0, then not employed. 
The following scoring instruction is used to score the four subscales from the 6-item validated 
questionnaire WPAI-diabetes.  
Four subscales: 
• 
Absenteeism (Percent work time missed due to diabetes): Q2 / (Q2 + Q4) 
• 
Presenteeism (Percent impairment while working due to diabetes): Q5 / 10 
• 
Work productivity loss (Percent overall work impairment due to diabetes):  
 
Q2 / (Q2 + Q4) + [(1 − (Q2 / (Q2 + Q4))) x (Q5 / 10)] 
• 
Activity Impairment (Percent activity impairment due to diabetes): Q6 / 10 
2.5.2.5 MOS Sleep  
Values for Sleep Quantity (ie, the average number of hours sleep each night during the past 4 
weeks) will be considered aberrant if they are >24. For these cases, the variable will be considered 
as missing. 
2.5.3 Missing data  
For categorical variables, patients with missing data are not included in calculations of 
percentages unless otherwise specified. When relevant, the number of patients with missing data 
is presented. 
Handling of computation of treatment duration if investigational medicinal product end of 
treatment date is missing  
For the calculation of the treatment duration, the date of the last dose of IMP is equal to the date 
of last administration reported on the Completion of End of Study/Follow-up case report form 
page. If this date is missing, the exposure duration should be left as missing.  
Handling of medication missing/partial dates 
No imputation of medication start/end dates or times will be performed. If a medication date or 
time is missing or partially missing and it cannot be determined whether it was taken prior or 
concomitantly, it will be considered a prior, concomitant, and post-treatment medication. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 42 
Handling of adverse events with missing or partial date/time of onset 
Missing or partial adverse event onset dates and times will be imputed so that if the partial 
adverse event onset date/time information does not indicate that the adverse event started prior to 
treatment or after the treatment-emergent adverse event period, the adverse event will be 
classified as treatment-emergent. No imputation of adverse event end dates/times will be 
performed. These data imputations are for categorization purpose only and will not be used in 
listings. No imputation is planned for the date/time of adverse event resolution. 
Handling of adverse events when date and time of first investigational medicinal product 
administration is missing 
When the date and time of the first IMP administration is missing, all adverse events that occurred 
on or after the day of randomization should be considered as treatment-emergent adverse events. 
The exposure duration should be kept as missing. 
Handling of missing assessment of relationship of adverse events to investigational medicinal 
product  
If the assessment of the relationship to IMP is missing, then the relationship to IMP has to be 
assumed and the adverse event considered as such in the frequency tables of possibly related 
adverse events, but no imputation should be done at the data level. 
Handling of missing responses of DTSQc and DTSQs  
The total treatment satisfaction score is the sum of items 1, 4, 5, 6, 7 and 8. 
If no more than 2 out of the 6 questions comprising the total treatment satisfaction score are 
missing, the total treatment satisfaction score is imputed by calculating the average of the scores 
from the answered questions, dividing this sum by the number of answered questions and 
multiplying the average by six. 
If items 2 or 3 are not answered, the frequency of hypoglycemia or hyperglycemia scores is 
considered as missing. 
Handling of missing responses of WPAI 
If the patient is employed, and Q2, Q4 Q5, and Q6 is missing then the scores will be imputed 
using average of all scores from other patients who answer the questions. Otherwise, only Q6 will 
be imputed using average of all scores from other patients. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 43 
Multiple imputation for primary analysis  
Multiple imputation under MAR assumptions 
Once the missing data pattern will be assessed, the programming process for this primary analysis 
will follow three steps (if monotone missing pattern is observed for all patients, then proceed 
directly with Step 1b): 
• 
Step 1a: Use PROC MI to produce a monotone missing data pattern. A monotone Monte 
Carlo Markov Chain MCMC imputation model will be used to impute interim missing 
data. A sample SAS code for this imputation is shown below: 
PROC MI NIMPUTE=1000 DATA=orig OUT=impute1 SEED=14947 MIN=0 MAX=100; 
 BY ARM; 
 MCMC IMPUTE=MONOTONE;  
 VAR BASE PTIR;  
RUN;  
• 
Step 1b: Use PROC MI to execute the second imputation using the data set produced in 
the first imputation. A sample SAS code for this imputation is shown below (if Step 1a 
was not done due to monotone missing, then NIMPUTE=1000 and DATA=ORIG, BY 
statement not needed):  
PROC MI NIMPUTE=1 DATA=impute1 OUT=impute2 SEED=14947 MIN=0 MAX=100; 
 CLASS ARM HBACRIT1; 
  BY _IMPUTATION_; 
 MONOTONE METHOD=REG 
 VAR ARM HBACRIT1 BASE PTIR;  
RUN; 
• 
Step 2: Each of the 1000 imputed datasets will undergo an ANCOVA using fixed 
categorical effects of treatment group (Toujeo, Tresiba), randomization stratum of 
screening HbA1c (<8.0% versus ≥8.0%), and the baseline percent time in range value 1 
using the following ESTIMATE statement in PROC GLM 
PROC GLM DATA=impute2; 
 BY _IMPUTATION_; 
 CLASS ARM HBACRIT1; 
 MODEL PTIR = ARM HBACRIT1 BASE; 
 ESTIMATE “TOUJEO-0.9 TRESIBA” INTERCEPT 0.1 TREAT 1 -0.9; 
RUN; 
• 
Step 3: The 1000 analysis results will be combined using PROC MIANALYZE (Rubin’s 
rule). A sample SAS code for this combined analysis is shown below: 
PROC MIANALYZE PARMS=est; 
 MODELEFFECTS estimate; 
RUN; 
In this SAS code above:  
• 
orig: input dataset including one observation per patient in the  ITT population 
• 
BASE: Percentage of time in the glucose range of ≥70 to ≤180 mg/dL all time at baseline 
• 
PTIR: Percentage of time in the glucose range of ≥70 to ≤180 mg/dL all time at Week 12 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 44 
• 
ARM: treatment group as per randomized (TOUJEO/ TRESIBA) 
• 
seed: the seed (14947) has been chosen arbitrarily and is based on the study code 
(LPS14947). 
• 
HBACRIT1: randomization stratum of screening HbA1c (<8.0% versus ≥8.0%) 
2.5.4 Windows for time points  
The windows below will be employed for the main primary and secondary efficacy endpoints as 
well as vital sign which will also be collected during the study for both scheduled and 
unscheduled visits. 
CGM 
CGM values measured outside the visit window will be flagged for exclusion from analyses. No 
derivations of CGM endpoints will be performed for CGM data collected outside of the analysis 
CGM window. Study days for CGM evaluations are calculated from the randomization date, and 
Day 1 indicates the day of randomization. 
 
 
Target CGM visit in Study day 
Analysis CGM window in study 
day 
CGM study visit 
 
 
Week- 3 to Week -1 
Day -20 to Day -1 
-28 to -1 
Week 10 to Week 12  
Day 64 to 84 
57 to 91 
For 7-point SMPG, HbA1c, FPG and PROs:  Day indicates days relative to randomization date, 
and Day 1 indicates the day of randomization. 
7-point SMPG 
 
 
Target Study day 
Analysis window in study day 
Time point 
 
 
Week 12  
84 
77 to 91 
HbA1c, FPG  
 
 
Targeted Study Day 
Analysis window in study days 
Time Point 
 
 
Week 12 
84 
77 to 91 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 45 
PROs 
 
 
Targeted Study Day 
Analysis window in study days 
Time Point 
 
 
Week 12 
84 
77 to 91 
Vital signs - Safety 
Study days for vital signs evaluations are calculated from the day of first IMP injection, the day of 
first IMP injection being Day 1. The last assessment before the first study drug intake will be 
considered as Baseline. 
 
 
Target visit in Study day 
Analysis window in study day 
Time Point 
 
 
Week 8 
56 
49 to 63 
Week 12 
84 
77 to 91 
One or more results for a required parameter may be recorded within a given visit window. In 
such an event, the assessment with the closest date to the scheduled visit date will be used. In the 
event of 2 observations within a given visit window being equidistant to the scheduled visit date, 
the first observation will be used for descriptive tabulations or figures.  
2.5.5 Unscheduled visits  
Unscheduled visit measurements of vital signs will not be included in the by-visit summaries but 
will be used for computation of baseline and analysis visit definition. 
2.5.6 Pooling of centers for statistical analyses  
No pooling of centers is planned for statistical analyses: center and country will not be included in 
statistical analysis. 
2.5.7 Statistical technical issues  
Not applicable for the study. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 46 
3 
INTERIM ANALYSIS  
No interim analysis is planned. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 47 
4 
DATABASE LOCK  
The database is planned to be locked 4 weeks after last patient last visit. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 48 
5 
SOFTWARE DOCUMENTATION  
All summaries and statistical analyses will be generated using SAS version 9.4 or higher. 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 49 
6 
REFERENCES  
1. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for 
continuous glucose monitoring data interpretation: recommendations from the international 
consensus on time in range. Diabetes Care. 2019 Aug;42(8):1593-603. 
2. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al. Glucose 
management indicator (GMI): a new term for estimating A1C from continuous glucose 
monitoring. Diabetes Care. 2018 Nov;41(11):2275-80. 
3. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International 
consensus on use of continuous glucose monitoring. Diabetes Care. 2017 Dec;40(12):1631-40. 
4. Hochber Y, Tamhane AC. Multiple comparison procedures, John Wiley & Sons (print 1987). 
Published online: 27 May 2008. 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 50 
7 
LIST OF APPENDICES  
Appendix A: Summary of statistical analyses 
Appendix B: Questionnaires (PROs) 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 51 
APPENDIX A: SUMMARY OF STATISTICAL ANALYSES  
 
EFFICACY ANALYSIS 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
Primary endpoint 
Percent of time in glucose 
range of ≥70 to ≤180 mg/dL 
(≥3.9 to ≤10 mmol/L) using 
continuous glucose 
monitoring (CGM) at 
Week 12 
ITT, PP, ITT 
COVID 19 free 
For ITT population: ANCOVA with 
fixed categorical effects Trt and  
randomization stratum HbA1c and 
continuous fixed covariate of baseline 
percent in range value with multiple 
imputation of missing data  
 
Non inferiority with a relative non-
inferiority margin of 10 % is the primary 
analysis 
 
 
1st Sensitivity 
analyses: same 
modeling 
(ANCOVA) with MI 
on PP population 
 
2nd Sensitivity 
analyses same 
modeling 
(ANCOVA) with 
multiple imputation 
of missing data 
being imputed in 
conjunction with 
MNAR assumption 
from ITT 
population. 
 
3rd sensitivity 
analyses: same 
modeling 
(ANCOVA) with MI 
on Population 
without trial impact 
(disruption) due to 
COVID-19 
Yes, subgroup by 
screening and 
baseline factors 
such as duration of 
diabetes, Gender, 
Randomization 
strata, BMI. 
 
In addition to the non-inferiority testing that is the 
primary analysis, and only if non-inferiority of 
Toujeo in comparison to Tresiba on the percent 
time in the range of 70-180 mg/dL is demonstrated 
and if non-inferiority of Toujeo versus Tresiba on 
the glucose total CV is demonstrated, superiority of 
Toujeo over Tresiba on the percent time in the 
range of 70-180 mg/dL will be tested 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 52 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
 
Secondary endpoints 
Glucose total CV using 
CGM at Week 12 
(Main secondary endpoint) 
ITT 
ANCOVA model to perform the 
analysis includes the fixed categorical 
effects of treatment group (Toujeo, 
Tresiba),and  randomization stratum of 
screening HbA1c (<8.0%versus 
≥8.0%), as well as, the continuous 
fixed covariate of baseline value for the 
corresponding endpoint 
 
As this is the main secondary 
endpoint: Multiple imputation (as for 
primary endpoint) and non-inferiority 
with a relative non-inferiority margin of 
10 % tested in case of non-inferiority 
demonstrated for primary analysis of 
primary endpoint  
No 
No 
No 
Glucose within-day CV 
using CGM 
at Week 12 
ITT 
The ANCOVA model to perform the 
analysis includes the fixed categorical 
effects of treatment group (Toujeo, 
Tresiba), and randomization stratum of 
screening HbA1c (<8.0%versus 
≥8.0%), as well as, the continuous 
fixed covariate of baseline value for the 
corresponding endpoint. 
No 
Yes, subgroup 
defined by glucose 
within day CV ≤36% 
vs. >36% at 
baseline. 
No 
Glucose between-day CV 
using CGM at Week 12 
ITT 
The ANCOVA model to perform the 
analysis includes the fixed categorical 
effects of treatment group (Toujeo, 
Tresiba), randomization stratum of 
screening HbA1c (<8.0%versus 
≥8.0%), as well as, the continuous 
No 
No 
No 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 53 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
fixed covariate of baseline value for the 
corresponding endpoint. 
HbA1c Change from 
baseline at Week 12 
ITT 
Change in HbA1c will be analyzed 
using an ANCOVA model including the 
fixed categorical effects of treatment 
group (Toujeo, Tresiba), as well as, the 
continuous fixed covariate of baseline 
HbA1c value. 
 
95% CI and P-values presented for 
these endpoints will be done for 
descriptive purposes only. 
No 
No 
No 
FPG Change from baseline 
at Week 12 
ITT 
Change in FPG will be analyzed using 
ANCOVA model including the fixed 
categorical effects of treatment group 
(Toujeo, Tresiba), and the 
randomization stratum of HbA1c at 
screening (<8.0%, ≥8.0%), as well as, 
the continuous fixed covariate of 
baseline FPG value. 
 
95% CI and P-values presented for 
these endpoints will be done for 
descriptive purposes only. 
No 
No 
No 
Tertiary/exploratory endpoints except PROs 
 
 
 
Change from baseline in 7-
point SMPG profiles (pre-
prandial and 2-hour 
postprandial plasma 
glucose at breakfast, lunch 
and dinner, and at bedtime) 
to Week 12 
ITT 
Descriptive summary statistics by 
treatment group 
 
No 
 
No 
 
No 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 54 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
Mean hours per day in the 
CGM glucose range of ≥70 
to ≤180 mg/dL (≥3.9 to ≤10 
mmol/L) 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Percent time and mean 
hours per day in the CGM 
glucose range of ≥70 to 
≤140 mg/dL (≥3.9 to ≤7.8 
mmol/L) (for all-time and 
during the night [00:00 to 
05:59]) 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Nocturnal percent time in 
CGM glucose range of ≥70 
to ≤180 mg/dL (≥3.9 to ≤10 
mmol/L) at Week 12, 
obtained using CGM 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Percent time and mean 
hours per day with CGM 
glucose: <54 mg/dL, (for all 
time and during the night 
[00:00 to 05:59]) 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Percent time with CGM 
glucose <70 mg/dL within 
the 12 hours after basal 
insulin injection 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Percent time and mean 
hours per day with CGM 
glucose >250 mg/dL 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Mean CGM glucose profile 
over 24-hour period 
ITT 
 Graphic presentation 
No 
No 
No 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 55 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
24h-AUC of CGM glucose 
values 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Mean glucose 
 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
GMI 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Percent time and mean 
hours per day in the CGM 
glucose range of ≥54 to 
<70 mg/dL (for all-time and 
during the night [00:00 to 
05:59]), 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Percent time and mean 
hours per day in the 
glucose range of ≥180 to 
<250 mg/dL (on all-time and 
during the night [00:00 to 
05:59]), 
ITT 
Descriptive summary statistics by 
treatment group 
No 
No 
No 
Daily insulin doses (total 
daily insulin, total basal 
insulin, total mealtime 
insulin, ratio of basal to 
mealtime insulin dose) in 
units and U/kg body weight  
Safety 
Descriptive summary statistics 
(including change from baseline to 
Week 12) by treatment group 
No 
No 
No 
PROs endpoints 
 
 
 
 
 
DTSQs 
ITT 
Change in DTSQs scores from 
baseline to Week 12 will be analyzed 
using an analysis of covariance 
(ANCOVA) model including the fixed 
categorical effects of treatment group 
(Toujeo, Tresiba), and the 
No 
No 
No 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 56 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
randomization stratum of HbA1c at 
screening (<8.0%, ≥8.0%), as well as, 
the continuous fixed covariate of 
baseline score. 
LS means and its corresponding 95% 
confidence interval by treatment for the 
change from baseline will be presented 
for descriptive purposes 
DTSQc 
 
ITT 
The DTSQc scores at Week 12 will be 
analyzed using an analysis of 
covariance (ANCOVA) model including 
the fixed categorical effects of 
treatment group (Toujeo, Tresiba),and  
the randomization stratum of HbA1c at 
screening (<8.0%, ≥8.0%). 
LS means and its corresponding 95% 
confidence interval by treatment for the 
change from baseline will be presented 
for descriptive purposes 
No 
No 
No 
MOS Sleep 
 
ITT 
Change in MOS-Sleep from baseline 
to Week 12 will be analyzed using an 
analysis of covariance (ANCOVA) 
model including the fixed categorical 
effects of treatment group (Toujeo, 
Tresiba), and the randomization 
stratum of HbA1c at screening (<8.0%, 
≥8.0%), as well as, the continuous 
fixed covariate of baseline score. 
LS means and its corresponding 95% 
confidence interval by treatment for the 
change from baseline will be presented 
for descriptive purposes 
No 
No 
No 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 57 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
WPAI 
ITT 
Change in WPAI scores from baseline 
to Week 12 will be analyzed using an 
analysis of covariance (ANCOVA) 
model including the fixed categorical 
effects of treatment group (Toujeo, 
Tresiba), and the randomization 
stratum of HbA1c at screening (<8.0%, 
≥8.0%), as well as, the continuous 
fixed covariate of baseline score 
LS means and its corresponding 95% 
confidence interval by treatment for the 
change from baseline will be presented 
for descriptive purposes 
No 
No 
No 
ANCOVA = analysis of covariance; ITT = intent-to-treat; PP = per-protocol 
 
SAFETY ANALYSES 
Endpoint 
Analysis 
population 
Primary analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
Number of patients with 
adverse events 
 
Safety 
 
Summary by treatment group using 
number and % of patients 
experiencing at least one adverse 
event, focusing on TEAE 
No 
No 
No 
Number of patients with at 
least one hypoglycemic 
event from baseline to 
Week 12 
Safety 
 
Summary by treatment group using 
number and % of patients 
experiencing at least one 
hypoglycemic event will be presented 
for any hypoglycemia and for each 
type of hypoglycemia, overall and 
according to time of occurrence 
(nocturnal [ie, 00:00 to 05:59], any 
time of day and daytime [ie, 06:00 to 
No 
No 
No 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 58 
Endpoint 
Analysis 
population 
Primary analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
23:59] during the 12-week on 
treatment period 
 
Logistic regression model adjusted on 
randomization strata of screening 
HbA1c to estimate Odds Ratio and its 
corresponding 95% CI for the Toujeo 
arm over the Tresiba arm for each 
hypoglycemic event  
Number of hypoglycemic 
events per participant-year 
from baseline to Week 12 
Safety 
 
Number and rate of hypoglycemic 
events (in patient-year of exposure) 
will be determined for any 
hypoglycemia and for each type of 
hypoglycemic event, overall and 
according to time of occurrence 
(nocturnal [ie, 00:00 to 05:59], any 
time of the day) during the 12-week on 
treatment period. 
Over-dispersed Poisson regression 
model adjusted on randomization 
strata of screening HbA1c to estimate 
for each hypoglycemic event, the rate 
ratio, and its corresponding 95% CI, of 
Toujeo arm over Tresiba arm 
No 
No 
No 
 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 59 
APPENDIX B: QUESTIONNAIRES (PROS)  
 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 60 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 61 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 62 
 
 
 
 
 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 63 
 
VV-CLIN-0612739 1.0


Statistical Analysis Plan  
01-Jul-2021 
HOE901-U300-LPS14947 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 64 
 
 
VV-CLIN-0612739 1.0


Signature Page for VV-CLIN-0612739 v1.0
lps14947-16-1-9-sap
Approve & eSign
Approve & eSign
Approve & eSign
VV-CLIN-0612739 1.0